{"id": "AIMed.d193.s1641_AIMed.d193.s1641.p0", "text": "Physical and functional interactions between the transcriptional inhibitors Id3 and ITF-2b. Evidence toward a novel mechanism regulating muscle-specific gene expression.", "text_with_entity_marker": "Physical and functional interactions between the transcriptional inhibitors [E1]Id3[/E1] and [E2]ITF-2b[/E2]. Evidence toward a novel mechanism regulating muscle-specific gene expression.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Id3", "entity_1_idx": [[76, 79]], "entity_1_idx_in_text_with_entity_marker": [80, 83], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ITF-2b", "entity_2_idx": [[84, 90]], "entity_2_idx_in_text_with_entity_marker": [97, 103], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d193.s1642_AIMed.d193.s1642.p0", "text": "We have used an interaction cloning strategy to identify an inhibitory isoform of the ITF-2 transcription factor, ITF-2b, that interacts with the transcriptional inhibitor Id3/HLH462.", "text_with_entity_marker": "We have used an interaction cloning strategy to identify an inhibitory isoform of the [E1]ITF-2[/E1] transcription factor, [E2]ITF-2b[/E2], that interacts with the transcriptional inhibitor Id3/HLH462.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ITF-2", "entity_1_idx": [[86, 91]], "entity_1_idx_in_text_with_entity_marker": [90, 95], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ITF-2b", "entity_2_idx": [[114, 120]], "entity_2_idx_in_text_with_entity_marker": [127, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d193.s1642_AIMed.d193.s1642.p1", "text": "We have used an interaction cloning strategy to identify an inhibitory isoform of the ITF-2 transcription factor, ITF-2b, that interacts with the transcriptional inhibitor Id3/HLH462.", "text_with_entity_marker": "We have used an interaction cloning strategy to identify an inhibitory isoform of the [E1]ITF-2[/E1] transcription factor, ITF-2b, that interacts with the transcriptional inhibitor [E2]Id3[/E2]/HLH462.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ITF-2", "entity_1_idx": [[86, 91]], "entity_1_idx_in_text_with_entity_marker": [90, 95], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Id3", "entity_2_idx": [[172, 175]], "entity_2_idx_in_text_with_entity_marker": [185, 188], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d193.s1642_AIMed.d193.s1642.p2", "text": "We have used an interaction cloning strategy to identify an inhibitory isoform of the ITF-2 transcription factor, ITF-2b, that interacts with the transcriptional inhibitor Id3/HLH462.", "text_with_entity_marker": "We have used an interaction cloning strategy to identify an inhibitory isoform of the [E1]ITF-2[/E1] transcription factor, ITF-2b, that interacts with the transcriptional inhibitor Id3/[E2]HLH462[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ITF-2", "entity_1_idx": [[86, 91]], "entity_1_idx_in_text_with_entity_marker": [90, 95], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HLH462", "entity_2_idx": [[176, 182]], "entity_2_idx_in_text_with_entity_marker": [189, 195], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d193.s1642_AIMed.d193.s1642.p3", "text": "We have used an interaction cloning strategy to identify an inhibitory isoform of the ITF-2 transcription factor, ITF-2b, that interacts with the transcriptional inhibitor Id3/HLH462.", "text_with_entity_marker": "We have used an interaction cloning strategy to identify an inhibitory isoform of the ITF-2 transcription factor, [E1]ITF-2b[/E1], that interacts with the transcriptional inhibitor [E2]Id3[/E2]/HLH462.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "ITF-2b", "entity_1_idx": [[114, 120]], "entity_1_idx_in_text_with_entity_marker": [118, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Id3", "entity_2_idx": [[172, 175]], "entity_2_idx_in_text_with_entity_marker": [185, 188], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d193.s1642_AIMed.d193.s1642.p4", "text": "We have used an interaction cloning strategy to identify an inhibitory isoform of the ITF-2 transcription factor, ITF-2b, that interacts with the transcriptional inhibitor Id3/HLH462.", "text_with_entity_marker": "We have used an interaction cloning strategy to identify an inhibitory isoform of the ITF-2 transcription factor, [E1]ITF-2b[/E1], that interacts with the transcriptional inhibitor Id3/[E2]HLH462[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "ITF-2b", "entity_1_idx": [[114, 120]], "entity_1_idx_in_text_with_entity_marker": [118, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HLH462", "entity_2_idx": [[176, 182]], "entity_2_idx_in_text_with_entity_marker": [189, 195], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d193.s1642_AIMed.d193.s1642.p5", "text": "We have used an interaction cloning strategy to identify an inhibitory isoform of the ITF-2 transcription factor, ITF-2b, that interacts with the transcriptional inhibitor Id3/HLH462.", "text_with_entity_marker": "We have used an interaction cloning strategy to identify an inhibitory isoform of the ITF-2 transcription factor, ITF-2b, that interacts with the transcriptional inhibitor [E1]Id3[/E1]/[E2]HLH462[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Id3", "entity_1_idx": [[172, 175]], "entity_1_idx_in_text_with_entity_marker": [176, 179], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HLH462", "entity_2_idx": [[176, 182]], "entity_2_idx_in_text_with_entity_marker": [189, 195], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d193.s1644_AIMed.d193.s1644.p0", "text": "As expected, overexpression of either Id3/HLH462 or ITF-2b effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor MyoD.", "text_with_entity_marker": "As expected, overexpression of either [E1]Id3[/E1]/[E2]HLH462[/E2] or ITF-2b effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor MyoD.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Id3", "entity_1_idx": [[38, 41]], "entity_1_idx_in_text_with_entity_marker": [42, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HLH462", "entity_2_idx": [[42, 48]], "entity_2_idx_in_text_with_entity_marker": [55, 61], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d193.s1644_AIMed.d193.s1644.p1", "text": "As expected, overexpression of either Id3/HLH462 or ITF-2b effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor MyoD.", "text_with_entity_marker": "As expected, overexpression of either [E1]Id3[/E1]/HLH462 or [E2]ITF-2b[/E2] effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor MyoD.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Id3", "entity_1_idx": [[38, 41]], "entity_1_idx_in_text_with_entity_marker": [42, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ITF-2b", "entity_2_idx": [[52, 58]], "entity_2_idx_in_text_with_entity_marker": [65, 71], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d193.s1644_AIMed.d193.s1644.p2", "text": "As expected, overexpression of either Id3/HLH462 or ITF-2b effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor MyoD.", "text_with_entity_marker": "As expected, overexpression of either [E1]Id3[/E1]/HLH462 or ITF-2b effectively inhibited the activation of the muscle-specific [E2]creatine kinase[/E2] promoter by the myogenic transcription factor MyoD.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Id3", "entity_1_idx": [[38, 41]], "entity_1_idx_in_text_with_entity_marker": [42, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "creatine kinase", "entity_2_idx": [[119, 134]], "entity_2_idx_in_text_with_entity_marker": [132, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d193.s1644_AIMed.d193.s1644.p3", "text": "As expected, overexpression of either Id3/HLH462 or ITF-2b effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor MyoD.", "text_with_entity_marker": "As expected, overexpression of either [E1]Id3[/E1]/HLH462 or ITF-2b effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor [E2]MyoD[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Id3", "entity_1_idx": [[38, 41]], "entity_1_idx_in_text_with_entity_marker": [42, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MyoD", "entity_2_idx": [[181, 185]], "entity_2_idx_in_text_with_entity_marker": [194, 198], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d193.s1644_AIMed.d193.s1644.p4", "text": "As expected, overexpression of either Id3/HLH462 or ITF-2b effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor MyoD.", "text_with_entity_marker": "As expected, overexpression of either Id3/[E1]HLH462[/E1] or [E2]ITF-2b[/E2] effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor MyoD.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HLH462", "entity_1_idx": [[42, 48]], "entity_1_idx_in_text_with_entity_marker": [46, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ITF-2b", "entity_2_idx": [[52, 58]], "entity_2_idx_in_text_with_entity_marker": [65, 71], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d193.s1644_AIMed.d193.s1644.p5", "text": "As expected, overexpression of either Id3/HLH462 or ITF-2b effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor MyoD.", "text_with_entity_marker": "As expected, overexpression of either Id3/[E1]HLH462[/E1] or ITF-2b effectively inhibited the activation of the muscle-specific [E2]creatine kinase[/E2] promoter by the myogenic transcription factor MyoD.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HLH462", "entity_1_idx": [[42, 48]], "entity_1_idx_in_text_with_entity_marker": [46, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "creatine kinase", "entity_2_idx": [[119, 134]], "entity_2_idx_in_text_with_entity_marker": [132, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d193.s1644_AIMed.d193.s1644.p6", "text": "As expected, overexpression of either Id3/HLH462 or ITF-2b effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor MyoD.", "text_with_entity_marker": "As expected, overexpression of either Id3/[E1]HLH462[/E1] or ITF-2b effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor [E2]MyoD[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HLH462", "entity_1_idx": [[42, 48]], "entity_1_idx_in_text_with_entity_marker": [46, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MyoD", "entity_2_idx": [[181, 185]], "entity_2_idx_in_text_with_entity_marker": [194, 198], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d193.s1644_AIMed.d193.s1644.p7", "text": "As expected, overexpression of either Id3/HLH462 or ITF-2b effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor MyoD.", "text_with_entity_marker": "As expected, overexpression of either Id3/HLH462 or [E1]ITF-2b[/E1] effectively inhibited the activation of the muscle-specific [E2]creatine kinase[/E2] promoter by the myogenic transcription factor MyoD.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ITF-2b", "entity_1_idx": [[52, 58]], "entity_1_idx_in_text_with_entity_marker": [56, 62], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "creatine kinase", "entity_2_idx": [[119, 134]], "entity_2_idx_in_text_with_entity_marker": [132, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d193.s1644_AIMed.d193.s1644.p8", "text": "As expected, overexpression of either Id3/HLH462 or ITF-2b effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor MyoD.", "text_with_entity_marker": "As expected, overexpression of either Id3/HLH462 or [E1]ITF-2b[/E1] effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor [E2]MyoD[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ITF-2b", "entity_1_idx": [[52, 58]], "entity_1_idx_in_text_with_entity_marker": [56, 62], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MyoD", "entity_2_idx": [[181, 185]], "entity_2_idx_in_text_with_entity_marker": [194, 198], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d193.s1644_AIMed.d193.s1644.p9", "text": "As expected, overexpression of either Id3/HLH462 or ITF-2b effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor MyoD.", "text_with_entity_marker": "As expected, overexpression of either Id3/HLH462 or ITF-2b effectively inhibited the activation of the muscle-specific [E1]creatine kinase[/E1] promoter by the myogenic transcription factor [E2]MyoD[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "creatine kinase", "entity_1_idx": [[119, 134]], "entity_1_idx_in_text_with_entity_marker": [123, 138], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MyoD", "entity_2_idx": [[181, 185]], "entity_2_idx_in_text_with_entity_marker": [194, 198], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d193.s1646_AIMed.d193.s1646.p0", "text": "Moreover, while ITF-2b inhibited the creatine kinase promoter, it acted as a weak transactivator on an artificial promoter consisting of three tandem copies of the consensus myogenic factor DNA binding site.", "text_with_entity_marker": "Moreover, while [E1]ITF-2b[/E1] inhibited the [E2]creatine kinase[/E2] promoter, it acted as a weak transactivator on an artificial promoter consisting of three tandem copies of the consensus myogenic factor DNA binding site.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ITF-2b", "entity_1_idx": [[16, 22]], "entity_1_idx_in_text_with_entity_marker": [20, 26], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "creatine kinase", "entity_2_idx": [[37, 52]], "entity_2_idx_in_text_with_entity_marker": [50, 65], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d193.s1647_AIMed.d193.s1647.p0", "text": "Further investigation indicated that the ITF-2b/MyoD heterodimer bound to its specific DNA binding site in vitro, and the DNA binding was effectively blocked by Id3/HLH462.", "text_with_entity_marker": "Further investigation indicated that the [E1]ITF-2b[/E1]/[E2]MyoD[/E2] heterodimer bound to its specific DNA binding site in vitro, and the DNA binding was effectively blocked by Id3/HLH462.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "ITF-2b", "entity_1_idx": [[41, 47]], "entity_1_idx_in_text_with_entity_marker": [45, 51], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MyoD", "entity_2_idx": [[48, 52]], "entity_2_idx_in_text_with_entity_marker": [61, 65], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d193.s1647_AIMed.d193.s1647.p1", "text": "Further investigation indicated that the ITF-2b/MyoD heterodimer bound to its specific DNA binding site in vitro, and the DNA binding was effectively blocked by Id3/HLH462.", "text_with_entity_marker": "Further investigation indicated that the [E1]ITF-2b[/E1]/MyoD heterodimer bound to its specific DNA binding site in vitro, and the DNA binding was effectively blocked by [E2]Id3[/E2]/HLH462.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ITF-2b", "entity_1_idx": [[41, 47]], "entity_1_idx_in_text_with_entity_marker": [45, 51], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Id3", "entity_2_idx": [[161, 164]], "entity_2_idx_in_text_with_entity_marker": [174, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d193.s1647_AIMed.d193.s1647.p2", "text": "Further investigation indicated that the ITF-2b/MyoD heterodimer bound to its specific DNA binding site in vitro, and the DNA binding was effectively blocked by Id3/HLH462.", "text_with_entity_marker": "Further investigation indicated that the [E1]ITF-2b[/E1]/MyoD heterodimer bound to its specific DNA binding site in vitro, and the DNA binding was effectively blocked by Id3/[E2]HLH462[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ITF-2b", "entity_1_idx": [[41, 47]], "entity_1_idx_in_text_with_entity_marker": [45, 51], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HLH462", "entity_2_idx": [[165, 171]], "entity_2_idx_in_text_with_entity_marker": [178, 184], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d193.s1647_AIMed.d193.s1647.p3", "text": "Further investigation indicated that the ITF-2b/MyoD heterodimer bound to its specific DNA binding site in vitro, and the DNA binding was effectively blocked by Id3/HLH462.", "text_with_entity_marker": "Further investigation indicated that the ITF-2b/[E1]MyoD[/E1] heterodimer bound to its specific DNA binding site in vitro, and the DNA binding was effectively blocked by [E2]Id3[/E2]/HLH462.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MyoD", "entity_1_idx": [[48, 52]], "entity_1_idx_in_text_with_entity_marker": [52, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Id3", "entity_2_idx": [[161, 164]], "entity_2_idx_in_text_with_entity_marker": [174, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d193.s1647_AIMed.d193.s1647.p4", "text": "Further investigation indicated that the ITF-2b/MyoD heterodimer bound to its specific DNA binding site in vitro, and the DNA binding was effectively blocked by Id3/HLH462.", "text_with_entity_marker": "Further investigation indicated that the ITF-2b/[E1]MyoD[/E1] heterodimer bound to its specific DNA binding site in vitro, and the DNA binding was effectively blocked by Id3/[E2]HLH462[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MyoD", "entity_1_idx": [[48, 52]], "entity_1_idx_in_text_with_entity_marker": [52, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HLH462", "entity_2_idx": [[165, 171]], "entity_2_idx_in_text_with_entity_marker": [178, 184], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d193.s1647_AIMed.d193.s1647.p5", "text": "Further investigation indicated that the ITF-2b/MyoD heterodimer bound to its specific DNA binding site in vitro, and the DNA binding was effectively blocked by Id3/HLH462.", "text_with_entity_marker": "Further investigation indicated that the ITF-2b/MyoD heterodimer bound to its specific DNA binding site in vitro, and the DNA binding was effectively blocked by [E1]Id3[/E1]/[E2]HLH462[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Id3", "entity_1_idx": [[161, 164]], "entity_1_idx_in_text_with_entity_marker": [165, 168], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HLH462", "entity_2_idx": [[165, 171]], "entity_2_idx_in_text_with_entity_marker": [178, 184], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d193.s1648_AIMed.d193.s1648.p0", "text": "Additional analysis revealed the presence of transcripts for both the activating (ITF-2a) and inhibitory (ITF-2b) isoforms in differentiating C2C12 cultures, suggesting that both isoforms might participate in regulating the differentiation process.", "text_with_entity_marker": "Additional analysis revealed the presence of transcripts for both the activating ([E1]ITF-2a[/E1]) and inhibitory ([E2]ITF-2b[/E2]) isoforms in differentiating C2C12 cultures, suggesting that both isoforms might participate in regulating the differentiation process.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ITF-2a", "entity_1_idx": [[82, 88]], "entity_1_idx_in_text_with_entity_marker": [86, 92], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ITF-2b", "entity_2_idx": [[106, 112]], "entity_2_idx_in_text_with_entity_marker": [119, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s256_AIMed.d31.s256.p0", "text": "A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis.", "text_with_entity_marker": "A newly identified member of tumor necrosis factor receptor superfamily ([E1]TR6[/E1]) suppresses [E2]LIGHT[/E2]-mediated apoptosis.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TR6", "entity_1_idx": [[73, 76]], "entity_1_idx_in_text_with_entity_marker": [77, 80], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LIGHT", "entity_2_idx": [[89, 94]], "entity_2_idx_in_text_with_entity_marker": [102, 107], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s257_AIMed.d31.s257.p0", "text": "TR6 (decoy receptor 3 (DcR3)) is a new member of the tumor necrosis factor receptor (TNFR) family.", "text_with_entity_marker": "[E1]TR6[/E1] ([E2]decoy receptor 3[/E2] (DcR3)) is a new member of the tumor necrosis factor receptor (TNFR) family.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TR6", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "decoy receptor 3", "entity_2_idx": [[5, 21]], "entity_2_idx_in_text_with_entity_marker": [18, 34], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s257_AIMed.d31.s257.p1", "text": "TR6 (decoy receptor 3 (DcR3)) is a new member of the tumor necrosis factor receptor (TNFR) family.", "text_with_entity_marker": "[E1]TR6[/E1] (decoy receptor 3 ([E2]DcR3[/E2])) is a new member of the tumor necrosis factor receptor (TNFR) family.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TR6", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "DcR3", "entity_2_idx": [[23, 27]], "entity_2_idx_in_text_with_entity_marker": [36, 40], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s257_AIMed.d31.s257.p2", "text": "TR6 (decoy receptor 3 (DcR3)) is a new member of the tumor necrosis factor receptor (TNFR) family.", "text_with_entity_marker": "TR6 ([E1]decoy receptor 3[/E1] ([E2]DcR3[/E2])) is a new member of the tumor necrosis factor receptor (TNFR) family.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "decoy receptor 3", "entity_1_idx": [[5, 21]], "entity_1_idx_in_text_with_entity_marker": [9, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "DcR3", "entity_2_idx": [[23, 27]], "entity_2_idx_in_text_with_entity_marker": [36, 40], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s262_AIMed.d31.s262.p0", "text": "Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).", "text_with_entity_marker": "Here, we demonstrate that [E1]TR6[/E1] specifically binds two cellular ligands, [E2]LIGHT[/E2] (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TR6", "entity_1_idx": [[26, 29]], "entity_1_idx_in_text_with_entity_marker": [30, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LIGHT", "entity_2_idx": [[71, 76]], "entity_2_idx_in_text_with_entity_marker": [84, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s262_AIMed.d31.s262.p1", "text": "Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).", "text_with_entity_marker": "Here, we demonstrate that [E1]TR6[/E1] specifically binds two cellular ligands, LIGHT (herpes virus entry mediator ([E2]HVEM[/E2])-L) and Fas ligand (FasL/CD95L).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TR6", "entity_1_idx": [[26, 29]], "entity_1_idx_in_text_with_entity_marker": [30, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HVEM", "entity_2_idx": [[107, 111]], "entity_2_idx_in_text_with_entity_marker": [120, 124], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s262_AIMed.d31.s262.p2", "text": "Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).", "text_with_entity_marker": "Here, we demonstrate that [E1]TR6[/E1] specifically binds two cellular ligands, LIGHT ([E2]herpes virus entry mediator (HVEM)-L[/E2]) and Fas ligand (FasL/CD95L).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TR6", "entity_1_idx": [[26, 29]], "entity_1_idx_in_text_with_entity_marker": [30, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "herpes virus entry mediator (HVEM)-L", "entity_2_idx": [[78, 114]], "entity_2_idx_in_text_with_entity_marker": [91, 127], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s262_AIMed.d31.s262.p3", "text": "Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).", "text_with_entity_marker": "Here, we demonstrate that [E1]TR6[/E1] specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and [E2]Fas ligand[/E2] (FasL/CD95L).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TR6", "entity_1_idx": [[26, 29]], "entity_1_idx_in_text_with_entity_marker": [30, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas ligand", "entity_2_idx": [[120, 130]], "entity_2_idx_in_text_with_entity_marker": [133, 143], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s262_AIMed.d31.s262.p4", "text": "Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).", "text_with_entity_marker": "Here, we demonstrate that [E1]TR6[/E1] specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand ([E2]FasL[/E2]/CD95L).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TR6", "entity_1_idx": [[26, 29]], "entity_1_idx_in_text_with_entity_marker": [30, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FasL", "entity_2_idx": [[132, 136]], "entity_2_idx_in_text_with_entity_marker": [145, 149], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s262_AIMed.d31.s262.p5", "text": "Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).", "text_with_entity_marker": "Here, we demonstrate that [E1]TR6[/E1] specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/[E2]CD95L[/E2]).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TR6", "entity_1_idx": [[26, 29]], "entity_1_idx_in_text_with_entity_marker": [30, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD95L", "entity_2_idx": [[137, 142]], "entity_2_idx_in_text_with_entity_marker": [150, 155], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s262_AIMed.d31.s262.p6", "text": "Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).", "text_with_entity_marker": "Here, we demonstrate that TR6 specifically binds two cellular ligands, [E1]LIGHT[/E1] (herpes virus entry mediator ([E2]HVEM[/E2])-L) and Fas ligand (FasL/CD95L).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LIGHT", "entity_1_idx": [[71, 76]], "entity_1_idx_in_text_with_entity_marker": [75, 80], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HVEM", "entity_2_idx": [[107, 111]], "entity_2_idx_in_text_with_entity_marker": [120, 124], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s262_AIMed.d31.s262.p7", "text": "Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).", "text_with_entity_marker": "Here, we demonstrate that TR6 specifically binds two cellular ligands, [E1]LIGHT[/E1] ([E2]herpes virus entry mediator (HVEM)-L[/E2]) and Fas ligand (FasL/CD95L).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LIGHT", "entity_1_idx": [[71, 76]], "entity_1_idx_in_text_with_entity_marker": [75, 80], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "herpes virus entry mediator (HVEM)-L", "entity_2_idx": [[78, 114]], "entity_2_idx_in_text_with_entity_marker": [91, 127], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s262_AIMed.d31.s262.p8", "text": "Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).", "text_with_entity_marker": "Here, we demonstrate that TR6 specifically binds two cellular ligands, [E1]LIGHT[/E1] (herpes virus entry mediator (HVEM)-L) and [E2]Fas ligand[/E2] (FasL/CD95L).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LIGHT", "entity_1_idx": [[71, 76]], "entity_1_idx_in_text_with_entity_marker": [75, 80], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas ligand", "entity_2_idx": [[120, 130]], "entity_2_idx_in_text_with_entity_marker": [133, 143], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s262_AIMed.d31.s262.p9", "text": "Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).", "text_with_entity_marker": "Here, we demonstrate that TR6 specifically binds two cellular ligands, [E1]LIGHT[/E1] (herpes virus entry mediator (HVEM)-L) and Fas ligand ([E2]FasL[/E2]/CD95L).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LIGHT", "entity_1_idx": [[71, 76]], "entity_1_idx_in_text_with_entity_marker": [75, 80], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FasL", "entity_2_idx": [[132, 136]], "entity_2_idx_in_text_with_entity_marker": [145, 149], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s262_AIMed.d31.s262.p10", "text": "Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).", "text_with_entity_marker": "Here, we demonstrate that TR6 specifically binds two cellular ligands, [E1]LIGHT[/E1] (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/[E2]CD95L[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LIGHT", "entity_1_idx": [[71, 76]], "entity_1_idx_in_text_with_entity_marker": [75, 80], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD95L", "entity_2_idx": [[137, 142]], "entity_2_idx_in_text_with_entity_marker": [150, 155], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s262_AIMed.d31.s262.p11", "text": "Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).", "text_with_entity_marker": "Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT ([E1]herpes virus entry mediator (HVEM)-L[/E1][E2]HVEM[/E2])-L) and Fas ligand (FasL/CD95L).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "herpes virus entry mediator (HVEM)-L", "entity_1_idx": [[78, 114]], "entity_1_idx_in_text_with_entity_marker": [82, 118], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HVEM", "entity_2_idx": [[107, 111]], "entity_2_idx_in_text_with_entity_marker": [127, 131], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s262_AIMed.d31.s262.p12", "text": "Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).", "text_with_entity_marker": "Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator ([E1]HVEM[/E1])-L) and [E2]Fas ligand[/E2] (FasL/CD95L).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HVEM", "entity_1_idx": [[107, 111]], "entity_1_idx_in_text_with_entity_marker": [111, 115], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas ligand", "entity_2_idx": [[120, 130]], "entity_2_idx_in_text_with_entity_marker": [133, 143], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s262_AIMed.d31.s262.p13", "text": "Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).", "text_with_entity_marker": "Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator ([E1]HVEM[/E1])-L) and Fas ligand ([E2]FasL[/E2]/CD95L).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HVEM", "entity_1_idx": [[107, 111]], "entity_1_idx_in_text_with_entity_marker": [111, 115], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FasL", "entity_2_idx": [[132, 136]], "entity_2_idx_in_text_with_entity_marker": [145, 149], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s262_AIMed.d31.s262.p14", "text": "Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).", "text_with_entity_marker": "Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator ([E1]HVEM[/E1])-L) and Fas ligand (FasL/[E2]CD95L[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HVEM", "entity_1_idx": [[107, 111]], "entity_1_idx_in_text_with_entity_marker": [111, 115], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD95L", "entity_2_idx": [[137, 142]], "entity_2_idx_in_text_with_entity_marker": [150, 155], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s262_AIMed.d31.s262.p15", "text": "Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).", "text_with_entity_marker": "Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT ([E1]herpes virus entry mediator (HVEM)-L[/E1]) and [E2]Fas ligand[/E2] (FasL/CD95L).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "herpes virus entry mediator (HVEM)-L", "entity_1_idx": [[78, 114]], "entity_1_idx_in_text_with_entity_marker": [82, 118], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas ligand", "entity_2_idx": [[120, 130]], "entity_2_idx_in_text_with_entity_marker": [133, 143], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s262_AIMed.d31.s262.p16", "text": "Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).", "text_with_entity_marker": "Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT ([E1]herpes virus entry mediator (HVEM)-L[/E1]) and Fas ligand ([E2]FasL[/E2]/CD95L).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "herpes virus entry mediator (HVEM)-L", "entity_1_idx": [[78, 114]], "entity_1_idx_in_text_with_entity_marker": [82, 118], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FasL", "entity_2_idx": [[132, 136]], "entity_2_idx_in_text_with_entity_marker": [145, 149], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s262_AIMed.d31.s262.p17", "text": "Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).", "text_with_entity_marker": "Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT ([E1]herpes virus entry mediator (HVEM)-L[/E1]) and Fas ligand (FasL/[E2]CD95L[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "herpes virus entry mediator (HVEM)-L", "entity_1_idx": [[78, 114]], "entity_1_idx_in_text_with_entity_marker": [82, 118], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD95L", "entity_2_idx": [[137, 142]], "entity_2_idx_in_text_with_entity_marker": [150, 155], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s262_AIMed.d31.s262.p18", "text": "Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).", "text_with_entity_marker": "Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and [E1]Fas ligand[/E1] ([E2]FasL[/E2]/CD95L).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas ligand", "entity_1_idx": [[120, 130]], "entity_1_idx_in_text_with_entity_marker": [124, 134], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FasL", "entity_2_idx": [[132, 136]], "entity_2_idx_in_text_with_entity_marker": [145, 149], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s262_AIMed.d31.s262.p19", "text": "Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).", "text_with_entity_marker": "Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and [E1]Fas ligand[/E1] (FasL/[E2]CD95L[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas ligand", "entity_1_idx": [[120, 130]], "entity_1_idx_in_text_with_entity_marker": [124, 134], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD95L", "entity_2_idx": [[137, 142]], "entity_2_idx_in_text_with_entity_marker": [150, 155], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s262_AIMed.d31.s262.p20", "text": "Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).", "text_with_entity_marker": "Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand ([E1]FasL[/E1]/[E2]CD95L[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FasL", "entity_1_idx": [[132, 136]], "entity_1_idx_in_text_with_entity_marker": [136, 140], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD95L", "entity_2_idx": [[137, 142]], "entity_2_idx_in_text_with_entity_marker": [150, 155], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s264_AIMed.d31.s264.p0", "text": "TR6 inhibited LIGHT-induced cytotoxicity in HT29 cells.", "text_with_entity_marker": "[E1]TR6[/E1] inhibited [E2]LIGHT[/E2]-induced cytotoxicity in HT29 cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TR6", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LIGHT", "entity_2_idx": [[14, 19]], "entity_2_idx_in_text_with_entity_marker": [27, 32], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s265_AIMed.d31.s265.p0", "text": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.", "text_with_entity_marker": "It has been shown that [E1]LIGHT[/E1] triggers apoptosis of various tumor cells including HT29 cells that express both [E2]lymphotoxin beta[/E2] receptor (LTbetaR) and HVEM/TR2 receptors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LIGHT", "entity_1_idx": [[23, 28]], "entity_1_idx_in_text_with_entity_marker": [27, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "lymphotoxin beta", "entity_2_idx": [[110, 126]], "entity_2_idx_in_text_with_entity_marker": [123, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s265_AIMed.d31.s265.p1", "text": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.", "text_with_entity_marker": "It has been shown that [E1]LIGHT[/E1] triggers apoptosis of various tumor cells including HT29 cells that express both [E2]lymphotoxin beta receptor[/E2] (LTbetaR) and HVEM/TR2 receptors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LIGHT", "entity_1_idx": [[23, 28]], "entity_1_idx_in_text_with_entity_marker": [27, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "lymphotoxin beta receptor", "entity_2_idx": [[110, 135]], "entity_2_idx_in_text_with_entity_marker": [123, 148], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s265_AIMed.d31.s265.p2", "text": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.", "text_with_entity_marker": "It has been shown that [E1]LIGHT[/E1] triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ([E2]LTbetaR[/E2]) and HVEM/TR2 receptors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LIGHT", "entity_1_idx": [[23, 28]], "entity_1_idx_in_text_with_entity_marker": [27, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LTbetaR", "entity_2_idx": [[137, 144]], "entity_2_idx_in_text_with_entity_marker": [150, 157], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s265_AIMed.d31.s265.p3", "text": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.", "text_with_entity_marker": "It has been shown that [E1]LIGHT[/E1] triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and [E2]HVEM[/E2]/TR2 receptors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LIGHT", "entity_1_idx": [[23, 28]], "entity_1_idx_in_text_with_entity_marker": [27, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HVEM", "entity_2_idx": [[150, 154]], "entity_2_idx_in_text_with_entity_marker": [163, 167], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s265_AIMed.d31.s265.p4", "text": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.", "text_with_entity_marker": "It has been shown that [E1]LIGHT[/E1] triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/[E2]TR2[/E2] receptors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LIGHT", "entity_1_idx": [[23, 28]], "entity_1_idx_in_text_with_entity_marker": [27, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TR2", "entity_2_idx": [[155, 158]], "entity_2_idx_in_text_with_entity_marker": [168, 171], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s265_AIMed.d31.s265.p5", "text": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.", "text_with_entity_marker": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both [E1-E2]lymphotoxin beta[/E1] receptor[/E2] (LTbetaR) and HVEM/TR2 receptors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "lymphotoxin beta", "entity_1_idx": [[110, 126]], "entity_1_idx_in_text_with_entity_marker": [117, 133], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "lymphotoxin beta[/E1] receptor", "entity_2_idx": [[110, 135]], "entity_2_idx_in_text_with_entity_marker": [117, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s265_AIMed.d31.s265.p6", "text": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.", "text_with_entity_marker": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both [E1]lymphotoxin beta[/E1] receptor ([E2]LTbetaR[/E2]) and HVEM/TR2 receptors.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "lymphotoxin beta", "entity_1_idx": [[110, 126]], "entity_1_idx_in_text_with_entity_marker": [114, 130], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LTbetaR", "entity_2_idx": [[137, 144]], "entity_2_idx_in_text_with_entity_marker": [150, 157], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s265_AIMed.d31.s265.p7", "text": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.", "text_with_entity_marker": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both [E1]lymphotoxin beta[/E1] receptor (LTbetaR) and [E2]HVEM[/E2]/TR2 receptors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "lymphotoxin beta", "entity_1_idx": [[110, 126]], "entity_1_idx_in_text_with_entity_marker": [114, 130], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HVEM", "entity_2_idx": [[150, 154]], "entity_2_idx_in_text_with_entity_marker": [163, 167], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s265_AIMed.d31.s265.p8", "text": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.", "text_with_entity_marker": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both [E1]lymphotoxin beta[/E1] receptor (LTbetaR) and HVEM/[E2]TR2[/E2] receptors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "lymphotoxin beta", "entity_1_idx": [[110, 126]], "entity_1_idx_in_text_with_entity_marker": [114, 130], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TR2", "entity_2_idx": [[155, 158]], "entity_2_idx_in_text_with_entity_marker": [168, 171], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s265_AIMed.d31.s265.p9", "text": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.", "text_with_entity_marker": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both [E1]lymphotoxin beta receptor[/E1] ([E2]LTbetaR[/E2]) and HVEM/TR2 receptors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "lymphotoxin beta receptor", "entity_1_idx": [[110, 135]], "entity_1_idx_in_text_with_entity_marker": [114, 139], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LTbetaR", "entity_2_idx": [[137, 144]], "entity_2_idx_in_text_with_entity_marker": [150, 157], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s265_AIMed.d31.s265.p10", "text": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.", "text_with_entity_marker": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both [E1]lymphotoxin beta receptor[/E1] (LTbetaR) and [E2]HVEM[/E2]/TR2 receptors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "lymphotoxin beta receptor", "entity_1_idx": [[110, 135]], "entity_1_idx_in_text_with_entity_marker": [114, 139], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HVEM", "entity_2_idx": [[150, 154]], "entity_2_idx_in_text_with_entity_marker": [163, 167], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s265_AIMed.d31.s265.p11", "text": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.", "text_with_entity_marker": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both [E1]lymphotoxin beta receptor[/E1] (LTbetaR) and HVEM/[E2]TR2[/E2] receptors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "lymphotoxin beta receptor", "entity_1_idx": [[110, 135]], "entity_1_idx_in_text_with_entity_marker": [114, 139], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TR2", "entity_2_idx": [[155, 158]], "entity_2_idx_in_text_with_entity_marker": [168, 171], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s265_AIMed.d31.s265.p12", "text": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.", "text_with_entity_marker": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ([E1]LTbetaR[/E1]) and [E2]HVEM[/E2]/TR2 receptors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LTbetaR", "entity_1_idx": [[137, 144]], "entity_1_idx_in_text_with_entity_marker": [141, 148], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HVEM", "entity_2_idx": [[150, 154]], "entity_2_idx_in_text_with_entity_marker": [163, 167], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s265_AIMed.d31.s265.p13", "text": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.", "text_with_entity_marker": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ([E1]LTbetaR[/E1]) and HVEM/[E2]TR2[/E2] receptors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LTbetaR", "entity_1_idx": [[137, 144]], "entity_1_idx_in_text_with_entity_marker": [141, 148], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TR2", "entity_2_idx": [[155, 158]], "entity_2_idx_in_text_with_entity_marker": [168, 171], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s265_AIMed.d31.s265.p14", "text": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.", "text_with_entity_marker": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and [E1]HVEM[/E1]/[E2]TR2[/E2] receptors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HVEM", "entity_1_idx": [[150, 154]], "entity_1_idx_in_text_with_entity_marker": [154, 158], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TR2", "entity_2_idx": [[155, 158]], "entity_2_idx_in_text_with_entity_marker": [168, 171], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s266_AIMed.d31.s266.p0", "text": "Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.", "text_with_entity_marker": "Our data suggest that [E1]TR6[/E1] inhibits the interactions of [E2]LIGHT[/E2] with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TR6", "entity_1_idx": [[22, 25]], "entity_1_idx_in_text_with_entity_marker": [26, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LIGHT", "entity_2_idx": [[55, 60]], "entity_2_idx_in_text_with_entity_marker": [68, 73], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s266_AIMed.d31.s266.p1", "text": "Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.", "text_with_entity_marker": "Our data suggest that [E1]TR6[/E1] inhibits the interactions of LIGHT with [E2]HVEM[/E2]/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TR6", "entity_1_idx": [[22, 25]], "entity_1_idx_in_text_with_entity_marker": [26, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HVEM", "entity_2_idx": [[66, 70]], "entity_2_idx_in_text_with_entity_marker": [79, 83], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s266_AIMed.d31.s266.p2", "text": "Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.", "text_with_entity_marker": "Our data suggest that [E1]TR6[/E1] inhibits the interactions of LIGHT with HVEM/[E2]TR2[/E2] and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TR6", "entity_1_idx": [[22, 25]], "entity_1_idx_in_text_with_entity_marker": [26, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TR2", "entity_2_idx": [[71, 74]], "entity_2_idx_in_text_with_entity_marker": [84, 87], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s266_AIMed.d31.s266.p3", "text": "Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.", "text_with_entity_marker": "Our data suggest that [E1]TR6[/E1] inhibits the interactions of LIGHT with HVEM/TR2 and [E2]LTbetaR[/E2], thereby suppressing LIGHT- mediated HT29 cell death.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TR6", "entity_1_idx": [[22, 25]], "entity_1_idx_in_text_with_entity_marker": [26, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LTbetaR", "entity_2_idx": [[79, 86]], "entity_2_idx_in_text_with_entity_marker": [92, 99], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s266_AIMed.d31.s266.p4", "text": "Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.", "text_with_entity_marker": "Our data suggest that [E1]TR6[/E1] inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing [E2]LIGHT[/E2]- mediated HT29 cell death.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TR6", "entity_1_idx": [[22, 25]], "entity_1_idx_in_text_with_entity_marker": [26, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LIGHT", "entity_2_idx": [[108, 113]], "entity_2_idx_in_text_with_entity_marker": [121, 126], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s266_AIMed.d31.s266.p5", "text": "Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.", "text_with_entity_marker": "Our data suggest that TR6 inhibits the interactions of [E1]LIGHT[/E1] with [E2]HVEM[/E2]/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "LIGHT", "entity_1_idx": [[55, 60]], "entity_1_idx_in_text_with_entity_marker": [59, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HVEM", "entity_2_idx": [[66, 70]], "entity_2_idx_in_text_with_entity_marker": [79, 83], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s266_AIMed.d31.s266.p6", "text": "Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.", "text_with_entity_marker": "Our data suggest that TR6 inhibits the interactions of [E1]LIGHT[/E1] with HVEM/[E2]TR2[/E2] and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "LIGHT", "entity_1_idx": [[55, 60]], "entity_1_idx_in_text_with_entity_marker": [59, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TR2", "entity_2_idx": [[71, 74]], "entity_2_idx_in_text_with_entity_marker": [84, 87], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s266_AIMed.d31.s266.p7", "text": "Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.", "text_with_entity_marker": "Our data suggest that TR6 inhibits the interactions of [E1]LIGHT[/E1] with HVEM/TR2 and [E2]LTbetaR[/E2], thereby suppressing LIGHT- mediated HT29 cell death.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "LIGHT", "entity_1_idx": [[55, 60]], "entity_1_idx_in_text_with_entity_marker": [59, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LTbetaR", "entity_2_idx": [[79, 86]], "entity_2_idx_in_text_with_entity_marker": [92, 99], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s266_AIMed.d31.s266.p8", "text": "Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.", "text_with_entity_marker": "Our data suggest that TR6 inhibits the interactions of [E1]LIGHT[/E1] with HVEM/TR2 and LTbetaR, thereby suppressing [E2]LIGHT[/E2]- mediated HT29 cell death.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LIGHT", "entity_1_idx": [[55, 60]], "entity_1_idx_in_text_with_entity_marker": [59, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LIGHT", "entity_2_idx": [[108, 113]], "entity_2_idx_in_text_with_entity_marker": [121, 126], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s266_AIMed.d31.s266.p9", "text": "Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.", "text_with_entity_marker": "Our data suggest that TR6 inhibits the interactions of LIGHT with [E1]HVEM[/E1]/[E2]TR2[/E2] and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HVEM", "entity_1_idx": [[66, 70]], "entity_1_idx_in_text_with_entity_marker": [70, 74], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TR2", "entity_2_idx": [[71, 74]], "entity_2_idx_in_text_with_entity_marker": [84, 87], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s266_AIMed.d31.s266.p10", "text": "Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.", "text_with_entity_marker": "Our data suggest that TR6 inhibits the interactions of LIGHT with [E1]HVEM[/E1]/TR2 and [E2]LTbetaR[/E2], thereby suppressing LIGHT- mediated HT29 cell death.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HVEM", "entity_1_idx": [[66, 70]], "entity_1_idx_in_text_with_entity_marker": [70, 74], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LTbetaR", "entity_2_idx": [[79, 86]], "entity_2_idx_in_text_with_entity_marker": [92, 99], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s266_AIMed.d31.s266.p11", "text": "Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.", "text_with_entity_marker": "Our data suggest that TR6 inhibits the interactions of LIGHT with [E1]HVEM[/E1]/TR2 and LTbetaR, thereby suppressing [E2]LIGHT[/E2]- mediated HT29 cell death.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HVEM", "entity_1_idx": [[66, 70]], "entity_1_idx_in_text_with_entity_marker": [70, 74], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LIGHT", "entity_2_idx": [[108, 113]], "entity_2_idx_in_text_with_entity_marker": [121, 126], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s266_AIMed.d31.s266.p12", "text": "Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.", "text_with_entity_marker": "Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/[E1]TR2[/E1] and [E2]LTbetaR[/E2], thereby suppressing LIGHT- mediated HT29 cell death.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TR2", "entity_1_idx": [[71, 74]], "entity_1_idx_in_text_with_entity_marker": [75, 78], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LTbetaR", "entity_2_idx": [[79, 86]], "entity_2_idx_in_text_with_entity_marker": [92, 99], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s266_AIMed.d31.s266.p13", "text": "Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.", "text_with_entity_marker": "Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/[E1]TR2[/E1] and LTbetaR, thereby suppressing [E2]LIGHT[/E2]- mediated HT29 cell death.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TR2", "entity_1_idx": [[71, 74]], "entity_1_idx_in_text_with_entity_marker": [75, 78], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LIGHT", "entity_2_idx": [[108, 113]], "entity_2_idx_in_text_with_entity_marker": [121, 126], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s266_AIMed.d31.s266.p14", "text": "Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.", "text_with_entity_marker": "Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and [E1]LTbetaR[/E1], thereby suppressing [E2]LIGHT[/E2]- mediated HT29 cell death.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LTbetaR", "entity_1_idx": [[79, 86]], "entity_1_idx_in_text_with_entity_marker": [83, 90], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LIGHT", "entity_2_idx": [[108, 113]], "entity_2_idx_in_text_with_entity_marker": [121, 126], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s267_AIMed.d31.s267.p0", "text": "Thus, TR6 may play a regulatory role for suppressing in FasL- and LIGHT-mediated cell death.", "text_with_entity_marker": "Thus, [E1]TR6[/E1] may play a regulatory role for suppressing in [E2]FasL[/E2]- and LIGHT-mediated cell death.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TR6", "entity_1_idx": [[6, 9]], "entity_1_idx_in_text_with_entity_marker": [10, 13], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FasL", "entity_2_idx": [[56, 60]], "entity_2_idx_in_text_with_entity_marker": [69, 73], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s267_AIMed.d31.s267.p1", "text": "Thus, TR6 may play a regulatory role for suppressing in FasL- and LIGHT-mediated cell death.", "text_with_entity_marker": "Thus, [E1]TR6[/E1] may play a regulatory role for suppressing in FasL- and [E2]LIGHT[/E2]-mediated cell death.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TR6", "entity_1_idx": [[6, 9]], "entity_1_idx_in_text_with_entity_marker": [10, 13], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LIGHT", "entity_2_idx": [[66, 71]], "entity_2_idx_in_text_with_entity_marker": [79, 84], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s267_AIMed.d31.s267.p2", "text": "Thus, TR6 may play a regulatory role for suppressing in FasL- and LIGHT-mediated cell death.", "text_with_entity_marker": "Thus, TR6 may play a regulatory role for suppressing in [E1]FasL[/E1]- and [E2]LIGHT[/E2]-mediated cell death.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FasL", "entity_1_idx": [[56, 60]], "entity_1_idx_in_text_with_entity_marker": [60, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LIGHT", "entity_2_idx": [[66, 71]], "entity_2_idx_in_text_with_entity_marker": [79, 84], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d52.s464_AIMed.d52.s464.p0", "text": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "text_with_entity_marker": "We show that the S252W mutation allows the mesenchymal splice form of [E1]FGFR2[/E1] ([E2]FGFR2c[/E2]) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR2", "entity_1_idx": [[70, 75]], "entity_1_idx_in_text_with_entity_marker": [74, 79], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR2c", "entity_2_idx": [[77, 83]], "entity_2_idx_in_text_with_entity_marker": [90, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d52.s464_AIMed.d52.s464.p1", "text": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "text_with_entity_marker": "We show that the S252W mutation allows the mesenchymal splice form of [E1]FGFR2[/E1] (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands [E2]FGF7[/E2] or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR2", "entity_1_idx": [[70, 75]], "entity_1_idx_in_text_with_entity_marker": [74, 79], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF7", "entity_2_idx": [[152, 156]], "entity_2_idx_in_text_with_entity_marker": [165, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d52.s464_AIMed.d52.s464.p2", "text": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "text_with_entity_marker": "We show that the S252W mutation allows the mesenchymal splice form of [E1]FGFR2[/E1] (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or [E2]FGF10[/E2] and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR2", "entity_1_idx": [[70, 75]], "entity_1_idx_in_text_with_entity_marker": [74, 79], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF10", "entity_2_idx": [[160, 165]], "entity_2_idx_in_text_with_entity_marker": [173, 178], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d52.s464_AIMed.d52.s464.p3", "text": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "text_with_entity_marker": "We show that the S252W mutation allows the mesenchymal splice form of [E1]FGFR2[/E1] (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of [E2]FGFR2[/E2] (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR2", "entity_1_idx": [[70, 75]], "entity_1_idx_in_text_with_entity_marker": [74, 79], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR2", "entity_2_idx": [[200, 205]], "entity_2_idx_in_text_with_entity_marker": [213, 218], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d52.s464_AIMed.d52.s464.p4", "text": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "text_with_entity_marker": "We show that the S252W mutation allows the mesenchymal splice form of [E1]FGFR2[/E1] (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 ([E2]FGFR2b[/E2]) to be activated by FGF2, FGF6, and FGF9.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR2", "entity_1_idx": [[70, 75]], "entity_1_idx_in_text_with_entity_marker": [74, 79], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR2b", "entity_2_idx": [[207, 213]], "entity_2_idx_in_text_with_entity_marker": [220, 226], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d52.s464_AIMed.d52.s464.p5", "text": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "text_with_entity_marker": "We show that the S252W mutation allows the mesenchymal splice form of [E1]FGFR2[/E1] (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by [E2]FGF2[/E2], FGF6, and FGF9.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR2", "entity_1_idx": [[70, 75]], "entity_1_idx_in_text_with_entity_marker": [74, 79], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF2", "entity_2_idx": [[234, 238]], "entity_2_idx_in_text_with_entity_marker": [247, 251], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d52.s464_AIMed.d52.s464.p6", "text": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "text_with_entity_marker": "We show that the S252W mutation allows the mesenchymal splice form of [E1]FGFR2[/E1] (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, [E2]FGF6[/E2], and FGF9.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR2", "entity_1_idx": [[70, 75]], "entity_1_idx_in_text_with_entity_marker": [74, 79], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF6", "entity_2_idx": [[240, 244]], "entity_2_idx_in_text_with_entity_marker": [253, 257], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d52.s464_AIMed.d52.s464.p7", "text": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "text_with_entity_marker": "We show that the S252W mutation allows the mesenchymal splice form of [E1]FGFR2[/E1] (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and [E2]FGF9[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR2", "entity_1_idx": [[70, 75]], "entity_1_idx_in_text_with_entity_marker": [74, 79], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF9", "entity_2_idx": [[250, 254]], "entity_2_idx_in_text_with_entity_marker": [263, 267], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d52.s464_AIMed.d52.s464.p8", "text": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "text_with_entity_marker": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ([E1]FGFR2c[/E1]) to bind and to be activated by the mesenchymally expressed ligands [E2]FGF7[/E2] or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FGFR2c", "entity_1_idx": [[77, 83]], "entity_1_idx_in_text_with_entity_marker": [81, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF7", "entity_2_idx": [[152, 156]], "entity_2_idx_in_text_with_entity_marker": [165, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d52.s464_AIMed.d52.s464.p9", "text": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "text_with_entity_marker": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ([E1]FGFR2c[/E1]) to bind and to be activated by the mesenchymally expressed ligands FGF7 or [E2]FGF10[/E2] and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FGFR2c", "entity_1_idx": [[77, 83]], "entity_1_idx_in_text_with_entity_marker": [81, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF10", "entity_2_idx": [[160, 165]], "entity_2_idx_in_text_with_entity_marker": [173, 178], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d52.s464_AIMed.d52.s464.p10", "text": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "text_with_entity_marker": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ([E1]FGFR2c[/E1]) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of [E2]FGFR2[/E2] (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR2c", "entity_1_idx": [[77, 83]], "entity_1_idx_in_text_with_entity_marker": [81, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR2", "entity_2_idx": [[200, 205]], "entity_2_idx_in_text_with_entity_marker": [213, 218], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d52.s464_AIMed.d52.s464.p11", "text": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "text_with_entity_marker": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ([E1]FGFR2c[/E1]) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 ([E2]FGFR2b[/E2]) to be activated by FGF2, FGF6, and FGF9.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR2c", "entity_1_idx": [[77, 83]], "entity_1_idx_in_text_with_entity_marker": [81, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR2b", "entity_2_idx": [[207, 213]], "entity_2_idx_in_text_with_entity_marker": [220, 226], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d52.s464_AIMed.d52.s464.p12", "text": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "text_with_entity_marker": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ([E1]FGFR2c[/E1]) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by [E2]FGF2[/E2], FGF6, and FGF9.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR2c", "entity_1_idx": [[77, 83]], "entity_1_idx_in_text_with_entity_marker": [81, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF2", "entity_2_idx": [[234, 238]], "entity_2_idx_in_text_with_entity_marker": [247, 251], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d52.s464_AIMed.d52.s464.p13", "text": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "text_with_entity_marker": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ([E1]FGFR2c[/E1]) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, [E2]FGF6[/E2], and FGF9.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR2c", "entity_1_idx": [[77, 83]], "entity_1_idx_in_text_with_entity_marker": [81, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF6", "entity_2_idx": [[240, 244]], "entity_2_idx_in_text_with_entity_marker": [253, 257], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d52.s464_AIMed.d52.s464.p14", "text": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "text_with_entity_marker": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ([E1]FGFR2c[/E1]) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and [E2]FGF9[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR2c", "entity_1_idx": [[77, 83]], "entity_1_idx_in_text_with_entity_marker": [81, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF9", "entity_2_idx": [[250, 254]], "entity_2_idx_in_text_with_entity_marker": [263, 267], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d52.s464_AIMed.d52.s464.p15", "text": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "text_with_entity_marker": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands [E1]FGF7[/E1] or [E2]FGF10[/E2] and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGF7", "entity_1_idx": [[152, 156]], "entity_1_idx_in_text_with_entity_marker": [156, 160], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF10", "entity_2_idx": [[160, 165]], "entity_2_idx_in_text_with_entity_marker": [173, 178], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d52.s464_AIMed.d52.s464.p16", "text": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "text_with_entity_marker": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands [E1]FGF7[/E1] or FGF10 and the epithelial splice form of [E2]FGFR2[/E2] (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGF7", "entity_1_idx": [[152, 156]], "entity_1_idx_in_text_with_entity_marker": [156, 160], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR2", "entity_2_idx": [[200, 205]], "entity_2_idx_in_text_with_entity_marker": [213, 218], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d52.s464_AIMed.d52.s464.p17", "text": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "text_with_entity_marker": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands [E1]FGF7[/E1] or FGF10 and the epithelial splice form of FGFR2 ([E2]FGFR2b[/E2]) to be activated by FGF2, FGF6, and FGF9.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGF7", "entity_1_idx": [[152, 156]], "entity_1_idx_in_text_with_entity_marker": [156, 160], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR2b", "entity_2_idx": [[207, 213]], "entity_2_idx_in_text_with_entity_marker": [220, 226], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d52.s464_AIMed.d52.s464.p18", "text": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "text_with_entity_marker": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands [E1]FGF7[/E1] or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by [E2]FGF2[/E2], FGF6, and FGF9.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGF7", "entity_1_idx": [[152, 156]], "entity_1_idx_in_text_with_entity_marker": [156, 160], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF2", "entity_2_idx": [[234, 238]], "entity_2_idx_in_text_with_entity_marker": [247, 251], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d52.s464_AIMed.d52.s464.p19", "text": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "text_with_entity_marker": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands [E1]FGF7[/E1] or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, [E2]FGF6[/E2], and FGF9.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGF7", "entity_1_idx": [[152, 156]], "entity_1_idx_in_text_with_entity_marker": [156, 160], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF6", "entity_2_idx": [[240, 244]], "entity_2_idx_in_text_with_entity_marker": [253, 257], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d52.s464_AIMed.d52.s464.p20", "text": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "text_with_entity_marker": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands [E1]FGF7[/E1] or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and [E2]FGF9[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGF7", "entity_1_idx": [[152, 156]], "entity_1_idx_in_text_with_entity_marker": [156, 160], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF9", "entity_2_idx": [[250, 254]], "entity_2_idx_in_text_with_entity_marker": [263, 267], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d52.s464_AIMed.d52.s464.p21", "text": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "text_with_entity_marker": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or [E1]FGF10[/E1] and the epithelial splice form of [E2]FGFR2[/E2] (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGF10", "entity_1_idx": [[160, 165]], "entity_1_idx_in_text_with_entity_marker": [164, 169], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR2", "entity_2_idx": [[200, 205]], "entity_2_idx_in_text_with_entity_marker": [213, 218], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d52.s464_AIMed.d52.s464.p22", "text": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "text_with_entity_marker": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or [E1]FGF10[/E1] and the epithelial splice form of FGFR2 ([E2]FGFR2b[/E2]) to be activated by FGF2, FGF6, and FGF9.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGF10", "entity_1_idx": [[160, 165]], "entity_1_idx_in_text_with_entity_marker": [164, 169], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR2b", "entity_2_idx": [[207, 213]], "entity_2_idx_in_text_with_entity_marker": [220, 226], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d52.s464_AIMed.d52.s464.p23", "text": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "text_with_entity_marker": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or [E1]FGF10[/E1] and the epithelial splice form of FGFR2 (FGFR2b) to be activated by [E2]FGF2[/E2], FGF6, and FGF9.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGF10", "entity_1_idx": [[160, 165]], "entity_1_idx_in_text_with_entity_marker": [164, 169], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF2", "entity_2_idx": [[234, 238]], "entity_2_idx_in_text_with_entity_marker": [247, 251], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d52.s464_AIMed.d52.s464.p24", "text": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "text_with_entity_marker": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or [E1]FGF10[/E1] and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, [E2]FGF6[/E2], and FGF9.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGF10", "entity_1_idx": [[160, 165]], "entity_1_idx_in_text_with_entity_marker": [164, 169], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF6", "entity_2_idx": [[240, 244]], "entity_2_idx_in_text_with_entity_marker": [253, 257], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d52.s464_AIMed.d52.s464.p25", "text": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "text_with_entity_marker": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or [E1]FGF10[/E1] and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and [E2]FGF9[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGF10", "entity_1_idx": [[160, 165]], "entity_1_idx_in_text_with_entity_marker": [164, 169], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF9", "entity_2_idx": [[250, 254]], "entity_2_idx_in_text_with_entity_marker": [263, 267], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d52.s464_AIMed.d52.s464.p26", "text": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "text_with_entity_marker": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of [E1]FGFR2[/E1] ([E2]FGFR2b[/E2]) to be activated by FGF2, FGF6, and FGF9.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR2", "entity_1_idx": [[200, 205]], "entity_1_idx_in_text_with_entity_marker": [204, 209], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR2b", "entity_2_idx": [[207, 213]], "entity_2_idx_in_text_with_entity_marker": [220, 226], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d52.s464_AIMed.d52.s464.p27", "text": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "text_with_entity_marker": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of [E1]FGFR2[/E1] (FGFR2b) to be activated by [E2]FGF2[/E2], FGF6, and FGF9.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR2", "entity_1_idx": [[200, 205]], "entity_1_idx_in_text_with_entity_marker": [204, 209], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF2", "entity_2_idx": [[234, 238]], "entity_2_idx_in_text_with_entity_marker": [247, 251], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d52.s464_AIMed.d52.s464.p28", "text": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "text_with_entity_marker": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of [E1]FGFR2[/E1] (FGFR2b) to be activated by FGF2, [E2]FGF6[/E2], and FGF9.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR2", "entity_1_idx": [[200, 205]], "entity_1_idx_in_text_with_entity_marker": [204, 209], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF6", "entity_2_idx": [[240, 244]], "entity_2_idx_in_text_with_entity_marker": [253, 257], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d52.s464_AIMed.d52.s464.p29", "text": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "text_with_entity_marker": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of [E1]FGFR2[/E1] (FGFR2b) to be activated by FGF2, FGF6, and [E2]FGF9[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR2", "entity_1_idx": [[200, 205]], "entity_1_idx_in_text_with_entity_marker": [204, 209], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF9", "entity_2_idx": [[250, 254]], "entity_2_idx_in_text_with_entity_marker": [263, 267], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d52.s464_AIMed.d52.s464.p30", "text": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "text_with_entity_marker": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 ([E1]FGFR2b[/E1]) to be activated by [E2]FGF2[/E2], FGF6, and FGF9.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FGFR2b", "entity_1_idx": [[207, 213]], "entity_1_idx_in_text_with_entity_marker": [211, 217], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF2", "entity_2_idx": [[234, 238]], "entity_2_idx_in_text_with_entity_marker": [247, 251], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d52.s464_AIMed.d52.s464.p31", "text": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "text_with_entity_marker": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 ([E1]FGFR2b[/E1]) to be activated by FGF2, [E2]FGF6[/E2], and FGF9.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FGFR2b", "entity_1_idx": [[207, 213]], "entity_1_idx_in_text_with_entity_marker": [211, 217], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF6", "entity_2_idx": [[240, 244]], "entity_2_idx_in_text_with_entity_marker": [253, 257], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d52.s464_AIMed.d52.s464.p32", "text": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "text_with_entity_marker": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 ([E1]FGFR2b[/E1]) to be activated by FGF2, FGF6, and [E2]FGF9[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FGFR2b", "entity_1_idx": [[207, 213]], "entity_1_idx_in_text_with_entity_marker": [211, 217], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF9", "entity_2_idx": [[250, 254]], "entity_2_idx_in_text_with_entity_marker": [263, 267], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d52.s464_AIMed.d52.s464.p33", "text": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "text_with_entity_marker": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by [E1]FGF2[/E1], [E2]FGF6[/E2], and FGF9.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGF2", "entity_1_idx": [[234, 238]], "entity_1_idx_in_text_with_entity_marker": [238, 242], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF6", "entity_2_idx": [[240, 244]], "entity_2_idx_in_text_with_entity_marker": [253, 257], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d52.s464_AIMed.d52.s464.p34", "text": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "text_with_entity_marker": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by [E1]FGF2[/E1], FGF6, and [E2]FGF9[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGF2", "entity_1_idx": [[234, 238]], "entity_1_idx_in_text_with_entity_marker": [238, 242], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF9", "entity_2_idx": [[250, 254]], "entity_2_idx_in_text_with_entity_marker": [263, 267], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d52.s464_AIMed.d52.s464.p35", "text": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9.", "text_with_entity_marker": "We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, [E1]FGF6[/E1], and [E2]FGF9[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGF6", "entity_1_idx": [[240, 244]], "entity_1_idx_in_text_with_entity_marker": [244, 248], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF9", "entity_2_idx": [[250, 254]], "entity_2_idx_in_text_with_entity_marker": [263, 267], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d162.s1367_AIMed.d162.s1367.p0", "text": "We found that the human TR subtype beta 1 (h-TR beta 1) physically interacted with p53 via its DNA binding domain.", "text_with_entity_marker": "We found that the human [E1]TR subtype beta 1[/E1] ([E2]h-TR beta 1[/E2]) physically interacted with p53 via its DNA binding domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TR subtype beta 1", "entity_1_idx": [[24, 41]], "entity_1_idx_in_text_with_entity_marker": [28, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "h-TR beta 1", "entity_2_idx": [[43, 54]], "entity_2_idx_in_text_with_entity_marker": [56, 67], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d162.s1367_AIMed.d162.s1367.p1", "text": "We found that the human TR subtype beta 1 (h-TR beta 1) physically interacted with p53 via its DNA binding domain.", "text_with_entity_marker": "We found that the human [E1]TR subtype beta 1[/E1] (h-TR beta 1) physically interacted with [E2]p53[/E2] via its DNA binding domain.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TR subtype beta 1", "entity_1_idx": [[24, 41]], "entity_1_idx_in_text_with_entity_marker": [28, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[83, 86]], "entity_2_idx_in_text_with_entity_marker": [96, 99], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d162.s1367_AIMed.d162.s1367.p2", "text": "We found that the human TR subtype beta 1 (h-TR beta 1) physically interacted with p53 via its DNA binding domain.", "text_with_entity_marker": "We found that the human TR subtype beta 1 ([E1]h-TR beta 1[/E1]) physically interacted with [E2]p53[/E2] via its DNA binding domain.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "h-TR beta 1", "entity_1_idx": [[43, 54]], "entity_1_idx_in_text_with_entity_marker": [47, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[83, 86]], "entity_2_idx_in_text_with_entity_marker": [96, 99], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d162.s1368_AIMed.d162.s1368.p0", "text": "As a result of this physical interaction, binding of h-TR beta 1 to its hormone response elements either as homodimer or as a heterodimer with the retinoic X receptor was inhibited by p53 in a concentration-dependent manner.", "text_with_entity_marker": "As a result of this physical interaction, binding of [E1]h-TR beta 1[/E1] to its hormone response elements either as homodimer or as a heterodimer with the [E2]retinoic X receptor[/E2] was inhibited by p53 in a concentration-dependent manner.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "h-TR beta 1", "entity_1_idx": [[53, 64]], "entity_1_idx_in_text_with_entity_marker": [57, 68], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "retinoic X receptor", "entity_2_idx": [[147, 166]], "entity_2_idx_in_text_with_entity_marker": [160, 179], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d162.s1368_AIMed.d162.s1368.p1", "text": "As a result of this physical interaction, binding of h-TR beta 1 to its hormone response elements either as homodimer or as a heterodimer with the retinoic X receptor was inhibited by p53 in a concentration-dependent manner.", "text_with_entity_marker": "As a result of this physical interaction, binding of [E1]h-TR beta 1[/E1] to its hormone response elements either as homodimer or as a heterodimer with the retinoic X receptor was inhibited by [E2]p53[/E2] in a concentration-dependent manner.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "h-TR beta 1", "entity_1_idx": [[53, 64]], "entity_1_idx_in_text_with_entity_marker": [57, 68], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[184, 187]], "entity_2_idx_in_text_with_entity_marker": [197, 200], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d162.s1368_AIMed.d162.s1368.p2", "text": "As a result of this physical interaction, binding of h-TR beta 1 to its hormone response elements either as homodimer or as a heterodimer with the retinoic X receptor was inhibited by p53 in a concentration-dependent manner.", "text_with_entity_marker": "As a result of this physical interaction, binding of h-TR beta 1 to its hormone response elements either as homodimer or as a heterodimer with the [E1]retinoic X receptor[/E1] was inhibited by [E2]p53[/E2] in a concentration-dependent manner.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "retinoic X receptor", "entity_1_idx": [[147, 166]], "entity_1_idx_in_text_with_entity_marker": [151, 170], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[184, 187]], "entity_2_idx_in_text_with_entity_marker": [197, 200], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d162.s1369_AIMed.d162.s1369.p0", "text": "In transfected cells, wild-type p53 repressed the hormone-dependent transcriptional activation of h-TR beta 1.", "text_with_entity_marker": "In transfected cells, wild-type [E1]p53[/E1] repressed the hormone-dependent transcriptional activation of [E2]h-TR beta 1[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p53", "entity_1_idx": [[32, 35]], "entity_1_idx_in_text_with_entity_marker": [36, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "h-TR beta 1", "entity_2_idx": [[98, 109]], "entity_2_idx_in_text_with_entity_marker": [111, 122], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d162.s1370_AIMed.d162.s1370.p0", "text": "In contrast, mutant p53 either had no effect or activated the transcriptional activity of h-TR beta 1 depending on the type of hormone response elements.", "text_with_entity_marker": "In contrast, mutant [E1]p53[/E1] either had no effect or activated the transcriptional activity of [E2]h-TR beta 1[/E2] depending on the type of hormone response elements.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[20, 23]], "entity_1_idx_in_text_with_entity_marker": [24, 27], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "h-TR beta 1", "entity_2_idx": [[90, 101]], "entity_2_idx_in_text_with_entity_marker": [103, 114], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d50.s441_AIMed.d50.s441.p0", "text": "Type I interferons bind to two cell surface receptors, ifnar1 and ifnar2, as the first step in the activation of several signal transduction pathways that elicit an anti-viral state and an anti-proliferative response.", "text_with_entity_marker": "Type I interferons bind to two cell surface receptors, [E1]ifnar1[/E1] and [E2]ifnar2[/E2], as the first step in the activation of several signal transduction pathways that elicit an anti-viral state and an anti-proliferative response.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ifnar1", "entity_1_idx": [[55, 61]], "entity_1_idx_in_text_with_entity_marker": [59, 65], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ifnar2", "entity_2_idx": [[66, 72]], "entity_2_idx_in_text_with_entity_marker": [79, 85], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d50.s442_AIMed.d50.s442.p0", "text": "Here, we quantitatively mapped the complete binding region of ifnar2 on interferon (IFN)alpha2 by 35 individual mutations to alanine and isosteric residues.", "text_with_entity_marker": "Here, we quantitatively mapped the complete binding region of [E1]ifnar2[/E1] on [E2]interferon (IFN)alpha2[/E2] by 35 individual mutations to alanine and isosteric residues.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "ifnar2", "entity_1_idx": [[62, 68]], "entity_1_idx_in_text_with_entity_marker": [66, 72], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interferon (IFN)alpha2", "entity_2_idx": [[72, 94]], "entity_2_idx_in_text_with_entity_marker": [85, 107], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d50.s445_AIMed.d50.s445.p0", "text": "Interestingly, the ifnar2 binding site overlaps the largest continuous hydrophobic patch on IFNalpha2.", "text_with_entity_marker": "Interestingly, the [E1]ifnar2[/E1] binding site overlaps the largest continuous hydrophobic patch on [E2]IFNalpha2[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "ifnar2", "entity_1_idx": [[19, 25]], "entity_1_idx_in_text_with_entity_marker": [23, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFNalpha2", "entity_2_idx": [[92, 101]], "entity_2_idx_in_text_with_entity_marker": [105, 114], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d50.s447_AIMed.d50.s447.p0", "text": "Relating the anti-viral and anti-proliferative activity of the various interferon mutants with their affinity toward ifnar2 results in linear function over the whole range of affinities investigated, suggesting that ifnar2 binding is the rate-determining step in cellular activation.", "text_with_entity_marker": "Relating the anti-viral and anti-proliferative activity of the various interferon mutants with their affinity toward [E1]ifnar2[/E1] results in linear function over the whole range of affinities investigated, suggesting that [E2]ifnar2[/E2] binding is the rate-determining step in cellular activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ifnar2", "entity_1_idx": [[117, 123]], "entity_1_idx_in_text_with_entity_marker": [121, 127], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ifnar2", "entity_2_idx": [[216, 222]], "entity_2_idx_in_text_with_entity_marker": [229, 235], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s268_AIMed.d32.s268.p0", "text": "Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide.", "text_with_entity_marker": "Shared and unique determinants of the [E1]erythropoietin[/E1] ([E2]EPO[/E2]) receptor are important for binding EPO and EPO mimetic peptide.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "erythropoietin", "entity_1_idx": [[38, 52]], "entity_1_idx_in_text_with_entity_marker": [42, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[54, 57]], "entity_2_idx_in_text_with_entity_marker": [67, 70], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s268_AIMed.d32.s268.p1", "text": "Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide.", "text_with_entity_marker": "Shared and unique determinants of the [E1-E2]erythropoietin[/E1] (EPO) receptor[/E2] are important for binding EPO and EPO mimetic peptide.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "erythropoietin", "entity_1_idx": [[38, 52]], "entity_1_idx_in_text_with_entity_marker": [45, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "erythropoietin[/E1] (EPO) receptor", "entity_2_idx": [[38, 67]], "entity_2_idx_in_text_with_entity_marker": [45, 79], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s268_AIMed.d32.s268.p2", "text": "Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide.", "text_with_entity_marker": "Shared and unique determinants of the [E1]erythropoietin[/E1] (EPO) receptor are important for binding [E2]EPO[/E2] and EPO mimetic peptide.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "erythropoietin", "entity_1_idx": [[38, 52]], "entity_1_idx_in_text_with_entity_marker": [42, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[94, 97]], "entity_2_idx_in_text_with_entity_marker": [107, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s268_AIMed.d32.s268.p3", "text": "Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide.", "text_with_entity_marker": "Shared and unique determinants of the [E1]erythropoietin[/E1] (EPO) receptor are important for binding EPO and [E2]EPO[/E2] mimetic peptide.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "erythropoietin", "entity_1_idx": [[38, 52]], "entity_1_idx_in_text_with_entity_marker": [42, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[102, 105]], "entity_2_idx_in_text_with_entity_marker": [115, 118], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s268_AIMed.d32.s268.p4", "text": "Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide.", "text_with_entity_marker": "Shared and unique determinants of the [E1]erythropoietin[/E1] (EPO) receptor are important for binding EPO and [E2]EPO mimetic peptide[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "erythropoietin", "entity_1_idx": [[38, 52]], "entity_1_idx_in_text_with_entity_marker": [42, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO mimetic peptide", "entity_2_idx": [[102, 121]], "entity_2_idx_in_text_with_entity_marker": [115, 134], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s268_AIMed.d32.s268.p5", "text": "Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide.", "text_with_entity_marker": "Shared and unique determinants of the [E1]erythropoietin (EPO) receptor[/E1][E2]EPO[/E2]) receptor are important for binding EPO and EPO mimetic peptide.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "erythropoietin (EPO) receptor", "entity_1_idx": [[38, 67]], "entity_1_idx_in_text_with_entity_marker": [42, 71], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[54, 57]], "entity_2_idx_in_text_with_entity_marker": [80, 83], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s268_AIMed.d32.s268.p6", "text": "Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide.", "text_with_entity_marker": "Shared and unique determinants of the erythropoietin ([E1]EPO[/E1]) receptor are important for binding [E2]EPO[/E2] and EPO mimetic peptide.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPO", "entity_1_idx": [[54, 57]], "entity_1_idx_in_text_with_entity_marker": [58, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[94, 97]], "entity_2_idx_in_text_with_entity_marker": [107, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s268_AIMed.d32.s268.p7", "text": "Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide.", "text_with_entity_marker": "Shared and unique determinants of the erythropoietin ([E1]EPO[/E1]) receptor are important for binding EPO and [E2]EPO[/E2] mimetic peptide.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPO", "entity_1_idx": [[54, 57]], "entity_1_idx_in_text_with_entity_marker": [58, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[102, 105]], "entity_2_idx_in_text_with_entity_marker": [115, 118], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s268_AIMed.d32.s268.p8", "text": "Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide.", "text_with_entity_marker": "Shared and unique determinants of the erythropoietin ([E1]EPO[/E1]) receptor are important for binding EPO and [E2]EPO mimetic peptide[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPO", "entity_1_idx": [[54, 57]], "entity_1_idx_in_text_with_entity_marker": [58, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO mimetic peptide", "entity_2_idx": [[102, 121]], "entity_2_idx_in_text_with_entity_marker": [115, 134], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s268_AIMed.d32.s268.p9", "text": "Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide.", "text_with_entity_marker": "Shared and unique determinants of the [E1]erythropoietin (EPO) receptor[/E1] are important for binding [E2]EPO[/E2] and EPO mimetic peptide.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "erythropoietin (EPO) receptor", "entity_1_idx": [[38, 67]], "entity_1_idx_in_text_with_entity_marker": [42, 71], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[94, 97]], "entity_2_idx_in_text_with_entity_marker": [107, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s268_AIMed.d32.s268.p10", "text": "Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide.", "text_with_entity_marker": "Shared and unique determinants of the [E1]erythropoietin (EPO) receptor[/E1] are important for binding EPO and [E2]EPO[/E2] mimetic peptide.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "erythropoietin (EPO) receptor", "entity_1_idx": [[38, 67]], "entity_1_idx_in_text_with_entity_marker": [42, 71], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[102, 105]], "entity_2_idx_in_text_with_entity_marker": [115, 118], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s268_AIMed.d32.s268.p11", "text": "Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide.", "text_with_entity_marker": "Shared and unique determinants of the [E1]erythropoietin (EPO) receptor[/E1] are important for binding EPO and [E2]EPO mimetic peptide[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "erythropoietin (EPO) receptor", "entity_1_idx": [[38, 67]], "entity_1_idx_in_text_with_entity_marker": [42, 71], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO mimetic peptide", "entity_2_idx": [[102, 121]], "entity_2_idx_in_text_with_entity_marker": [115, 134], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s268_AIMed.d32.s268.p12", "text": "Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide.", "text_with_entity_marker": "Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding [E1]EPO[/E1] and [E2]EPO[/E2] mimetic peptide.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPO", "entity_1_idx": [[94, 97]], "entity_1_idx_in_text_with_entity_marker": [98, 101], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[102, 105]], "entity_2_idx_in_text_with_entity_marker": [115, 118], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s268_AIMed.d32.s268.p13", "text": "Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide.", "text_with_entity_marker": "Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding [E1]EPO[/E1] and [E2]EPO mimetic peptide[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPO", "entity_1_idx": [[94, 97]], "entity_1_idx_in_text_with_entity_marker": [98, 101], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO mimetic peptide", "entity_2_idx": [[102, 121]], "entity_2_idx_in_text_with_entity_marker": [115, 134], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s268_AIMed.d32.s268.p14", "text": "Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide.", "text_with_entity_marker": "Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and [E1-E2]EPO[/E1] mimetic peptide[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPO", "entity_1_idx": [[102, 105]], "entity_1_idx_in_text_with_entity_marker": [109, 112], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO[/E1] mimetic peptide", "entity_2_idx": [[102, 121]], "entity_2_idx_in_text_with_entity_marker": [109, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p0", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the [E1]erythropoietin[/E1] ([E2]EPO[/E2]) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "erythropoietin", "entity_1_idx": [[71, 85]], "entity_1_idx_in_text_with_entity_marker": [75, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[87, 90]], "entity_2_idx_in_text_with_entity_marker": [100, 103], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p1", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the [E1-E2]erythropoietin[/E1] (EPO) receptor[/E2] (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "erythropoietin", "entity_1_idx": [[71, 85]], "entity_1_idx_in_text_with_entity_marker": [78, 92], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "erythropoietin[/E1] (EPO) receptor", "entity_2_idx": [[71, 100]], "entity_2_idx_in_text_with_entity_marker": [78, 112], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p2", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the [E1]erythropoietin[/E1] (EPO) receptor ([E2]EPOR[/E2]) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "erythropoietin", "entity_1_idx": [[71, 85]], "entity_1_idx_in_text_with_entity_marker": [75, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPOR", "entity_2_idx": [[102, 106]], "entity_2_idx_in_text_with_entity_marker": [115, 119], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p3", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the [E1]erythropoietin[/E1] (EPO) receptor (EPOR) is crucial for binding [E2]EPO[/E2].Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "erythropoietin", "entity_1_idx": [[71, 85]], "entity_1_idx_in_text_with_entity_marker": [75, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[131, 134]], "entity_2_idx_in_text_with_entity_marker": [144, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p4", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the [E1]erythropoietin[/E1] (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in [E2]EPO[/E2] binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "erythropoietin", "entity_1_idx": [[71, 85]], "entity_1_idx_in_text_with_entity_marker": [75, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[205, 208]], "entity_2_idx_in_text_with_entity_marker": [218, 221], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p5", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the [E1]erythropoietin[/E1] (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the [E2]EPOR[/E2] (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "erythropoietin", "entity_1_idx": [[71, 85]], "entity_1_idx_in_text_with_entity_marker": [75, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPOR", "entity_2_idx": [[279, 283]], "entity_2_idx_in_text_with_entity_marker": [292, 296], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p6", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the [E1]erythropoietin[/E1] (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR ([E2]EPO[/E2]-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "erythropoietin", "entity_1_idx": [[71, 85]], "entity_1_idx_in_text_with_entity_marker": [75, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[285, 288]], "entity_2_idx_in_text_with_entity_marker": [298, 301], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p7", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the [E1]erythropoietin[/E1] (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR ([E2]EPO-binding protein[/E2] or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "erythropoietin", "entity_1_idx": [[71, 85]], "entity_1_idx_in_text_with_entity_marker": [75, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO-binding protein", "entity_2_idx": [[285, 304]], "entity_2_idx_in_text_with_entity_marker": [298, 317], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p8", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the [E1]erythropoietin[/E1] (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or [E2]EBP[/E2]) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "erythropoietin", "entity_1_idx": [[71, 85]], "entity_1_idx_in_text_with_entity_marker": [75, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EBP", "entity_2_idx": [[308, 311]], "entity_2_idx_in_text_with_entity_marker": [321, 324], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p9", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the [E1]erythropoietin (EPO) receptor[/E1][E2]EPO[/E2]) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "erythropoietin (EPO) receptor", "entity_1_idx": [[71, 100]], "entity_1_idx_in_text_with_entity_marker": [75, 104], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[87, 90]], "entity_2_idx_in_text_with_entity_marker": [113, 116], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p10", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin ([E1]EPO[/E1]) receptor ([E2]EPOR[/E2]) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "EPO", "entity_1_idx": [[87, 90]], "entity_1_idx_in_text_with_entity_marker": [91, 94], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPOR", "entity_2_idx": [[102, 106]], "entity_2_idx_in_text_with_entity_marker": [115, 119], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p11", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin ([E1]EPO[/E1]) receptor (EPOR) is crucial for binding [E2]EPO[/E2].Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPO", "entity_1_idx": [[87, 90]], "entity_1_idx_in_text_with_entity_marker": [91, 94], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[131, 134]], "entity_2_idx_in_text_with_entity_marker": [144, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p12", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin ([E1]EPO[/E1]) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in [E2]EPO[/E2] binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPO", "entity_1_idx": [[87, 90]], "entity_1_idx_in_text_with_entity_marker": [91, 94], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[205, 208]], "entity_2_idx_in_text_with_entity_marker": [218, 221], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p13", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin ([E1]EPO[/E1]) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the [E2]EPOR[/E2] (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPO", "entity_1_idx": [[87, 90]], "entity_1_idx_in_text_with_entity_marker": [91, 94], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPOR", "entity_2_idx": [[279, 283]], "entity_2_idx_in_text_with_entity_marker": [292, 296], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p14", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin ([E1]EPO[/E1]) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR ([E2]EPO[/E2]-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPO", "entity_1_idx": [[87, 90]], "entity_1_idx_in_text_with_entity_marker": [91, 94], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[285, 288]], "entity_2_idx_in_text_with_entity_marker": [298, 301], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p15", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin ([E1]EPO[/E1]) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR ([E2]EPO-binding protein[/E2] or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPO", "entity_1_idx": [[87, 90]], "entity_1_idx_in_text_with_entity_marker": [91, 94], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO-binding protein", "entity_2_idx": [[285, 304]], "entity_2_idx_in_text_with_entity_marker": [298, 317], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p16", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin ([E1]EPO[/E1]) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or [E2]EBP[/E2]) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPO", "entity_1_idx": [[87, 90]], "entity_1_idx_in_text_with_entity_marker": [91, 94], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EBP", "entity_2_idx": [[308, 311]], "entity_2_idx_in_text_with_entity_marker": [321, 324], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p17", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the [E1]erythropoietin (EPO) receptor[/E1] ([E2]EPOR[/E2]) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "erythropoietin (EPO) receptor", "entity_1_idx": [[71, 100]], "entity_1_idx_in_text_with_entity_marker": [75, 104], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPOR", "entity_2_idx": [[102, 106]], "entity_2_idx_in_text_with_entity_marker": [115, 119], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p18", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the [E1]erythropoietin (EPO) receptor[/E1] (EPOR) is crucial for binding [E2]EPO[/E2].Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "erythropoietin (EPO) receptor", "entity_1_idx": [[71, 100]], "entity_1_idx_in_text_with_entity_marker": [75, 104], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[131, 134]], "entity_2_idx_in_text_with_entity_marker": [144, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p19", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the [E1]erythropoietin (EPO) receptor[/E1] (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in [E2]EPO[/E2] binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "erythropoietin (EPO) receptor", "entity_1_idx": [[71, 100]], "entity_1_idx_in_text_with_entity_marker": [75, 104], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[205, 208]], "entity_2_idx_in_text_with_entity_marker": [218, 221], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p20", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the [E1]erythropoietin (EPO) receptor[/E1] (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the [E2]EPOR[/E2] (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "erythropoietin (EPO) receptor", "entity_1_idx": [[71, 100]], "entity_1_idx_in_text_with_entity_marker": [75, 104], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPOR", "entity_2_idx": [[279, 283]], "entity_2_idx_in_text_with_entity_marker": [292, 296], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p21", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the [E1]erythropoietin (EPO) receptor[/E1] (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR ([E2]EPO[/E2]-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "erythropoietin (EPO) receptor", "entity_1_idx": [[71, 100]], "entity_1_idx_in_text_with_entity_marker": [75, 104], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[285, 288]], "entity_2_idx_in_text_with_entity_marker": [298, 301], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p22", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the [E1]erythropoietin (EPO) receptor[/E1] (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR ([E2]EPO-binding protein[/E2] or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "erythropoietin (EPO) receptor", "entity_1_idx": [[71, 100]], "entity_1_idx_in_text_with_entity_marker": [75, 104], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO-binding protein", "entity_2_idx": [[285, 304]], "entity_2_idx_in_text_with_entity_marker": [298, 317], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p23", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the [E1]erythropoietin (EPO) receptor[/E1] (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or [E2]EBP[/E2]) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "erythropoietin (EPO) receptor", "entity_1_idx": [[71, 100]], "entity_1_idx_in_text_with_entity_marker": [75, 104], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EBP", "entity_2_idx": [[308, 311]], "entity_2_idx_in_text_with_entity_marker": [321, 324], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p24", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor ([E1]EPOR[/E1]) is crucial for binding [E2]EPO[/E2].Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "EPOR", "entity_1_idx": [[102, 106]], "entity_1_idx_in_text_with_entity_marker": [106, 110], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[131, 134]], "entity_2_idx_in_text_with_entity_marker": [144, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p25", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor ([E1]EPOR[/E1]) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in [E2]EPO[/E2] binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPOR", "entity_1_idx": [[102, 106]], "entity_1_idx_in_text_with_entity_marker": [106, 110], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[205, 208]], "entity_2_idx_in_text_with_entity_marker": [218, 221], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p26", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor ([E1]EPOR[/E1]) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the [E2]EPOR[/E2] (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPOR", "entity_1_idx": [[102, 106]], "entity_1_idx_in_text_with_entity_marker": [106, 110], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPOR", "entity_2_idx": [[279, 283]], "entity_2_idx_in_text_with_entity_marker": [292, 296], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p27", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor ([E1]EPOR[/E1]) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR ([E2]EPO[/E2]-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPOR", "entity_1_idx": [[102, 106]], "entity_1_idx_in_text_with_entity_marker": [106, 110], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[285, 288]], "entity_2_idx_in_text_with_entity_marker": [298, 301], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p28", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor ([E1]EPOR[/E1]) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR ([E2]EPO-binding protein[/E2] or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPOR", "entity_1_idx": [[102, 106]], "entity_1_idx_in_text_with_entity_marker": [106, 110], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO-binding protein", "entity_2_idx": [[285, 304]], "entity_2_idx_in_text_with_entity_marker": [298, 317], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p29", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor ([E1]EPOR[/E1]) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or [E2]EBP[/E2]) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPOR", "entity_1_idx": [[102, 106]], "entity_1_idx_in_text_with_entity_marker": [106, 110], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EBP", "entity_2_idx": [[308, 311]], "entity_2_idx_in_text_with_entity_marker": [321, 324], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p30", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding [E1]EPO[/E1].Substitution of Phe93 with alanine resulted in a dramatic decrease in [E2]EPO[/E2] binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPO", "entity_1_idx": [[131, 134]], "entity_1_idx_in_text_with_entity_marker": [135, 138], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[205, 208]], "entity_2_idx_in_text_with_entity_marker": [218, 221], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p31", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding [E1]EPO[/E1].Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the [E2]EPOR[/E2] (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPO", "entity_1_idx": [[131, 134]], "entity_1_idx_in_text_with_entity_marker": [135, 138], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPOR", "entity_2_idx": [[279, 283]], "entity_2_idx_in_text_with_entity_marker": [292, 296], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p32", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding [E1]EPO[/E1].Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR ([E2]EPO[/E2]-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPO", "entity_1_idx": [[131, 134]], "entity_1_idx_in_text_with_entity_marker": [135, 138], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[285, 288]], "entity_2_idx_in_text_with_entity_marker": [298, 301], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p33", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding [E1]EPO[/E1].Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR ([E2]EPO-binding protein[/E2] or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPO", "entity_1_idx": [[131, 134]], "entity_1_idx_in_text_with_entity_marker": [135, 138], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO-binding protein", "entity_2_idx": [[285, 304]], "entity_2_idx_in_text_with_entity_marker": [298, 317], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p34", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding [E1]EPO[/E1].Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or [E2]EBP[/E2]) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPO", "entity_1_idx": [[131, 134]], "entity_1_idx_in_text_with_entity_marker": [135, 138], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EBP", "entity_2_idx": [[308, 311]], "entity_2_idx_in_text_with_entity_marker": [321, 324], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p35", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in [E1]EPO[/E1] binding to the Escherichia coli-expressed extracellular domain of the [E2]EPOR[/E2] (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "EPO", "entity_1_idx": [[205, 208]], "entity_1_idx_in_text_with_entity_marker": [209, 212], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPOR", "entity_2_idx": [[279, 283]], "entity_2_idx_in_text_with_entity_marker": [292, 296], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p36", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in [E1]EPO[/E1] binding to the Escherichia coli-expressed extracellular domain of the EPOR ([E2]EPO[/E2]-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPO", "entity_1_idx": [[205, 208]], "entity_1_idx_in_text_with_entity_marker": [209, 212], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[285, 288]], "entity_2_idx_in_text_with_entity_marker": [298, 301], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p37", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in [E1]EPO[/E1] binding to the Escherichia coli-expressed extracellular domain of the EPOR ([E2]EPO-binding protein[/E2] or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "EPO", "entity_1_idx": [[205, 208]], "entity_1_idx_in_text_with_entity_marker": [209, 212], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO-binding protein", "entity_2_idx": [[285, 304]], "entity_2_idx_in_text_with_entity_marker": [298, 317], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p38", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in [E1]EPO[/E1] binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or [E2]EBP[/E2]) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "EPO", "entity_1_idx": [[205, 208]], "entity_1_idx_in_text_with_entity_marker": [209, 212], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EBP", "entity_2_idx": [[308, 311]], "entity_2_idx_in_text_with_entity_marker": [321, 324], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p39", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the [E1]EPOR[/E1] ([E2]EPO[/E2]-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPOR", "entity_1_idx": [[279, 283]], "entity_1_idx_in_text_with_entity_marker": [283, 287], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[285, 288]], "entity_2_idx_in_text_with_entity_marker": [298, 301], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p40", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the [E1]EPOR[/E1] ([E2]EPO-binding protein[/E2] or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPOR", "entity_1_idx": [[279, 283]], "entity_1_idx_in_text_with_entity_marker": [283, 287], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO-binding protein", "entity_2_idx": [[285, 304]], "entity_2_idx_in_text_with_entity_marker": [298, 317], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p41", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the [E1]EPOR[/E1] (EPO-binding protein or [E2]EBP[/E2]) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPOR", "entity_1_idx": [[279, 283]], "entity_1_idx_in_text_with_entity_marker": [283, 287], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EBP", "entity_2_idx": [[308, 311]], "entity_2_idx_in_text_with_entity_marker": [321, 324], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p42", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR ([E1-E2]EPO[/E1]-binding protein[/E2] or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPO", "entity_1_idx": [[285, 288]], "entity_1_idx_in_text_with_entity_marker": [292, 295], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO[/E1]-binding protein", "entity_2_idx": [[285, 304]], "entity_2_idx_in_text_with_entity_marker": [292, 316], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p43", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR ([E1]EPO[/E1]-binding protein or [E2]EBP[/E2]) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPO", "entity_1_idx": [[285, 288]], "entity_1_idx_in_text_with_entity_marker": [289, 292], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EBP", "entity_2_idx": [[308, 311]], "entity_2_idx_in_text_with_entity_marker": [321, 324], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s269_AIMed.d32.s269.p44", "text": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR (EPO-binding protein or EBP) and no detectable binding to full-length mutant receptor expressed in COS cells.", "text_with_entity_marker": "We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor (EPOR) is crucial for binding EPO.Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli-expressed extracellular domain of the EPOR ([E1]EPO-binding protein[/E1] or [E2]EBP[/E2]) and no detectable binding to full-length mutant receptor expressed in COS cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPO-binding protein", "entity_1_idx": [[285, 304]], "entity_1_idx_in_text_with_entity_marker": [289, 308], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EBP", "entity_2_idx": [[308, 311]], "entity_2_idx_in_text_with_entity_marker": [321, 324], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s270_AIMed.d32.s270.p0", "text": "Remarkably, Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the EBP bound to an EPO-mimetic peptide (EMP1), suggesting that Phe93 is also important for EMP1 binding.", "text_with_entity_marker": "Remarkably, Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the [E1]EBP[/E1] bound to an [E2]EPO[/E2]-mimetic peptide (EMP1), suggesting that Phe93 is also important for EMP1 binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EBP", "entity_1_idx": [[97, 100]], "entity_1_idx_in_text_with_entity_marker": [101, 104], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[113, 116]], "entity_2_idx_in_text_with_entity_marker": [126, 129], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s270_AIMed.d32.s270.p1", "text": "Remarkably, Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the EBP bound to an EPO-mimetic peptide (EMP1), suggesting that Phe93 is also important for EMP1 binding.", "text_with_entity_marker": "Remarkably, Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the [E1]EBP[/E1] bound to an [E2]EPO-mimetic peptide[/E2] (EMP1), suggesting that Phe93 is also important for EMP1 binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EBP", "entity_1_idx": [[97, 100]], "entity_1_idx_in_text_with_entity_marker": [101, 104], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO-mimetic peptide", "entity_2_idx": [[113, 132]], "entity_2_idx_in_text_with_entity_marker": [126, 145], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s270_AIMed.d32.s270.p2", "text": "Remarkably, Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the EBP bound to an EPO-mimetic peptide (EMP1), suggesting that Phe93 is also important for EMP1 binding.", "text_with_entity_marker": "Remarkably, Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the [E1]EBP[/E1] bound to an EPO-mimetic peptide ([E2]EMP1[/E2]), suggesting that Phe93 is also important for EMP1 binding.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "EBP", "entity_1_idx": [[97, 100]], "entity_1_idx_in_text_with_entity_marker": [101, 104], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EMP1", "entity_2_idx": [[134, 138]], "entity_2_idx_in_text_with_entity_marker": [147, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s270_AIMed.d32.s270.p3", "text": "Remarkably, Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the EBP bound to an EPO-mimetic peptide (EMP1), suggesting that Phe93 is also important for EMP1 binding.", "text_with_entity_marker": "Remarkably, Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the [E1]EBP[/E1] bound to an EPO-mimetic peptide (EMP1), suggesting that Phe93 is also important for [E2]EMP1[/E2] binding.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "EBP", "entity_1_idx": [[97, 100]], "entity_1_idx_in_text_with_entity_marker": [101, 104], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EMP1", "entity_2_idx": [[185, 189]], "entity_2_idx_in_text_with_entity_marker": [198, 202], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s270_AIMed.d32.s270.p4", "text": "Remarkably, Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the EBP bound to an EPO-mimetic peptide (EMP1), suggesting that Phe93 is also important for EMP1 binding.", "text_with_entity_marker": "Remarkably, Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the EBP bound to an [E1-E2]EPO[/E1]-mimetic peptide[/E2] (EMP1), suggesting that Phe93 is also important for EMP1 binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPO", "entity_1_idx": [[113, 116]], "entity_1_idx_in_text_with_entity_marker": [120, 123], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO[/E1]-mimetic peptide", "entity_2_idx": [[113, 132]], "entity_2_idx_in_text_with_entity_marker": [120, 144], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s270_AIMed.d32.s270.p5", "text": "Remarkably, Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the EBP bound to an EPO-mimetic peptide (EMP1), suggesting that Phe93 is also important for EMP1 binding.", "text_with_entity_marker": "Remarkably, Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the EBP bound to an [E1]EPO[/E1]-mimetic peptide ([E2]EMP1[/E2]), suggesting that Phe93 is also important for EMP1 binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPO", "entity_1_idx": [[113, 116]], "entity_1_idx_in_text_with_entity_marker": [117, 120], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EMP1", "entity_2_idx": [[134, 138]], "entity_2_idx_in_text_with_entity_marker": [147, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s270_AIMed.d32.s270.p6", "text": "Remarkably, Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the EBP bound to an EPO-mimetic peptide (EMP1), suggesting that Phe93 is also important for EMP1 binding.", "text_with_entity_marker": "Remarkably, Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the EBP bound to an [E1]EPO[/E1]-mimetic peptide (EMP1), suggesting that Phe93 is also important for [E2]EMP1[/E2] binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPO", "entity_1_idx": [[113, 116]], "entity_1_idx_in_text_with_entity_marker": [117, 120], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EMP1", "entity_2_idx": [[185, 189]], "entity_2_idx_in_text_with_entity_marker": [198, 202], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s270_AIMed.d32.s270.p7", "text": "Remarkably, Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the EBP bound to an EPO-mimetic peptide (EMP1), suggesting that Phe93 is also important for EMP1 binding.", "text_with_entity_marker": "Remarkably, Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the EBP bound to an [E1]EPO-mimetic peptide[/E1] ([E2]EMP1[/E2]), suggesting that Phe93 is also important for EMP1 binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPO-mimetic peptide", "entity_1_idx": [[113, 132]], "entity_1_idx_in_text_with_entity_marker": [117, 136], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EMP1", "entity_2_idx": [[134, 138]], "entity_2_idx_in_text_with_entity_marker": [147, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s270_AIMed.d32.s270.p8", "text": "Remarkably, Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the EBP bound to an EPO-mimetic peptide (EMP1), suggesting that Phe93 is also important for EMP1 binding.", "text_with_entity_marker": "Remarkably, Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the EBP bound to an [E1]EPO-mimetic peptide[/E1] (EMP1), suggesting that Phe93 is also important for [E2]EMP1[/E2] binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPO-mimetic peptide", "entity_1_idx": [[113, 132]], "entity_1_idx_in_text_with_entity_marker": [117, 136], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EMP1", "entity_2_idx": [[185, 189]], "entity_2_idx_in_text_with_entity_marker": [198, 202], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s270_AIMed.d32.s270.p9", "text": "Remarkably, Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the EBP bound to an EPO-mimetic peptide (EMP1), suggesting that Phe93 is also important for EMP1 binding.", "text_with_entity_marker": "Remarkably, Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the EBP bound to an EPO-mimetic peptide ([E1]EMP1[/E1]), suggesting that Phe93 is also important for [E2]EMP1[/E2] binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EMP1", "entity_1_idx": [[134, 138]], "entity_1_idx_in_text_with_entity_marker": [138, 142], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EMP1", "entity_2_idx": [[185, 189]], "entity_2_idx_in_text_with_entity_marker": [198, 202], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s271_AIMed.d32.s271.p0", "text": "We used alanine substitution of EBP residues that contact EMP1 in the crystal structure to investigate the function of these residues in both EMP1 and EPO binding.", "text_with_entity_marker": "We used alanine substitution of [E1]EBP[/E1] residues that contact [E2]EMP1[/E2] in the crystal structure to investigate the function of these residues in both EMP1 and EPO binding.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "EBP", "entity_1_idx": [[32, 35]], "entity_1_idx_in_text_with_entity_marker": [36, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EMP1", "entity_2_idx": [[58, 62]], "entity_2_idx_in_text_with_entity_marker": [71, 75], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s271_AIMed.d32.s271.p1", "text": "We used alanine substitution of EBP residues that contact EMP1 in the crystal structure to investigate the function of these residues in both EMP1 and EPO binding.", "text_with_entity_marker": "We used alanine substitution of [E1]EBP[/E1] residues that contact EMP1 in the crystal structure to investigate the function of these residues in both [E2]EMP1[/E2] and EPO binding.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "EBP", "entity_1_idx": [[32, 35]], "entity_1_idx_in_text_with_entity_marker": [36, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EMP1", "entity_2_idx": [[142, 146]], "entity_2_idx_in_text_with_entity_marker": [155, 159], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s271_AIMed.d32.s271.p2", "text": "We used alanine substitution of EBP residues that contact EMP1 in the crystal structure to investigate the function of these residues in both EMP1 and EPO binding.", "text_with_entity_marker": "We used alanine substitution of [E1]EBP[/E1] residues that contact EMP1 in the crystal structure to investigate the function of these residues in both EMP1 and [E2]EPO[/E2] binding.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "EBP", "entity_1_idx": [[32, 35]], "entity_1_idx_in_text_with_entity_marker": [36, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[151, 154]], "entity_2_idx_in_text_with_entity_marker": [164, 167], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s271_AIMed.d32.s271.p3", "text": "We used alanine substitution of EBP residues that contact EMP1 in the crystal structure to investigate the function of these residues in both EMP1 and EPO binding.", "text_with_entity_marker": "We used alanine substitution of EBP residues that contact [E1]EMP1[/E1] in the crystal structure to investigate the function of these residues in both [E2]EMP1[/E2] and EPO binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EMP1", "entity_1_idx": [[58, 62]], "entity_1_idx_in_text_with_entity_marker": [62, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EMP1", "entity_2_idx": [[142, 146]], "entity_2_idx_in_text_with_entity_marker": [155, 159], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s271_AIMed.d32.s271.p4", "text": "We used alanine substitution of EBP residues that contact EMP1 in the crystal structure to investigate the function of these residues in both EMP1 and EPO binding.", "text_with_entity_marker": "We used alanine substitution of EBP residues that contact [E1]EMP1[/E1] in the crystal structure to investigate the function of these residues in both EMP1 and [E2]EPO[/E2] binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EMP1", "entity_1_idx": [[58, 62]], "entity_1_idx_in_text_with_entity_marker": [62, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[151, 154]], "entity_2_idx_in_text_with_entity_marker": [164, 167], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s271_AIMed.d32.s271.p5", "text": "We used alanine substitution of EBP residues that contact EMP1 in the crystal structure to investigate the function of these residues in both EMP1 and EPO binding.", "text_with_entity_marker": "We used alanine substitution of EBP residues that contact EMP1 in the crystal structure to investigate the function of these residues in both [E1]EMP1[/E1] and [E2]EPO[/E2] binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EMP1", "entity_1_idx": [[142, 146]], "entity_1_idx_in_text_with_entity_marker": [146, 150], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[151, 154]], "entity_2_idx_in_text_with_entity_marker": [164, 167], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s273_AIMed.d32.s273.p0", "text": "Our results indicate that Phe93 and Phe205 are important for both EPO and EMP1 binding, Met150 is not important for EPO binding but is critical for EMP1 binding, and Thr151 is not important for binding either ligand.", "text_with_entity_marker": "Our results indicate that Phe93 and Phe205 are important for both [E1]EPO[/E1] and [E2]EMP1[/E2] binding, Met150 is not important for EPO binding but is critical for EMP1 binding, and Thr151 is not important for binding either ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPO", "entity_1_idx": [[66, 69]], "entity_1_idx_in_text_with_entity_marker": [70, 73], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EMP1", "entity_2_idx": [[74, 78]], "entity_2_idx_in_text_with_entity_marker": [87, 91], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s273_AIMed.d32.s273.p1", "text": "Our results indicate that Phe93 and Phe205 are important for both EPO and EMP1 binding, Met150 is not important for EPO binding but is critical for EMP1 binding, and Thr151 is not important for binding either ligand.", "text_with_entity_marker": "Our results indicate that Phe93 and Phe205 are important for both [E1]EPO[/E1] and EMP1 binding, Met150 is not important for [E2]EPO[/E2] binding but is critical for EMP1 binding, and Thr151 is not important for binding either ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPO", "entity_1_idx": [[66, 69]], "entity_1_idx_in_text_with_entity_marker": [70, 73], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[116, 119]], "entity_2_idx_in_text_with_entity_marker": [129, 132], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s273_AIMed.d32.s273.p2", "text": "Our results indicate that Phe93 and Phe205 are important for both EPO and EMP1 binding, Met150 is not important for EPO binding but is critical for EMP1 binding, and Thr151 is not important for binding either ligand.", "text_with_entity_marker": "Our results indicate that Phe93 and Phe205 are important for both [E1]EPO[/E1] and EMP1 binding, Met150 is not important for EPO binding but is critical for [E2]EMP1[/E2] binding, and Thr151 is not important for binding either ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPO", "entity_1_idx": [[66, 69]], "entity_1_idx_in_text_with_entity_marker": [70, 73], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EMP1", "entity_2_idx": [[148, 152]], "entity_2_idx_in_text_with_entity_marker": [161, 165], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s273_AIMed.d32.s273.p3", "text": "Our results indicate that Phe93 and Phe205 are important for both EPO and EMP1 binding, Met150 is not important for EPO binding but is critical for EMP1 binding, and Thr151 is not important for binding either ligand.", "text_with_entity_marker": "Our results indicate that Phe93 and Phe205 are important for both EPO and [E1]EMP1[/E1] binding, Met150 is not important for [E2]EPO[/E2] binding but is critical for EMP1 binding, and Thr151 is not important for binding either ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EMP1", "entity_1_idx": [[74, 78]], "entity_1_idx_in_text_with_entity_marker": [78, 82], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[116, 119]], "entity_2_idx_in_text_with_entity_marker": [129, 132], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s273_AIMed.d32.s273.p4", "text": "Our results indicate that Phe93 and Phe205 are important for both EPO and EMP1 binding, Met150 is not important for EPO binding but is critical for EMP1 binding, and Thr151 is not important for binding either ligand.", "text_with_entity_marker": "Our results indicate that Phe93 and Phe205 are important for both EPO and [E1]EMP1[/E1] binding, Met150 is not important for EPO binding but is critical for [E2]EMP1[/E2] binding, and Thr151 is not important for binding either ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EMP1", "entity_1_idx": [[74, 78]], "entity_1_idx_in_text_with_entity_marker": [78, 82], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EMP1", "entity_2_idx": [[148, 152]], "entity_2_idx_in_text_with_entity_marker": [161, 165], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s273_AIMed.d32.s273.p5", "text": "Our results indicate that Phe93 and Phe205 are important for both EPO and EMP1 binding, Met150 is not important for EPO binding but is critical for EMP1 binding, and Thr151 is not important for binding either ligand.", "text_with_entity_marker": "Our results indicate that Phe93 and Phe205 are important for both EPO and EMP1 binding, Met150 is not important for [E1]EPO[/E1] binding but is critical for [E2]EMP1[/E2] binding, and Thr151 is not important for binding either ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPO", "entity_1_idx": [[116, 119]], "entity_1_idx_in_text_with_entity_marker": [120, 123], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EMP1", "entity_2_idx": [[148, 152]], "entity_2_idx_in_text_with_entity_marker": [161, 165], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s274_AIMed.d32.s274.p0", "text": "Thus, Phe93 and Phe205 are important binding determinants for both EPO and EMP1, even though these ligands share no sequence or structural homology, suggesting that these residues may represent a minimum epitope on the EPOR for productive ligand binding.", "text_with_entity_marker": "Thus, Phe93 and Phe205 are important binding determinants for both [E1]EPO[/E1] and [E2]EMP1[/E2], even though these ligands share no sequence or structural homology, suggesting that these residues may represent a minimum epitope on the EPOR for productive ligand binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPO", "entity_1_idx": [[67, 70]], "entity_1_idx_in_text_with_entity_marker": [71, 74], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EMP1", "entity_2_idx": [[75, 79]], "entity_2_idx_in_text_with_entity_marker": [88, 92], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s274_AIMed.d32.s274.p1", "text": "Thus, Phe93 and Phe205 are important binding determinants for both EPO and EMP1, even though these ligands share no sequence or structural homology, suggesting that these residues may represent a minimum epitope on the EPOR for productive ligand binding.", "text_with_entity_marker": "Thus, Phe93 and Phe205 are important binding determinants for both [E1]EPO[/E1] and EMP1, even though these ligands share no sequence or structural homology, suggesting that these residues may represent a minimum epitope on the [E2]EPOR[/E2] for productive ligand binding.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "EPO", "entity_1_idx": [[67, 70]], "entity_1_idx_in_text_with_entity_marker": [71, 74], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPOR", "entity_2_idx": [[219, 223]], "entity_2_idx_in_text_with_entity_marker": [232, 236], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d32.s274_AIMed.d32.s274.p2", "text": "Thus, Phe93 and Phe205 are important binding determinants for both EPO and EMP1, even though these ligands share no sequence or structural homology, suggesting that these residues may represent a minimum epitope on the EPOR for productive ligand binding.", "text_with_entity_marker": "Thus, Phe93 and Phe205 are important binding determinants for both EPO and [E1]EMP1[/E1], even though these ligands share no sequence or structural homology, suggesting that these residues may represent a minimum epitope on the [E2]EPOR[/E2] for productive ligand binding.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "EMP1", "entity_1_idx": [[75, 79]], "entity_1_idx_in_text_with_entity_marker": [79, 83], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPOR", "entity_2_idx": [[219, 223]], "entity_2_idx_in_text_with_entity_marker": [232, 236], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1466_AIMed.d174.s1466.p0", "text": "Influence of interleukin-6 (IL-6) dimerization on formation of the high affinity hexameric IL-6.receptor complex.", "text_with_entity_marker": "Influence of [E1]interleukin-6[/E1] ([E2]IL-6[/E2]) dimerization on formation of the high affinity hexameric IL-6.receptor complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin-6", "entity_1_idx": [[13, 26]], "entity_1_idx_in_text_with_entity_marker": [17, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[28, 32]], "entity_2_idx_in_text_with_entity_marker": [41, 45], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1466_AIMed.d174.s1466.p1", "text": "Influence of interleukin-6 (IL-6) dimerization on formation of the high affinity hexameric IL-6.receptor complex.", "text_with_entity_marker": "Influence of [E1]interleukin-6[/E1] (IL-6) dimerization on formation of the high affinity hexameric [E2]IL-6[/E2].receptor complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin-6", "entity_1_idx": [[13, 26]], "entity_1_idx_in_text_with_entity_marker": [17, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[91, 95]], "entity_2_idx_in_text_with_entity_marker": [104, 108], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1466_AIMed.d174.s1466.p2", "text": "Influence of interleukin-6 (IL-6) dimerization on formation of the high affinity hexameric IL-6.receptor complex.", "text_with_entity_marker": "Influence of [E1]interleukin-6[/E1] (IL-6) dimerization on formation of the high affinity hexameric [E2]IL-6.receptor[/E2] complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin-6", "entity_1_idx": [[13, 26]], "entity_1_idx_in_text_with_entity_marker": [17, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6.receptor", "entity_2_idx": [[91, 104]], "entity_2_idx_in_text_with_entity_marker": [104, 117], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1466_AIMed.d174.s1466.p3", "text": "Influence of interleukin-6 (IL-6) dimerization on formation of the high affinity hexameric IL-6.receptor complex.", "text_with_entity_marker": "Influence of interleukin-6 ([E1]IL-6[/E1]) dimerization on formation of the high affinity hexameric [E2]IL-6[/E2].receptor complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[28, 32]], "entity_1_idx_in_text_with_entity_marker": [32, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[91, 95]], "entity_2_idx_in_text_with_entity_marker": [104, 108], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1466_AIMed.d174.s1466.p4", "text": "Influence of interleukin-6 (IL-6) dimerization on formation of the high affinity hexameric IL-6.receptor complex.", "text_with_entity_marker": "Influence of interleukin-6 ([E1]IL-6[/E1]) dimerization on formation of the high affinity hexameric [E2]IL-6.receptor[/E2] complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[28, 32]], "entity_1_idx_in_text_with_entity_marker": [32, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6.receptor", "entity_2_idx": [[91, 104]], "entity_2_idx_in_text_with_entity_marker": [104, 117], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1466_AIMed.d174.s1466.p5", "text": "Influence of interleukin-6 (IL-6) dimerization on formation of the high affinity hexameric IL-6.receptor complex.", "text_with_entity_marker": "Influence of interleukin-6 (IL-6) dimerization on formation of the high affinity hexameric [E1-E2]IL-6[/E1].receptor[/E2] complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[91, 95]], "entity_1_idx_in_text_with_entity_marker": [98, 102], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6[/E1].receptor", "entity_2_idx": [[91, 104]], "entity_2_idx_in_text_with_entity_marker": [98, 116], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1467_AIMed.d174.s1467.p0", "text": "The high affinity interleukin-6 (IL-6) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific IL-6 receptor and the affinity converter/signal transducing protein gp130.", "text_with_entity_marker": "The high affinity [E1]interleukin-6[/E1] ([E2]IL-6[/E2]) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific IL-6 receptor and the affinity converter/signal transducing protein gp130.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin-6", "entity_1_idx": [[18, 31]], "entity_1_idx_in_text_with_entity_marker": [22, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[33, 37]], "entity_2_idx_in_text_with_entity_marker": [46, 50], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1467_AIMed.d174.s1467.p1", "text": "The high affinity interleukin-6 (IL-6) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific IL-6 receptor and the affinity converter/signal transducing protein gp130.", "text_with_entity_marker": "The high affinity [E1]interleukin-6[/E1] (IL-6) signaling complex consists of [E2]IL-6[/E2] and two membrane-associated receptor components: a low affinity but specific IL-6 receptor and the affinity converter/signal transducing protein gp130.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin-6", "entity_1_idx": [[18, 31]], "entity_1_idx_in_text_with_entity_marker": [22, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[69, 73]], "entity_2_idx_in_text_with_entity_marker": [82, 86], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1467_AIMed.d174.s1467.p2", "text": "The high affinity interleukin-6 (IL-6) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific IL-6 receptor and the affinity converter/signal transducing protein gp130.", "text_with_entity_marker": "The high affinity [E1]interleukin-6[/E1] (IL-6) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific [E2]IL-6[/E2] receptor and the affinity converter/signal transducing protein gp130.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin-6", "entity_1_idx": [[18, 31]], "entity_1_idx_in_text_with_entity_marker": [22, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[151, 155]], "entity_2_idx_in_text_with_entity_marker": [164, 168], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1467_AIMed.d174.s1467.p3", "text": "The high affinity interleukin-6 (IL-6) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific IL-6 receptor and the affinity converter/signal transducing protein gp130.", "text_with_entity_marker": "The high affinity [E1]interleukin-6[/E1] (IL-6) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific [E2]IL-6 receptor[/E2] and the affinity converter/signal transducing protein gp130.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin-6", "entity_1_idx": [[18, 31]], "entity_1_idx_in_text_with_entity_marker": [22, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6 receptor", "entity_2_idx": [[151, 164]], "entity_2_idx_in_text_with_entity_marker": [164, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1467_AIMed.d174.s1467.p4", "text": "The high affinity interleukin-6 (IL-6) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific IL-6 receptor and the affinity converter/signal transducing protein gp130.", "text_with_entity_marker": "The high affinity [E1]interleukin-6[/E1] (IL-6) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific IL-6 receptor and the affinity converter/signal transducing protein [E2]gp130[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin-6", "entity_1_idx": [[18, 31]], "entity_1_idx_in_text_with_entity_marker": [22, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[219, 224]], "entity_2_idx_in_text_with_entity_marker": [232, 237], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1467_AIMed.d174.s1467.p5", "text": "The high affinity interleukin-6 (IL-6) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific IL-6 receptor and the affinity converter/signal transducing protein gp130.", "text_with_entity_marker": "The high affinity interleukin-6 ([E1]IL-6[/E1]) signaling complex consists of [E2]IL-6[/E2] and two membrane-associated receptor components: a low affinity but specific IL-6 receptor and the affinity converter/signal transducing protein gp130.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[33, 37]], "entity_1_idx_in_text_with_entity_marker": [37, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[69, 73]], "entity_2_idx_in_text_with_entity_marker": [82, 86], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1467_AIMed.d174.s1467.p6", "text": "The high affinity interleukin-6 (IL-6) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific IL-6 receptor and the affinity converter/signal transducing protein gp130.", "text_with_entity_marker": "The high affinity interleukin-6 ([E1]IL-6[/E1]) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific [E2]IL-6[/E2] receptor and the affinity converter/signal transducing protein gp130.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[33, 37]], "entity_1_idx_in_text_with_entity_marker": [37, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[151, 155]], "entity_2_idx_in_text_with_entity_marker": [164, 168], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1467_AIMed.d174.s1467.p7", "text": "The high affinity interleukin-6 (IL-6) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific IL-6 receptor and the affinity converter/signal transducing protein gp130.", "text_with_entity_marker": "The high affinity interleukin-6 ([E1]IL-6[/E1]) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific [E2]IL-6 receptor[/E2] and the affinity converter/signal transducing protein gp130.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[33, 37]], "entity_1_idx_in_text_with_entity_marker": [37, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6 receptor", "entity_2_idx": [[151, 164]], "entity_2_idx_in_text_with_entity_marker": [164, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1467_AIMed.d174.s1467.p8", "text": "The high affinity interleukin-6 (IL-6) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific IL-6 receptor and the affinity converter/signal transducing protein gp130.", "text_with_entity_marker": "The high affinity interleukin-6 ([E1]IL-6[/E1]) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific IL-6 receptor and the affinity converter/signal transducing protein [E2]gp130[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[33, 37]], "entity_1_idx_in_text_with_entity_marker": [37, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[219, 224]], "entity_2_idx_in_text_with_entity_marker": [232, 237], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1467_AIMed.d174.s1467.p9", "text": "The high affinity interleukin-6 (IL-6) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific IL-6 receptor and the affinity converter/signal transducing protein gp130.", "text_with_entity_marker": "The high affinity interleukin-6 (IL-6) signaling complex consists of [E1]IL-6[/E1] and two membrane-associated receptor components: a low affinity but specific [E2]IL-6[/E2] receptor and the affinity converter/signal transducing protein gp130.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[69, 73]], "entity_1_idx_in_text_with_entity_marker": [73, 77], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[151, 155]], "entity_2_idx_in_text_with_entity_marker": [164, 168], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1467_AIMed.d174.s1467.p10", "text": "The high affinity interleukin-6 (IL-6) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific IL-6 receptor and the affinity converter/signal transducing protein gp130.", "text_with_entity_marker": "The high affinity interleukin-6 (IL-6) signaling complex consists of [E1]IL-6[/E1] and two membrane-associated receptor components: a low affinity but specific [E2]IL-6 receptor[/E2] and the affinity converter/signal transducing protein gp130.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-6", "entity_1_idx": [[69, 73]], "entity_1_idx_in_text_with_entity_marker": [73, 77], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6 receptor", "entity_2_idx": [[151, 164]], "entity_2_idx_in_text_with_entity_marker": [164, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1467_AIMed.d174.s1467.p11", "text": "The high affinity interleukin-6 (IL-6) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific IL-6 receptor and the affinity converter/signal transducing protein gp130.", "text_with_entity_marker": "The high affinity interleukin-6 (IL-6) signaling complex consists of [E1]IL-6[/E1] and two membrane-associated receptor components: a low affinity but specific IL-6 receptor and the affinity converter/signal transducing protein [E2]gp130[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[69, 73]], "entity_1_idx_in_text_with_entity_marker": [73, 77], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[219, 224]], "entity_2_idx_in_text_with_entity_marker": [232, 237], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1467_AIMed.d174.s1467.p12", "text": "The high affinity interleukin-6 (IL-6) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific IL-6 receptor and the affinity converter/signal transducing protein gp130.", "text_with_entity_marker": "The high affinity interleukin-6 (IL-6) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific [E1-E2]IL-6[/E1] receptor[/E2] and the affinity converter/signal transducing protein gp130.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[151, 155]], "entity_1_idx_in_text_with_entity_marker": [158, 162], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6[/E1] receptor", "entity_2_idx": [[151, 164]], "entity_2_idx_in_text_with_entity_marker": [158, 176], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1467_AIMed.d174.s1467.p13", "text": "The high affinity interleukin-6 (IL-6) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific IL-6 receptor and the affinity converter/signal transducing protein gp130.", "text_with_entity_marker": "The high affinity interleukin-6 (IL-6) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific [E1]IL-6[/E1] receptor and the affinity converter/signal transducing protein [E2]gp130[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[151, 155]], "entity_1_idx_in_text_with_entity_marker": [155, 159], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[219, 224]], "entity_2_idx_in_text_with_entity_marker": [232, 237], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1467_AIMed.d174.s1467.p14", "text": "The high affinity interleukin-6 (IL-6) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific IL-6 receptor and the affinity converter/signal transducing protein gp130.", "text_with_entity_marker": "The high affinity interleukin-6 (IL-6) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific [E1]IL-6 receptor[/E1] and the affinity converter/signal transducing protein [E2]gp130[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6 receptor", "entity_1_idx": [[151, 164]], "entity_1_idx_in_text_with_entity_marker": [155, 168], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[219, 224]], "entity_2_idx_in_text_with_entity_marker": [232, 237], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1468_AIMed.d174.s1468.p0", "text": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "text_with_entity_marker": "Monomeric ([E1]IL-6M[/E1]) and dimeric ([E2]IL-6D[/E2]) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6M", "entity_1_idx": [[11, 16]], "entity_1_idx_in_text_with_entity_marker": [15, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6D", "entity_2_idx": [[31, 36]], "entity_2_idx_in_text_with_entity_marker": [44, 49], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1468_AIMed.d174.s1468.p1", "text": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "text_with_entity_marker": "Monomeric ([E1]IL-6M[/E1]) and dimeric (IL-6D) forms of Escherichia coli-derived human [E2]IL-6[/E2] and the extracellular (\"soluble\") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6M", "entity_1_idx": [[11, 16]], "entity_1_idx_in_text_with_entity_marker": [15, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[78, 82]], "entity_2_idx_in_text_with_entity_marker": [91, 95], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1468_AIMed.d174.s1468.p2", "text": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "text_with_entity_marker": "Monomeric ([E1]IL-6M[/E1]) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the [E2]IL-6[/E2] receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6M", "entity_1_idx": [[11, 16]], "entity_1_idx_in_text_with_entity_marker": [15, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[133, 137]], "entity_2_idx_in_text_with_entity_marker": [146, 150], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1468_AIMed.d174.s1468.p3", "text": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "text_with_entity_marker": "Monomeric ([E1]IL-6M[/E1]) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the [E2]IL-6 receptor[/E2] (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6M", "entity_1_idx": [[11, 16]], "entity_1_idx_in_text_with_entity_marker": [15, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6 receptor", "entity_2_idx": [[133, 146]], "entity_2_idx_in_text_with_entity_marker": [146, 159], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1468_AIMed.d174.s1468.p4", "text": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "text_with_entity_marker": "Monomeric ([E1]IL-6M[/E1]) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the IL-6 receptor ([E2]sIL-6R[/E2]) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6M", "entity_1_idx": [[11, 16]], "entity_1_idx_in_text_with_entity_marker": [15, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sIL-6R", "entity_2_idx": [[148, 154]], "entity_2_idx_in_text_with_entity_marker": [161, 167], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1468_AIMed.d174.s1468.p5", "text": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "text_with_entity_marker": "Monomeric ([E1]IL-6M[/E1]) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the IL-6 receptor (sIL-6R) and [E2]gp130[/E2] have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6M", "entity_1_idx": [[11, 16]], "entity_1_idx_in_text_with_entity_marker": [15, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[160, 165]], "entity_2_idx_in_text_with_entity_marker": [173, 178], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1468_AIMed.d174.s1468.p6", "text": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "text_with_entity_marker": "Monomeric ([E1]IL-6M[/E1]) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of [E2]IL-6[/E2] dimerization on binding to the receptor complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6M", "entity_1_idx": [[11, 16]], "entity_1_idx_in_text_with_entity_marker": [15, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[223, 227]], "entity_2_idx_in_text_with_entity_marker": [236, 240], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1468_AIMed.d174.s1468.p7", "text": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "text_with_entity_marker": "Monomeric (IL-6M) and dimeric ([E1]IL-6D[/E1]) forms of Escherichia coli-derived human [E2]IL-6[/E2] and the extracellular (\"soluble\") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6D", "entity_1_idx": [[31, 36]], "entity_1_idx_in_text_with_entity_marker": [35, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[78, 82]], "entity_2_idx_in_text_with_entity_marker": [91, 95], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1468_AIMed.d174.s1468.p8", "text": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "text_with_entity_marker": "Monomeric (IL-6M) and dimeric ([E1]IL-6D[/E1]) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the [E2]IL-6[/E2] receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6D", "entity_1_idx": [[31, 36]], "entity_1_idx_in_text_with_entity_marker": [35, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[133, 137]], "entity_2_idx_in_text_with_entity_marker": [146, 150], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1468_AIMed.d174.s1468.p9", "text": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "text_with_entity_marker": "Monomeric (IL-6M) and dimeric ([E1]IL-6D[/E1]) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the [E2]IL-6 receptor[/E2] (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6D", "entity_1_idx": [[31, 36]], "entity_1_idx_in_text_with_entity_marker": [35, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6 receptor", "entity_2_idx": [[133, 146]], "entity_2_idx_in_text_with_entity_marker": [146, 159], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1468_AIMed.d174.s1468.p10", "text": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "text_with_entity_marker": "Monomeric (IL-6M) and dimeric ([E1]IL-6D[/E1]) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the IL-6 receptor ([E2]sIL-6R[/E2]) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6D", "entity_1_idx": [[31, 36]], "entity_1_idx_in_text_with_entity_marker": [35, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sIL-6R", "entity_2_idx": [[148, 154]], "entity_2_idx_in_text_with_entity_marker": [161, 167], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1468_AIMed.d174.s1468.p11", "text": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "text_with_entity_marker": "Monomeric (IL-6M) and dimeric ([E1]IL-6D[/E1]) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the IL-6 receptor (sIL-6R) and [E2]gp130[/E2] have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6D", "entity_1_idx": [[31, 36]], "entity_1_idx_in_text_with_entity_marker": [35, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[160, 165]], "entity_2_idx_in_text_with_entity_marker": [173, 178], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1468_AIMed.d174.s1468.p12", "text": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "text_with_entity_marker": "Monomeric (IL-6M) and dimeric ([E1]IL-6D[/E1]) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of [E2]IL-6[/E2] dimerization on binding to the receptor complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6D", "entity_1_idx": [[31, 36]], "entity_1_idx_in_text_with_entity_marker": [35, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[223, 227]], "entity_2_idx_in_text_with_entity_marker": [236, 240], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1468_AIMed.d174.s1468.p13", "text": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "text_with_entity_marker": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human [E1]IL-6[/E1] and the extracellular (\"soluble\") portions of the [E2]IL-6[/E2] receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[78, 82]], "entity_1_idx_in_text_with_entity_marker": [82, 86], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[133, 137]], "entity_2_idx_in_text_with_entity_marker": [146, 150], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1468_AIMed.d174.s1468.p14", "text": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "text_with_entity_marker": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human [E1]IL-6[/E1] and the extracellular (\"soluble\") portions of the [E2]IL-6 receptor[/E2] (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[78, 82]], "entity_1_idx_in_text_with_entity_marker": [82, 86], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6 receptor", "entity_2_idx": [[133, 146]], "entity_2_idx_in_text_with_entity_marker": [146, 159], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1468_AIMed.d174.s1468.p15", "text": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "text_with_entity_marker": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human [E1]IL-6[/E1] and the extracellular (\"soluble\") portions of the IL-6 receptor ([E2]sIL-6R[/E2]) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[78, 82]], "entity_1_idx_in_text_with_entity_marker": [82, 86], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sIL-6R", "entity_2_idx": [[148, 154]], "entity_2_idx_in_text_with_entity_marker": [161, 167], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1468_AIMed.d174.s1468.p16", "text": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "text_with_entity_marker": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human [E1]IL-6[/E1] and the extracellular (\"soluble\") portions of the IL-6 receptor (sIL-6R) and [E2]gp130[/E2] have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[78, 82]], "entity_1_idx_in_text_with_entity_marker": [82, 86], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[160, 165]], "entity_2_idx_in_text_with_entity_marker": [173, 178], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1468_AIMed.d174.s1468.p17", "text": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "text_with_entity_marker": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human [E1]IL-6[/E1] and the extracellular (\"soluble\") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of [E2]IL-6[/E2] dimerization on binding to the receptor complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[78, 82]], "entity_1_idx_in_text_with_entity_marker": [82, 86], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[223, 227]], "entity_2_idx_in_text_with_entity_marker": [236, 240], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1468_AIMed.d174.s1468.p18", "text": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "text_with_entity_marker": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the [E1-E2]IL-6[/E1] receptor[/E2] (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[133, 137]], "entity_1_idx_in_text_with_entity_marker": [140, 144], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6[/E1] receptor", "entity_2_idx": [[133, 146]], "entity_2_idx_in_text_with_entity_marker": [140, 158], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1468_AIMed.d174.s1468.p19", "text": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "text_with_entity_marker": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the [E1]IL-6[/E1] receptor ([E2]sIL-6R[/E2]) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-6", "entity_1_idx": [[133, 137]], "entity_1_idx_in_text_with_entity_marker": [137, 141], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sIL-6R", "entity_2_idx": [[148, 154]], "entity_2_idx_in_text_with_entity_marker": [161, 167], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1468_AIMed.d174.s1468.p20", "text": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "text_with_entity_marker": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the [E1]IL-6[/E1] receptor (sIL-6R) and [E2]gp130[/E2] have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[133, 137]], "entity_1_idx_in_text_with_entity_marker": [137, 141], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[160, 165]], "entity_2_idx_in_text_with_entity_marker": [173, 178], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1468_AIMed.d174.s1468.p21", "text": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "text_with_entity_marker": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the [E1]IL-6[/E1] receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of [E2]IL-6[/E2] dimerization on binding to the receptor complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[133, 137]], "entity_1_idx_in_text_with_entity_marker": [137, 141], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[223, 227]], "entity_2_idx_in_text_with_entity_marker": [236, 240], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1468_AIMed.d174.s1468.p22", "text": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "text_with_entity_marker": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the [E1]IL-6 receptor[/E1] ([E2]sIL-6R[/E2]) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6 receptor", "entity_1_idx": [[133, 146]], "entity_1_idx_in_text_with_entity_marker": [137, 150], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sIL-6R", "entity_2_idx": [[148, 154]], "entity_2_idx_in_text_with_entity_marker": [161, 167], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1468_AIMed.d174.s1468.p23", "text": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "text_with_entity_marker": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the [E1]IL-6 receptor[/E1] (sIL-6R) and [E2]gp130[/E2] have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6 receptor", "entity_1_idx": [[133, 146]], "entity_1_idx_in_text_with_entity_marker": [137, 150], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[160, 165]], "entity_2_idx_in_text_with_entity_marker": [173, 178], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1468_AIMed.d174.s1468.p24", "text": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "text_with_entity_marker": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the [E1]IL-6 receptor[/E1] (sIL-6R) and gp130 have been purified in order to investigate the effect of [E2]IL-6[/E2] dimerization on binding to the receptor complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6 receptor", "entity_1_idx": [[133, 146]], "entity_1_idx_in_text_with_entity_marker": [137, 150], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[223, 227]], "entity_2_idx_in_text_with_entity_marker": [236, 240], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1468_AIMed.d174.s1468.p25", "text": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "text_with_entity_marker": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the IL-6 receptor ([E1]sIL-6R[/E1]) and [E2]gp130[/E2] have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "sIL-6R", "entity_1_idx": [[148, 154]], "entity_1_idx_in_text_with_entity_marker": [152, 158], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[160, 165]], "entity_2_idx_in_text_with_entity_marker": [173, 178], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1468_AIMed.d174.s1468.p26", "text": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "text_with_entity_marker": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the IL-6 receptor ([E1]sIL-6R[/E1]) and gp130 have been purified in order to investigate the effect of [E2]IL-6[/E2] dimerization on binding to the receptor complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "sIL-6R", "entity_1_idx": [[148, 154]], "entity_1_idx_in_text_with_entity_marker": [152, 158], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[223, 227]], "entity_2_idx_in_text_with_entity_marker": [236, 240], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1468_AIMed.d174.s1468.p27", "text": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "text_with_entity_marker": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the IL-6 receptor (sIL-6R) and [E1]gp130[/E1] have been purified in order to investigate the effect of [E2]IL-6[/E2] dimerization on binding to the receptor complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gp130", "entity_1_idx": [[160, 165]], "entity_1_idx_in_text_with_entity_marker": [164, 169], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[223, 227]], "entity_2_idx_in_text_with_entity_marker": [236, 240], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1469_AIMed.d174.s1469.p0", "text": "Although IL-6D has a higher binding affinity for immobilized sIL-6R, as determined by biosensor analysis employing surface plasmon resonance detection, IL-6M is more potent than IL-6D in a STAT3 phosphorylation assay.", "text_with_entity_marker": "Although [E1]IL-6D[/E1] has a higher binding affinity for immobilized [E2]sIL-6R[/E2], as determined by biosensor analysis employing surface plasmon resonance detection, IL-6M is more potent than IL-6D in a STAT3 phosphorylation assay.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-6D", "entity_1_idx": [[9, 14]], "entity_1_idx_in_text_with_entity_marker": [13, 18], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sIL-6R", "entity_2_idx": [[61, 67]], "entity_2_idx_in_text_with_entity_marker": [74, 80], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1469_AIMed.d174.s1469.p1", "text": "Although IL-6D has a higher binding affinity for immobilized sIL-6R, as determined by biosensor analysis employing surface plasmon resonance detection, IL-6M is more potent than IL-6D in a STAT3 phosphorylation assay.", "text_with_entity_marker": "Although [E1]IL-6D[/E1] has a higher binding affinity for immobilized sIL-6R, as determined by biosensor analysis employing surface plasmon resonance detection, [E2]IL-6M[/E2] is more potent than IL-6D in a STAT3 phosphorylation assay.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6D", "entity_1_idx": [[9, 14]], "entity_1_idx_in_text_with_entity_marker": [13, 18], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6M", "entity_2_idx": [[152, 157]], "entity_2_idx_in_text_with_entity_marker": [165, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1469_AIMed.d174.s1469.p2", "text": "Although IL-6D has a higher binding affinity for immobilized sIL-6R, as determined by biosensor analysis employing surface plasmon resonance detection, IL-6M is more potent than IL-6D in a STAT3 phosphorylation assay.", "text_with_entity_marker": "Although [E1]IL-6D[/E1] has a higher binding affinity for immobilized sIL-6R, as determined by biosensor analysis employing surface plasmon resonance detection, IL-6M is more potent than [E2]IL-6D[/E2] in a STAT3 phosphorylation assay.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6D", "entity_1_idx": [[9, 14]], "entity_1_idx_in_text_with_entity_marker": [13, 18], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6D", "entity_2_idx": [[178, 183]], "entity_2_idx_in_text_with_entity_marker": [191, 196], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1469_AIMed.d174.s1469.p3", "text": "Although IL-6D has a higher binding affinity for immobilized sIL-6R, as determined by biosensor analysis employing surface plasmon resonance detection, IL-6M is more potent than IL-6D in a STAT3 phosphorylation assay.", "text_with_entity_marker": "Although IL-6D has a higher binding affinity for immobilized [E1]sIL-6R[/E1], as determined by biosensor analysis employing surface plasmon resonance detection, [E2]IL-6M[/E2] is more potent than IL-6D in a STAT3 phosphorylation assay.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "sIL-6R", "entity_1_idx": [[61, 67]], "entity_1_idx_in_text_with_entity_marker": [65, 71], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6M", "entity_2_idx": [[152, 157]], "entity_2_idx_in_text_with_entity_marker": [165, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1469_AIMed.d174.s1469.p4", "text": "Although IL-6D has a higher binding affinity for immobilized sIL-6R, as determined by biosensor analysis employing surface plasmon resonance detection, IL-6M is more potent than IL-6D in a STAT3 phosphorylation assay.", "text_with_entity_marker": "Although IL-6D has a higher binding affinity for immobilized [E1]sIL-6R[/E1], as determined by biosensor analysis employing surface plasmon resonance detection, IL-6M is more potent than [E2]IL-6D[/E2] in a STAT3 phosphorylation assay.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "sIL-6R", "entity_1_idx": [[61, 67]], "entity_1_idx_in_text_with_entity_marker": [65, 71], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6D", "entity_2_idx": [[178, 183]], "entity_2_idx_in_text_with_entity_marker": [191, 196], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1469_AIMed.d174.s1469.p5", "text": "Although IL-6D has a higher binding affinity for immobilized sIL-6R, as determined by biosensor analysis employing surface plasmon resonance detection, IL-6M is more potent than IL-6D in a STAT3 phosphorylation assay.", "text_with_entity_marker": "Although IL-6D has a higher binding affinity for immobilized sIL-6R, as determined by biosensor analysis employing surface plasmon resonance detection, [E1]IL-6M[/E1] is more potent than [E2]IL-6D[/E2] in a STAT3 phosphorylation assay.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6M", "entity_1_idx": [[152, 157]], "entity_1_idx_in_text_with_entity_marker": [156, 161], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6D", "entity_2_idx": [[178, 183]], "entity_2_idx_in_text_with_entity_marker": [191, 196], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1471_AIMed.d174.s1471.p0", "text": "The increased binding affinity of IL-6D appears to be due to its ability to cross-link two sIL-6R molecules on the biosensor surface.", "text_with_entity_marker": "The increased binding affinity of [E1]IL-6D[/E1] appears to be due to its ability to cross-link two [E2]sIL-6R[/E2] molecules on the biosensor surface.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-6D", "entity_1_idx": [[34, 39]], "entity_1_idx_in_text_with_entity_marker": [38, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sIL-6R", "entity_2_idx": [[91, 97]], "entity_2_idx_in_text_with_entity_marker": [104, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1472_AIMed.d174.s1472.p0", "text": "Studies of the IL-6 ternary complex formation demonstrated that the reduced biological potency of IL-6D resulted from a decreased ability of the IL-6D (sIL-6R)2 complex to couple with the soluble portion of gp130.", "text_with_entity_marker": "Studies of the [E1]IL-6[/E1] ternary complex formation demonstrated that the reduced biological potency of [E2]IL-6D[/E2] resulted from a decreased ability of the IL-6D (sIL-6R)2 complex to couple with the soluble portion of gp130.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[15, 19]], "entity_1_idx_in_text_with_entity_marker": [19, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6D", "entity_2_idx": [[98, 103]], "entity_2_idx_in_text_with_entity_marker": [111, 116], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1472_AIMed.d174.s1472.p1", "text": "Studies of the IL-6 ternary complex formation demonstrated that the reduced biological potency of IL-6D resulted from a decreased ability of the IL-6D (sIL-6R)2 complex to couple with the soluble portion of gp130.", "text_with_entity_marker": "Studies of the [E1]IL-6[/E1] ternary complex formation demonstrated that the reduced biological potency of IL-6D resulted from a decreased ability of the [E2]IL-6D[/E2] (sIL-6R)2 complex to couple with the soluble portion of gp130.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[15, 19]], "entity_1_idx_in_text_with_entity_marker": [19, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6D", "entity_2_idx": [[145, 150]], "entity_2_idx_in_text_with_entity_marker": [158, 163], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1472_AIMed.d174.s1472.p2", "text": "Studies of the IL-6 ternary complex formation demonstrated that the reduced biological potency of IL-6D resulted from a decreased ability of the IL-6D (sIL-6R)2 complex to couple with the soluble portion of gp130.", "text_with_entity_marker": "Studies of the [E1]IL-6[/E1] ternary complex formation demonstrated that the reduced biological potency of IL-6D resulted from a decreased ability of the IL-6D ([E2]sIL-6R[/E2])2 complex to couple with the soluble portion of gp130.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[15, 19]], "entity_1_idx_in_text_with_entity_marker": [19, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sIL-6R", "entity_2_idx": [[152, 158]], "entity_2_idx_in_text_with_entity_marker": [165, 171], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1472_AIMed.d174.s1472.p3", "text": "Studies of the IL-6 ternary complex formation demonstrated that the reduced biological potency of IL-6D resulted from a decreased ability of the IL-6D (sIL-6R)2 complex to couple with the soluble portion of gp130.", "text_with_entity_marker": "Studies of the [E1]IL-6[/E1] ternary complex formation demonstrated that the reduced biological potency of IL-6D resulted from a decreased ability of the IL-6D (sIL-6R)2 complex to couple with the soluble portion of [E2]gp130[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[15, 19]], "entity_1_idx_in_text_with_entity_marker": [19, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[207, 212]], "entity_2_idx_in_text_with_entity_marker": [220, 225], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1472_AIMed.d174.s1472.p4", "text": "Studies of the IL-6 ternary complex formation demonstrated that the reduced biological potency of IL-6D resulted from a decreased ability of the IL-6D (sIL-6R)2 complex to couple with the soluble portion of gp130.", "text_with_entity_marker": "Studies of the IL-6 ternary complex formation demonstrated that the reduced biological potency of [E1]IL-6D[/E1] resulted from a decreased ability of the [E2]IL-6D[/E2] (sIL-6R)2 complex to couple with the soluble portion of gp130.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6D", "entity_1_idx": [[98, 103]], "entity_1_idx_in_text_with_entity_marker": [102, 107], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6D", "entity_2_idx": [[145, 150]], "entity_2_idx_in_text_with_entity_marker": [158, 163], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1472_AIMed.d174.s1472.p5", "text": "Studies of the IL-6 ternary complex formation demonstrated that the reduced biological potency of IL-6D resulted from a decreased ability of the IL-6D (sIL-6R)2 complex to couple with the soluble portion of gp130.", "text_with_entity_marker": "Studies of the IL-6 ternary complex formation demonstrated that the reduced biological potency of [E1]IL-6D[/E1] resulted from a decreased ability of the IL-6D ([E2]sIL-6R[/E2])2 complex to couple with the soluble portion of gp130.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6D", "entity_1_idx": [[98, 103]], "entity_1_idx_in_text_with_entity_marker": [102, 107], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sIL-6R", "entity_2_idx": [[152, 158]], "entity_2_idx_in_text_with_entity_marker": [165, 171], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1472_AIMed.d174.s1472.p6", "text": "Studies of the IL-6 ternary complex formation demonstrated that the reduced biological potency of IL-6D resulted from a decreased ability of the IL-6D (sIL-6R)2 complex to couple with the soluble portion of gp130.", "text_with_entity_marker": "Studies of the IL-6 ternary complex formation demonstrated that the reduced biological potency of [E1]IL-6D[/E1] resulted from a decreased ability of the IL-6D (sIL-6R)2 complex to couple with the soluble portion of [E2]gp130[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6D", "entity_1_idx": [[98, 103]], "entity_1_idx_in_text_with_entity_marker": [102, 107], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[207, 212]], "entity_2_idx_in_text_with_entity_marker": [220, 225], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1472_AIMed.d174.s1472.p7", "text": "Studies of the IL-6 ternary complex formation demonstrated that the reduced biological potency of IL-6D resulted from a decreased ability of the IL-6D (sIL-6R)2 complex to couple with the soluble portion of gp130.", "text_with_entity_marker": "Studies of the IL-6 ternary complex formation demonstrated that the reduced biological potency of IL-6D resulted from a decreased ability of the [E1]IL-6D[/E1] ([E2]sIL-6R[/E2])2 complex to couple with the soluble portion of gp130.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-6D", "entity_1_idx": [[145, 150]], "entity_1_idx_in_text_with_entity_marker": [149, 154], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sIL-6R", "entity_2_idx": [[152, 158]], "entity_2_idx_in_text_with_entity_marker": [165, 171], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1472_AIMed.d174.s1472.p8", "text": "Studies of the IL-6 ternary complex formation demonstrated that the reduced biological potency of IL-6D resulted from a decreased ability of the IL-6D (sIL-6R)2 complex to couple with the soluble portion of gp130.", "text_with_entity_marker": "Studies of the IL-6 ternary complex formation demonstrated that the reduced biological potency of IL-6D resulted from a decreased ability of the [E1]IL-6D[/E1] (sIL-6R)2 complex to couple with the soluble portion of [E2]gp130[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6D", "entity_1_idx": [[145, 150]], "entity_1_idx_in_text_with_entity_marker": [149, 154], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[207, 212]], "entity_2_idx_in_text_with_entity_marker": [220, 225], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1472_AIMed.d174.s1472.p9", "text": "Studies of the IL-6 ternary complex formation demonstrated that the reduced biological potency of IL-6D resulted from a decreased ability of the IL-6D (sIL-6R)2 complex to couple with the soluble portion of gp130.", "text_with_entity_marker": "Studies of the IL-6 ternary complex formation demonstrated that the reduced biological potency of IL-6D resulted from a decreased ability of the IL-6D ([E1]sIL-6R[/E1])2 complex to couple with the soluble portion of [E2]gp130[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "sIL-6R", "entity_1_idx": [[152, 158]], "entity_1_idx_in_text_with_entity_marker": [156, 162], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[207, 212]], "entity_2_idx_in_text_with_entity_marker": [220, 225], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1473_AIMed.d174.s1473.p0", "text": "These data imply that IL-6-induced dimerization of sIL-6R is not the driving force in promoting formation of the hexameric (IL-6 IL-6R gp130)2 complex.", "text_with_entity_marker": "These data imply that [E1]IL-6[/E1]-induced dimerization of [E2]sIL-6R[/E2] is not the driving force in promoting formation of the hexameric (IL-6 IL-6R gp130)2 complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[22, 26]], "entity_1_idx_in_text_with_entity_marker": [26, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sIL-6R", "entity_2_idx": [[51, 57]], "entity_2_idx_in_text_with_entity_marker": [64, 70], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1473_AIMed.d174.s1473.p1", "text": "These data imply that IL-6-induced dimerization of sIL-6R is not the driving force in promoting formation of the hexameric (IL-6 IL-6R gp130)2 complex.", "text_with_entity_marker": "These data imply that [E1]IL-6[/E1]-induced dimerization of sIL-6R is not the driving force in promoting formation of the hexameric ([E2]IL-6[/E2] IL-6R gp130)2 complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[22, 26]], "entity_1_idx_in_text_with_entity_marker": [26, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[124, 128]], "entity_2_idx_in_text_with_entity_marker": [137, 141], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1473_AIMed.d174.s1473.p2", "text": "These data imply that IL-6-induced dimerization of sIL-6R is not the driving force in promoting formation of the hexameric (IL-6 IL-6R gp130)2 complex.", "text_with_entity_marker": "These data imply that [E1]IL-6[/E1]-induced dimerization of sIL-6R is not the driving force in promoting formation of the hexameric (IL-6 [E2]IL-6R[/E2] gp130)2 complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[22, 26]], "entity_1_idx_in_text_with_entity_marker": [26, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6R", "entity_2_idx": [[129, 134]], "entity_2_idx_in_text_with_entity_marker": [142, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1473_AIMed.d174.s1473.p3", "text": "These data imply that IL-6-induced dimerization of sIL-6R is not the driving force in promoting formation of the hexameric (IL-6 IL-6R gp130)2 complex.", "text_with_entity_marker": "These data imply that [E1]IL-6[/E1]-induced dimerization of sIL-6R is not the driving force in promoting formation of the hexameric (IL-6 IL-6R [E2]gp130[/E2])2 complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[22, 26]], "entity_1_idx_in_text_with_entity_marker": [26, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[135, 140]], "entity_2_idx_in_text_with_entity_marker": [148, 153], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1473_AIMed.d174.s1473.p4", "text": "These data imply that IL-6-induced dimerization of sIL-6R is not the driving force in promoting formation of the hexameric (IL-6 IL-6R gp130)2 complex.", "text_with_entity_marker": "These data imply that IL-6-induced dimerization of [E1]sIL-6R[/E1] is not the driving force in promoting formation of the hexameric ([E2]IL-6[/E2] IL-6R gp130)2 complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "sIL-6R", "entity_1_idx": [[51, 57]], "entity_1_idx_in_text_with_entity_marker": [55, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[124, 128]], "entity_2_idx_in_text_with_entity_marker": [137, 141], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1473_AIMed.d174.s1473.p5", "text": "These data imply that IL-6-induced dimerization of sIL-6R is not the driving force in promoting formation of the hexameric (IL-6 IL-6R gp130)2 complex.", "text_with_entity_marker": "These data imply that IL-6-induced dimerization of [E1]sIL-6R[/E1] is not the driving force in promoting formation of the hexameric (IL-6 [E2]IL-6R[/E2] gp130)2 complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "sIL-6R", "entity_1_idx": [[51, 57]], "entity_1_idx_in_text_with_entity_marker": [55, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6R", "entity_2_idx": [[129, 134]], "entity_2_idx_in_text_with_entity_marker": [142, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1473_AIMed.d174.s1473.p6", "text": "These data imply that IL-6-induced dimerization of sIL-6R is not the driving force in promoting formation of the hexameric (IL-6 IL-6R gp130)2 complex.", "text_with_entity_marker": "These data imply that IL-6-induced dimerization of [E1]sIL-6R[/E1] is not the driving force in promoting formation of the hexameric (IL-6 IL-6R [E2]gp130[/E2])2 complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "sIL-6R", "entity_1_idx": [[51, 57]], "entity_1_idx_in_text_with_entity_marker": [55, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[135, 140]], "entity_2_idx_in_text_with_entity_marker": [148, 153], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1473_AIMed.d174.s1473.p7", "text": "These data imply that IL-6-induced dimerization of sIL-6R is not the driving force in promoting formation of the hexameric (IL-6 IL-6R gp130)2 complex.", "text_with_entity_marker": "These data imply that IL-6-induced dimerization of sIL-6R is not the driving force in promoting formation of the hexameric ([E1]IL-6[/E1] [E2]IL-6R[/E2] gp130)2 complex.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-6", "entity_1_idx": [[124, 128]], "entity_1_idx_in_text_with_entity_marker": [128, 132], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6R", "entity_2_idx": [[129, 134]], "entity_2_idx_in_text_with_entity_marker": [142, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1473_AIMed.d174.s1473.p8", "text": "These data imply that IL-6-induced dimerization of sIL-6R is not the driving force in promoting formation of the hexameric (IL-6 IL-6R gp130)2 complex.", "text_with_entity_marker": "These data imply that IL-6-induced dimerization of sIL-6R is not the driving force in promoting formation of the hexameric ([E1]IL-6[/E1] IL-6R [E2]gp130[/E2])2 complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[124, 128]], "entity_1_idx_in_text_with_entity_marker": [128, 132], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[135, 140]], "entity_2_idx_in_text_with_entity_marker": [148, 153], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1473_AIMed.d174.s1473.p9", "text": "These data imply that IL-6-induced dimerization of sIL-6R is not the driving force in promoting formation of the hexameric (IL-6 IL-6R gp130)2 complex.", "text_with_entity_marker": "These data imply that IL-6-induced dimerization of sIL-6R is not the driving force in promoting formation of the hexameric (IL-6 [E1]IL-6R[/E1] [E2]gp130[/E2])2 complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6R", "entity_1_idx": [[129, 134]], "entity_1_idx_in_text_with_entity_marker": [133, 138], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[135, 140]], "entity_2_idx_in_text_with_entity_marker": [148, 153], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1474_AIMed.d174.s1474.p0", "text": "A model is presented whereby the trimeric complex of IL-6R, gp130, and IL-6M forms before the functional hexamer.", "text_with_entity_marker": "A model is presented whereby the trimeric complex of [E1]IL-6R[/E1], [E2]gp130[/E2], and IL-6M forms before the functional hexamer.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-6R", "entity_1_idx": [[53, 58]], "entity_1_idx_in_text_with_entity_marker": [57, 62], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[60, 65]], "entity_2_idx_in_text_with_entity_marker": [73, 78], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1474_AIMed.d174.s1474.p1", "text": "A model is presented whereby the trimeric complex of IL-6R, gp130, and IL-6M forms before the functional hexamer.", "text_with_entity_marker": "A model is presented whereby the trimeric complex of [E1]IL-6R[/E1], gp130, and [E2]IL-6M[/E2] forms before the functional hexamer.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6R", "entity_1_idx": [[53, 58]], "entity_1_idx_in_text_with_entity_marker": [57, 62], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6M", "entity_2_idx": [[71, 76]], "entity_2_idx_in_text_with_entity_marker": [84, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1474_AIMed.d174.s1474.p2", "text": "A model is presented whereby the trimeric complex of IL-6R, gp130, and IL-6M forms before the functional hexamer.", "text_with_entity_marker": "A model is presented whereby the trimeric complex of IL-6R, [E1]gp130[/E1], and [E2]IL-6M[/E2] forms before the functional hexamer.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gp130", "entity_1_idx": [[60, 65]], "entity_1_idx_in_text_with_entity_marker": [64, 69], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6M", "entity_2_idx": [[71, 76]], "entity_2_idx_in_text_with_entity_marker": [84, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1475_AIMed.d174.s1475.p0", "text": "Due to its increased affinity for the IL-6R but its decreased ability to couple with gp130, we suggest that a stable IL-6 dimer may be an efficient IL-6 antagonist.", "text_with_entity_marker": "Due to its increased affinity for the [E1]IL-6R[/E1] but its decreased ability to couple with [E2]gp130[/E2], we suggest that a stable IL-6 dimer may be an efficient IL-6 antagonist.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6R", "entity_1_idx": [[38, 43]], "entity_1_idx_in_text_with_entity_marker": [42, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[85, 90]], "entity_2_idx_in_text_with_entity_marker": [98, 103], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1475_AIMed.d174.s1475.p1", "text": "Due to its increased affinity for the IL-6R but its decreased ability to couple with gp130, we suggest that a stable IL-6 dimer may be an efficient IL-6 antagonist.", "text_with_entity_marker": "Due to its increased affinity for the [E1]IL-6R[/E1] but its decreased ability to couple with gp130, we suggest that a stable [E2]IL-6[/E2] dimer may be an efficient IL-6 antagonist.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-6R", "entity_1_idx": [[38, 43]], "entity_1_idx_in_text_with_entity_marker": [42, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[117, 121]], "entity_2_idx_in_text_with_entity_marker": [130, 134], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1475_AIMed.d174.s1475.p2", "text": "Due to its increased affinity for the IL-6R but its decreased ability to couple with gp130, we suggest that a stable IL-6 dimer may be an efficient IL-6 antagonist.", "text_with_entity_marker": "Due to its increased affinity for the [E1]IL-6R[/E1] but its decreased ability to couple with gp130, we suggest that a stable IL-6 dimer may be an efficient [E2]IL-6[/E2] antagonist.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6R", "entity_1_idx": [[38, 43]], "entity_1_idx_in_text_with_entity_marker": [42, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[148, 152]], "entity_2_idx_in_text_with_entity_marker": [161, 165], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1475_AIMed.d174.s1475.p3", "text": "Due to its increased affinity for the IL-6R but its decreased ability to couple with gp130, we suggest that a stable IL-6 dimer may be an efficient IL-6 antagonist.", "text_with_entity_marker": "Due to its increased affinity for the IL-6R but its decreased ability to couple with [E1]gp130[/E1], we suggest that a stable [E2]IL-6[/E2] dimer may be an efficient IL-6 antagonist.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "gp130", "entity_1_idx": [[85, 90]], "entity_1_idx_in_text_with_entity_marker": [89, 94], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[117, 121]], "entity_2_idx_in_text_with_entity_marker": [130, 134], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1475_AIMed.d174.s1475.p4", "text": "Due to its increased affinity for the IL-6R but its decreased ability to couple with gp130, we suggest that a stable IL-6 dimer may be an efficient IL-6 antagonist.", "text_with_entity_marker": "Due to its increased affinity for the IL-6R but its decreased ability to couple with [E1]gp130[/E1], we suggest that a stable IL-6 dimer may be an efficient [E2]IL-6[/E2] antagonist.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gp130", "entity_1_idx": [[85, 90]], "entity_1_idx_in_text_with_entity_marker": [89, 94], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[148, 152]], "entity_2_idx_in_text_with_entity_marker": [161, 165], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1475_AIMed.d174.s1475.p5", "text": "Due to its increased affinity for the IL-6R but its decreased ability to couple with gp130, we suggest that a stable IL-6 dimer may be an efficient IL-6 antagonist.", "text_with_entity_marker": "Due to its increased affinity for the IL-6R but its decreased ability to couple with gp130, we suggest that a stable [E1]IL-6[/E1] dimer may be an efficient [E2]IL-6[/E2] antagonist.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[117, 121]], "entity_1_idx_in_text_with_entity_marker": [121, 125], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[148, 152]], "entity_2_idx_in_text_with_entity_marker": [161, 165], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d1.s12_AIMed.d1.s12.p0", "text": "This study describes the distributions of bone morphogenetic protein (BMP)-2 as well as mRNAs for BMP receptor type IB (BMPRIB). collagen types II (Col II) and III (Col III) in a growing \"cartilage cap\" of osteochondroma.", "text_with_entity_marker": "This study describes the distributions of [E1]bone morphogenetic protein (BMP)-2[/E1] as well as mRNAs for [E2]BMP receptor type IB[/E2] (BMPRIB). collagen types II (Col II) and III (Col III) in a growing \"cartilage cap\" of osteochondroma.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "bone morphogenetic protein (BMP)-2", "entity_1_idx": [[42, 76]], "entity_1_idx_in_text_with_entity_marker": [46, 80], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BMP receptor type IB", "entity_2_idx": [[98, 118]], "entity_2_idx_in_text_with_entity_marker": [111, 131], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d1.s12_AIMed.d1.s12.p1", "text": "This study describes the distributions of bone morphogenetic protein (BMP)-2 as well as mRNAs for BMP receptor type IB (BMPRIB). collagen types II (Col II) and III (Col III) in a growing \"cartilage cap\" of osteochondroma.", "text_with_entity_marker": "This study describes the distributions of [E1]bone morphogenetic protein (BMP)-2[/E1] as well as mRNAs for BMP receptor type IB ([E2]BMPRIB[/E2]). collagen types II (Col II) and III (Col III) in a growing \"cartilage cap\" of osteochondroma.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "bone morphogenetic protein (BMP)-2", "entity_1_idx": [[42, 76]], "entity_1_idx_in_text_with_entity_marker": [46, 80], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BMPRIB", "entity_2_idx": [[120, 126]], "entity_2_idx_in_text_with_entity_marker": [133, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d1.s12_AIMed.d1.s12.p2", "text": "This study describes the distributions of bone morphogenetic protein (BMP)-2 as well as mRNAs for BMP receptor type IB (BMPRIB). collagen types II (Col II) and III (Col III) in a growing \"cartilage cap\" of osteochondroma.", "text_with_entity_marker": "This study describes the distributions of [E1]bone morphogenetic protein (BMP)-2[/E1] as well as mRNAs for BMP receptor type IB (BMPRIB). collagen types II ([E2]Col II[/E2]) and III (Col III) in a growing \"cartilage cap\" of osteochondroma.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "bone morphogenetic protein (BMP)-2", "entity_1_idx": [[42, 76]], "entity_1_idx_in_text_with_entity_marker": [46, 80], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Col II", "entity_2_idx": [[148, 154]], "entity_2_idx_in_text_with_entity_marker": [161, 167], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d1.s12_AIMed.d1.s12.p3", "text": "This study describes the distributions of bone morphogenetic protein (BMP)-2 as well as mRNAs for BMP receptor type IB (BMPRIB). collagen types II (Col II) and III (Col III) in a growing \"cartilage cap\" of osteochondroma.", "text_with_entity_marker": "This study describes the distributions of [E1]bone morphogenetic protein (BMP)-2[/E1] as well as mRNAs for BMP receptor type IB (BMPRIB). collagen types II (Col II) and III ([E2]Col III[/E2]) in a growing \"cartilage cap\" of osteochondroma.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "bone morphogenetic protein (BMP)-2", "entity_1_idx": [[42, 76]], "entity_1_idx_in_text_with_entity_marker": [46, 80], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Col III", "entity_2_idx": [[165, 172]], "entity_2_idx_in_text_with_entity_marker": [178, 185], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d1.s12_AIMed.d1.s12.p4", "text": "This study describes the distributions of bone morphogenetic protein (BMP)-2 as well as mRNAs for BMP receptor type IB (BMPRIB). collagen types II (Col II) and III (Col III) in a growing \"cartilage cap\" of osteochondroma.", "text_with_entity_marker": "This study describes the distributions of bone morphogenetic protein (BMP)-2 as well as mRNAs for [E1]BMP receptor type IB[/E1] ([E2]BMPRIB[/E2]). collagen types II (Col II) and III (Col III) in a growing \"cartilage cap\" of osteochondroma.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BMP receptor type IB", "entity_1_idx": [[98, 118]], "entity_1_idx_in_text_with_entity_marker": [102, 122], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BMPRIB", "entity_2_idx": [[120, 126]], "entity_2_idx_in_text_with_entity_marker": [133, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d1.s12_AIMed.d1.s12.p5", "text": "This study describes the distributions of bone morphogenetic protein (BMP)-2 as well as mRNAs for BMP receptor type IB (BMPRIB). collagen types II (Col II) and III (Col III) in a growing \"cartilage cap\" of osteochondroma.", "text_with_entity_marker": "This study describes the distributions of bone morphogenetic protein (BMP)-2 as well as mRNAs for [E1]BMP receptor type IB[/E1] (BMPRIB). collagen types II ([E2]Col II[/E2]) and III (Col III) in a growing \"cartilage cap\" of osteochondroma.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BMP receptor type IB", "entity_1_idx": [[98, 118]], "entity_1_idx_in_text_with_entity_marker": [102, 122], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Col II", "entity_2_idx": [[148, 154]], "entity_2_idx_in_text_with_entity_marker": [161, 167], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d1.s12_AIMed.d1.s12.p6", "text": "This study describes the distributions of bone morphogenetic protein (BMP)-2 as well as mRNAs for BMP receptor type IB (BMPRIB). collagen types II (Col II) and III (Col III) in a growing \"cartilage cap\" of osteochondroma.", "text_with_entity_marker": "This study describes the distributions of bone morphogenetic protein (BMP)-2 as well as mRNAs for [E1]BMP receptor type IB[/E1] (BMPRIB). collagen types II (Col II) and III ([E2]Col III[/E2]) in a growing \"cartilage cap\" of osteochondroma.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BMP receptor type IB", "entity_1_idx": [[98, 118]], "entity_1_idx_in_text_with_entity_marker": [102, 122], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Col III", "entity_2_idx": [[165, 172]], "entity_2_idx_in_text_with_entity_marker": [178, 185], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d1.s12_AIMed.d1.s12.p7", "text": "This study describes the distributions of bone morphogenetic protein (BMP)-2 as well as mRNAs for BMP receptor type IB (BMPRIB). collagen types II (Col II) and III (Col III) in a growing \"cartilage cap\" of osteochondroma.", "text_with_entity_marker": "This study describes the distributions of bone morphogenetic protein (BMP)-2 as well as mRNAs for BMP receptor type IB ([E1]BMPRIB[/E1]). collagen types II ([E2]Col II[/E2]) and III (Col III) in a growing \"cartilage cap\" of osteochondroma.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BMPRIB", "entity_1_idx": [[120, 126]], "entity_1_idx_in_text_with_entity_marker": [124, 130], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Col II", "entity_2_idx": [[148, 154]], "entity_2_idx_in_text_with_entity_marker": [161, 167], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d1.s12_AIMed.d1.s12.p8", "text": "This study describes the distributions of bone morphogenetic protein (BMP)-2 as well as mRNAs for BMP receptor type IB (BMPRIB). collagen types II (Col II) and III (Col III) in a growing \"cartilage cap\" of osteochondroma.", "text_with_entity_marker": "This study describes the distributions of bone morphogenetic protein (BMP)-2 as well as mRNAs for BMP receptor type IB ([E1]BMPRIB[/E1]). collagen types II (Col II) and III ([E2]Col III[/E2]) in a growing \"cartilage cap\" of osteochondroma.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BMPRIB", "entity_1_idx": [[120, 126]], "entity_1_idx_in_text_with_entity_marker": [124, 130], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Col III", "entity_2_idx": [[165, 172]], "entity_2_idx_in_text_with_entity_marker": [178, 185], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d1.s12_AIMed.d1.s12.p9", "text": "This study describes the distributions of bone morphogenetic protein (BMP)-2 as well as mRNAs for BMP receptor type IB (BMPRIB). collagen types II (Col II) and III (Col III) in a growing \"cartilage cap\" of osteochondroma.", "text_with_entity_marker": "This study describes the distributions of bone morphogenetic protein (BMP)-2 as well as mRNAs for BMP receptor type IB (BMPRIB). collagen types II ([E1]Col II[/E1]) and III ([E2]Col III[/E2]) in a growing \"cartilage cap\" of osteochondroma.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Col II", "entity_1_idx": [[148, 154]], "entity_1_idx_in_text_with_entity_marker": [152, 158], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Col III", "entity_2_idx": [[165, 172]], "entity_2_idx_in_text_with_entity_marker": [178, 185], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d1.s14_AIMed.d1.s14.p0", "text": "BMP-2 was detected in mesenchymal cells in the outer fibrous layer and chondrocytes in the inner cartilaginous matrix, positive for Col III and Col II, respectively.", "text_with_entity_marker": "[E1]BMP-2[/E1] was detected in mesenchymal cells in the outer fibrous layer and chondrocytes in the inner cartilaginous matrix, positive for [E2]Col III[/E2] and Col II, respectively.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BMP-2", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Col III", "entity_2_idx": [[132, 139]], "entity_2_idx_in_text_with_entity_marker": [145, 152], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d1.s14_AIMed.d1.s14.p1", "text": "BMP-2 was detected in mesenchymal cells in the outer fibrous layer and chondrocytes in the inner cartilaginous matrix, positive for Col III and Col II, respectively.", "text_with_entity_marker": "[E1]BMP-2[/E1] was detected in mesenchymal cells in the outer fibrous layer and chondrocytes in the inner cartilaginous matrix, positive for Col III and [E2]Col II[/E2], respectively.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BMP-2", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Col II", "entity_2_idx": [[144, 150]], "entity_2_idx_in_text_with_entity_marker": [157, 163], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d1.s14_AIMed.d1.s14.p2", "text": "BMP-2 was detected in mesenchymal cells in the outer fibrous layer and chondrocytes in the inner cartilaginous matrix, positive for Col III and Col II, respectively.", "text_with_entity_marker": "BMP-2 was detected in mesenchymal cells in the outer fibrous layer and chondrocytes in the inner cartilaginous matrix, positive for [E1]Col III[/E1] and [E2]Col II[/E2], respectively.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Col III", "entity_1_idx": [[132, 139]], "entity_1_idx_in_text_with_entity_marker": [136, 143], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Col II", "entity_2_idx": [[144, 150]], "entity_2_idx_in_text_with_entity_marker": [157, 163], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d1.s16_AIMed.d1.s16.p0", "text": "This is the first study to provide observational evidence of the involvement of BMP-2 signaling in the pathogenesis of cartilage cap of osteochondroma. and suggests the role of BMP-2 in the growth of cartilage cap in osteochondroma.", "text_with_entity_marker": "This is the first study to provide observational evidence of the involvement of [E1]BMP-2[/E1] signaling in the pathogenesis of cartilage cap of osteochondroma. and suggests the role of [E2]BMP-2[/E2] in the growth of cartilage cap in osteochondroma.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BMP-2", "entity_1_idx": [[80, 85]], "entity_1_idx_in_text_with_entity_marker": [84, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BMP-2", "entity_2_idx": [[177, 182]], "entity_2_idx_in_text_with_entity_marker": [190, 195], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1188_AIMed.d141.s1188.p0", "text": "The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.", "text_with_entity_marker": "The [E1]p21[/E1] Cdk-interacting protein [E2]Cip1[/E2] is a potent inhibitor of G1 cyclin-dependent kinases.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p21", "entity_1_idx": [[4, 7]], "entity_1_idx_in_text_with_entity_marker": [8, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cip1", "entity_2_idx": [[32, 36]], "entity_2_idx_in_text_with_entity_marker": [45, 49], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1189_AIMed.d141.s1189.p0", "text": "The cyclin-dependent kinase Cdk2 associates with cyclins A, D, and E and has been implicated in the control of the G1 to S phase transition in mammals.", "text_with_entity_marker": "The cyclin-dependent kinase [E1]Cdk2[/E1] associates with [E2]cyclins A[/E2], D, and E and has been implicated in the control of the G1 to S phase transition in mammals.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Cdk2", "entity_1_idx": [[28, 32]], "entity_1_idx_in_text_with_entity_marker": [32, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclins A", "entity_2_idx": [[49, 58]], "entity_2_idx_in_text_with_entity_marker": [62, 71], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1191_AIMed.d141.s1191.p0", "text": "CIP1 encodes a novel 21 kd protein that is found in cyclin A, cyclin D1, cyclin E, and Cdk2 immunoprecipitates.", "text_with_entity_marker": "[E1]CIP1[/E1] encodes a novel 21 kd protein that is found in [E2]cyclin A[/E2], cyclin D1, cyclin E, and Cdk2 immunoprecipitates.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CIP1", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin A", "entity_2_idx": [[52, 60]], "entity_2_idx_in_text_with_entity_marker": [65, 73], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1191_AIMed.d141.s1191.p1", "text": "CIP1 encodes a novel 21 kd protein that is found in cyclin A, cyclin D1, cyclin E, and Cdk2 immunoprecipitates.", "text_with_entity_marker": "[E1]CIP1[/E1] encodes a novel 21 kd protein that is found in cyclin A, [E2]cyclin D1[/E2], cyclin E, and Cdk2 immunoprecipitates.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CIP1", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin D1", "entity_2_idx": [[62, 71]], "entity_2_idx_in_text_with_entity_marker": [75, 84], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1191_AIMed.d141.s1191.p2", "text": "CIP1 encodes a novel 21 kd protein that is found in cyclin A, cyclin D1, cyclin E, and Cdk2 immunoprecipitates.", "text_with_entity_marker": "[E1]CIP1[/E1] encodes a novel 21 kd protein that is found in cyclin A, cyclin D1, [E2]cyclin E[/E2], and Cdk2 immunoprecipitates.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CIP1", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin E", "entity_2_idx": [[73, 81]], "entity_2_idx_in_text_with_entity_marker": [86, 94], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1191_AIMed.d141.s1191.p3", "text": "CIP1 encodes a novel 21 kd protein that is found in cyclin A, cyclin D1, cyclin E, and Cdk2 immunoprecipitates.", "text_with_entity_marker": "[E1]CIP1[/E1] encodes a novel 21 kd protein that is found in cyclin A, cyclin D1, cyclin E, and [E2]Cdk2[/E2] immunoprecipitates.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CIP1", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk2", "entity_2_idx": [[87, 91]], "entity_2_idx_in_text_with_entity_marker": [100, 104], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1191_AIMed.d141.s1191.p4", "text": "CIP1 encodes a novel 21 kd protein that is found in cyclin A, cyclin D1, cyclin E, and Cdk2 immunoprecipitates.", "text_with_entity_marker": "CIP1 encodes a novel 21 kd protein that is found in [E1]cyclin A[/E1], [E2]cyclin D1[/E2], cyclin E, and Cdk2 immunoprecipitates.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclin A", "entity_1_idx": [[52, 60]], "entity_1_idx_in_text_with_entity_marker": [56, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin D1", "entity_2_idx": [[62, 71]], "entity_2_idx_in_text_with_entity_marker": [75, 84], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1191_AIMed.d141.s1191.p5", "text": "CIP1 encodes a novel 21 kd protein that is found in cyclin A, cyclin D1, cyclin E, and Cdk2 immunoprecipitates.", "text_with_entity_marker": "CIP1 encodes a novel 21 kd protein that is found in [E1]cyclin A[/E1], cyclin D1, [E2]cyclin E[/E2], and Cdk2 immunoprecipitates.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclin A", "entity_1_idx": [[52, 60]], "entity_1_idx_in_text_with_entity_marker": [56, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin E", "entity_2_idx": [[73, 81]], "entity_2_idx_in_text_with_entity_marker": [86, 94], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1191_AIMed.d141.s1191.p6", "text": "CIP1 encodes a novel 21 kd protein that is found in cyclin A, cyclin D1, cyclin E, and Cdk2 immunoprecipitates.", "text_with_entity_marker": "CIP1 encodes a novel 21 kd protein that is found in [E1]cyclin A[/E1], cyclin D1, cyclin E, and [E2]Cdk2[/E2] immunoprecipitates.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclin A", "entity_1_idx": [[52, 60]], "entity_1_idx_in_text_with_entity_marker": [56, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk2", "entity_2_idx": [[87, 91]], "entity_2_idx_in_text_with_entity_marker": [100, 104], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1191_AIMed.d141.s1191.p7", "text": "CIP1 encodes a novel 21 kd protein that is found in cyclin A, cyclin D1, cyclin E, and Cdk2 immunoprecipitates.", "text_with_entity_marker": "CIP1 encodes a novel 21 kd protein that is found in cyclin A, [E1]cyclin D1[/E1], [E2]cyclin E[/E2], and Cdk2 immunoprecipitates.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclin D1", "entity_1_idx": [[62, 71]], "entity_1_idx_in_text_with_entity_marker": [66, 75], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin E", "entity_2_idx": [[73, 81]], "entity_2_idx_in_text_with_entity_marker": [86, 94], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1191_AIMed.d141.s1191.p8", "text": "CIP1 encodes a novel 21 kd protein that is found in cyclin A, cyclin D1, cyclin E, and Cdk2 immunoprecipitates.", "text_with_entity_marker": "CIP1 encodes a novel 21 kd protein that is found in cyclin A, [E1]cyclin D1[/E1], cyclin E, and [E2]Cdk2[/E2] immunoprecipitates.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclin D1", "entity_1_idx": [[62, 71]], "entity_1_idx_in_text_with_entity_marker": [66, 75], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk2", "entity_2_idx": [[87, 91]], "entity_2_idx_in_text_with_entity_marker": [100, 104], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1191_AIMed.d141.s1191.p9", "text": "CIP1 encodes a novel 21 kd protein that is found in cyclin A, cyclin D1, cyclin E, and Cdk2 immunoprecipitates.", "text_with_entity_marker": "CIP1 encodes a novel 21 kd protein that is found in cyclin A, cyclin D1, [E1]cyclin E[/E1], and [E2]Cdk2[/E2] immunoprecipitates.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclin E", "entity_1_idx": [[73, 81]], "entity_1_idx_in_text_with_entity_marker": [77, 85], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk2", "entity_2_idx": [[87, 91]], "entity_2_idx_in_text_with_entity_marker": [100, 104], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p0", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "[E1]p21CIP1[/E1] is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of [E2]Rb[/E2] by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p21CIP1", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Rb", "entity_2_idx": [[92, 94]], "entity_2_idx_in_text_with_entity_marker": [105, 107], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p1", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "[E1]p21CIP1[/E1] is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by [E2]cyclin A[/E2]-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p21CIP1", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin A", "entity_2_idx": [[98, 106]], "entity_2_idx_in_text_with_entity_marker": [111, 119], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p2", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "[E1]p21CIP1[/E1] is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-[E2]Cdk2[/E2], cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p21CIP1", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk2", "entity_2_idx": [[107, 111]], "entity_2_idx_in_text_with_entity_marker": [120, 124], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p3", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "[E1]p21CIP1[/E1] is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, [E2]cyclin E[/E2]-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p21CIP1", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin E", "entity_2_idx": [[113, 121]], "entity_2_idx_in_text_with_entity_marker": [126, 134], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p4", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "[E1]p21CIP1[/E1] is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-[E2]Cdk2[/E2], cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p21CIP1", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk2", "entity_2_idx": [[122, 126]], "entity_2_idx_in_text_with_entity_marker": [135, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p5", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "[E1]p21CIP1[/E1] is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, [E2]cyclin D1[/E2]-Cdk4, and cyclin D2-Cdk4 complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p21CIP1", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin D1", "entity_2_idx": [[128, 137]], "entity_2_idx_in_text_with_entity_marker": [141, 150], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p6", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "[E1]p21CIP1[/E1] is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-[E2]Cdk4[/E2], and cyclin D2-Cdk4 complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p21CIP1", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk4", "entity_2_idx": [[138, 142]], "entity_2_idx_in_text_with_entity_marker": [151, 155], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p7", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "[E1]p21CIP1[/E1] is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and [E2]cyclin D2[/E2]-Cdk4 complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p21CIP1", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin D2", "entity_2_idx": [[148, 157]], "entity_2_idx_in_text_with_entity_marker": [161, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p8", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "[E1]p21CIP1[/E1] is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-[E2]Cdk4[/E2] complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p21CIP1", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk4", "entity_2_idx": [[158, 162]], "entity_2_idx_in_text_with_entity_marker": [171, 175], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p9", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of [E1]Rb[/E1] by [E2]cyclin A[/E2]-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rb", "entity_1_idx": [[92, 94]], "entity_1_idx_in_text_with_entity_marker": [96, 98], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin A", "entity_2_idx": [[98, 106]], "entity_2_idx_in_text_with_entity_marker": [111, 119], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p10", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of [E1]Rb[/E1] by cyclin A-[E2]Cdk2[/E2], cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rb", "entity_1_idx": [[92, 94]], "entity_1_idx_in_text_with_entity_marker": [96, 98], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk2", "entity_2_idx": [[107, 111]], "entity_2_idx_in_text_with_entity_marker": [120, 124], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p11", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of [E1]Rb[/E1] by cyclin A-Cdk2, [E2]cyclin E[/E2]-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rb", "entity_1_idx": [[92, 94]], "entity_1_idx_in_text_with_entity_marker": [96, 98], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin E", "entity_2_idx": [[113, 121]], "entity_2_idx_in_text_with_entity_marker": [126, 134], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p12", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of [E1]Rb[/E1] by cyclin A-Cdk2, cyclin E-[E2]Cdk2[/E2], cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rb", "entity_1_idx": [[92, 94]], "entity_1_idx_in_text_with_entity_marker": [96, 98], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk2", "entity_2_idx": [[122, 126]], "entity_2_idx_in_text_with_entity_marker": [135, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p13", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of [E1]Rb[/E1] by cyclin A-Cdk2, cyclin E-Cdk2, [E2]cyclin D1[/E2]-Cdk4, and cyclin D2-Cdk4 complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rb", "entity_1_idx": [[92, 94]], "entity_1_idx_in_text_with_entity_marker": [96, 98], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin D1", "entity_2_idx": [[128, 137]], "entity_2_idx_in_text_with_entity_marker": [141, 150], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p14", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of [E1]Rb[/E1] by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-[E2]Cdk4[/E2], and cyclin D2-Cdk4 complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rb", "entity_1_idx": [[92, 94]], "entity_1_idx_in_text_with_entity_marker": [96, 98], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk4", "entity_2_idx": [[138, 142]], "entity_2_idx_in_text_with_entity_marker": [151, 155], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p15", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of [E1]Rb[/E1] by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and [E2]cyclin D2[/E2]-Cdk4 complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rb", "entity_1_idx": [[92, 94]], "entity_1_idx_in_text_with_entity_marker": [96, 98], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin D2", "entity_2_idx": [[148, 157]], "entity_2_idx_in_text_with_entity_marker": [161, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p16", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of [E1]Rb[/E1] by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-[E2]Cdk4[/E2] complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rb", "entity_1_idx": [[92, 94]], "entity_1_idx_in_text_with_entity_marker": [96, 98], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk4", "entity_2_idx": [[158, 162]], "entity_2_idx_in_text_with_entity_marker": [171, 175], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p17", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by [E1]cyclin A[/E1]-[E2]Cdk2[/E2], cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "cyclin A", "entity_1_idx": [[98, 106]], "entity_1_idx_in_text_with_entity_marker": [102, 110], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk2", "entity_2_idx": [[107, 111]], "entity_2_idx_in_text_with_entity_marker": [120, 124], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p18", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by [E1]cyclin A[/E1]-Cdk2, [E2]cyclin E[/E2]-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclin A", "entity_1_idx": [[98, 106]], "entity_1_idx_in_text_with_entity_marker": [102, 110], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin E", "entity_2_idx": [[113, 121]], "entity_2_idx_in_text_with_entity_marker": [126, 134], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p19", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by [E1]cyclin A[/E1]-Cdk2, cyclin E-[E2]Cdk2[/E2], cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclin A", "entity_1_idx": [[98, 106]], "entity_1_idx_in_text_with_entity_marker": [102, 110], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk2", "entity_2_idx": [[122, 126]], "entity_2_idx_in_text_with_entity_marker": [135, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p20", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by [E1]cyclin A[/E1]-Cdk2, cyclin E-Cdk2, [E2]cyclin D1[/E2]-Cdk4, and cyclin D2-Cdk4 complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclin A", "entity_1_idx": [[98, 106]], "entity_1_idx_in_text_with_entity_marker": [102, 110], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin D1", "entity_2_idx": [[128, 137]], "entity_2_idx_in_text_with_entity_marker": [141, 150], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p21", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by [E1]cyclin A[/E1]-Cdk2, cyclin E-Cdk2, cyclin D1-[E2]Cdk4[/E2], and cyclin D2-Cdk4 complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclin A", "entity_1_idx": [[98, 106]], "entity_1_idx_in_text_with_entity_marker": [102, 110], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk4", "entity_2_idx": [[138, 142]], "entity_2_idx_in_text_with_entity_marker": [151, 155], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p22", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by [E1]cyclin A[/E1]-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and [E2]cyclin D2[/E2]-Cdk4 complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclin A", "entity_1_idx": [[98, 106]], "entity_1_idx_in_text_with_entity_marker": [102, 110], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin D2", "entity_2_idx": [[148, 157]], "entity_2_idx_in_text_with_entity_marker": [161, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p23", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by [E1]cyclin A[/E1]-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-[E2]Cdk4[/E2] complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclin A", "entity_1_idx": [[98, 106]], "entity_1_idx_in_text_with_entity_marker": [102, 110], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk4", "entity_2_idx": [[158, 162]], "entity_2_idx_in_text_with_entity_marker": [171, 175], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p24", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-[E1]Cdk2[/E1], [E2]cyclin E[/E2]-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Cdk2", "entity_1_idx": [[107, 111]], "entity_1_idx_in_text_with_entity_marker": [111, 115], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin E", "entity_2_idx": [[113, 121]], "entity_2_idx_in_text_with_entity_marker": [126, 134], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p25", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-[E1]Cdk2[/E1], cyclin E-[E2]Cdk2[/E2], cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Cdk2", "entity_1_idx": [[107, 111]], "entity_1_idx_in_text_with_entity_marker": [111, 115], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk2", "entity_2_idx": [[122, 126]], "entity_2_idx_in_text_with_entity_marker": [135, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p26", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-[E1]Cdk2[/E1], cyclin E-Cdk2, [E2]cyclin D1[/E2]-Cdk4, and cyclin D2-Cdk4 complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Cdk2", "entity_1_idx": [[107, 111]], "entity_1_idx_in_text_with_entity_marker": [111, 115], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin D1", "entity_2_idx": [[128, 137]], "entity_2_idx_in_text_with_entity_marker": [141, 150], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p27", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-[E1]Cdk2[/E1], cyclin E-Cdk2, cyclin D1-[E2]Cdk4[/E2], and cyclin D2-Cdk4 complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Cdk2", "entity_1_idx": [[107, 111]], "entity_1_idx_in_text_with_entity_marker": [111, 115], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk4", "entity_2_idx": [[138, 142]], "entity_2_idx_in_text_with_entity_marker": [151, 155], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p28", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-[E1]Cdk2[/E1], cyclin E-Cdk2, cyclin D1-Cdk4, and [E2]cyclin D2[/E2]-Cdk4 complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Cdk2", "entity_1_idx": [[107, 111]], "entity_1_idx_in_text_with_entity_marker": [111, 115], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin D2", "entity_2_idx": [[148, 157]], "entity_2_idx_in_text_with_entity_marker": [161, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p29", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-[E1]Cdk2[/E1], cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-[E2]Cdk4[/E2] complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Cdk2", "entity_1_idx": [[107, 111]], "entity_1_idx_in_text_with_entity_marker": [111, 115], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk4", "entity_2_idx": [[158, 162]], "entity_2_idx_in_text_with_entity_marker": [171, 175], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p30", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, [E1]cyclin E[/E1]-[E2]Cdk2[/E2], cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "cyclin E", "entity_1_idx": [[113, 121]], "entity_1_idx_in_text_with_entity_marker": [117, 125], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk2", "entity_2_idx": [[122, 126]], "entity_2_idx_in_text_with_entity_marker": [135, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p31", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, [E1]cyclin E[/E1]-Cdk2, [E2]cyclin D1[/E2]-Cdk4, and cyclin D2-Cdk4 complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclin E", "entity_1_idx": [[113, 121]], "entity_1_idx_in_text_with_entity_marker": [117, 125], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin D1", "entity_2_idx": [[128, 137]], "entity_2_idx_in_text_with_entity_marker": [141, 150], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p32", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, [E1]cyclin E[/E1]-Cdk2, cyclin D1-[E2]Cdk4[/E2], and cyclin D2-Cdk4 complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclin E", "entity_1_idx": [[113, 121]], "entity_1_idx_in_text_with_entity_marker": [117, 125], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk4", "entity_2_idx": [[138, 142]], "entity_2_idx_in_text_with_entity_marker": [151, 155], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p33", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, [E1]cyclin E[/E1]-Cdk2, cyclin D1-Cdk4, and [E2]cyclin D2[/E2]-Cdk4 complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclin E", "entity_1_idx": [[113, 121]], "entity_1_idx_in_text_with_entity_marker": [117, 125], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin D2", "entity_2_idx": [[148, 157]], "entity_2_idx_in_text_with_entity_marker": [161, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p34", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, [E1]cyclin E[/E1]-Cdk2, cyclin D1-Cdk4, and cyclin D2-[E2]Cdk4[/E2] complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclin E", "entity_1_idx": [[113, 121]], "entity_1_idx_in_text_with_entity_marker": [117, 125], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk4", "entity_2_idx": [[158, 162]], "entity_2_idx_in_text_with_entity_marker": [171, 175], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p35", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-[E1]Cdk2[/E1], [E2]cyclin D1[/E2]-Cdk4, and cyclin D2-Cdk4 complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Cdk2", "entity_1_idx": [[122, 126]], "entity_1_idx_in_text_with_entity_marker": [126, 130], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin D1", "entity_2_idx": [[128, 137]], "entity_2_idx_in_text_with_entity_marker": [141, 150], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p36", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-[E1]Cdk2[/E1], cyclin D1-[E2]Cdk4[/E2], and cyclin D2-Cdk4 complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Cdk2", "entity_1_idx": [[122, 126]], "entity_1_idx_in_text_with_entity_marker": [126, 130], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk4", "entity_2_idx": [[138, 142]], "entity_2_idx_in_text_with_entity_marker": [151, 155], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p37", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-[E1]Cdk2[/E1], cyclin D1-Cdk4, and [E2]cyclin D2[/E2]-Cdk4 complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Cdk2", "entity_1_idx": [[122, 126]], "entity_1_idx_in_text_with_entity_marker": [126, 130], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin D2", "entity_2_idx": [[148, 157]], "entity_2_idx_in_text_with_entity_marker": [161, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p38", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-[E1]Cdk2[/E1], cyclin D1-Cdk4, and cyclin D2-[E2]Cdk4[/E2] complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Cdk2", "entity_1_idx": [[122, 126]], "entity_1_idx_in_text_with_entity_marker": [126, 130], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk4", "entity_2_idx": [[158, 162]], "entity_2_idx_in_text_with_entity_marker": [171, 175], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p39", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, [E1]cyclin D1[/E1]-[E2]Cdk4[/E2], and cyclin D2-Cdk4 complexes.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "cyclin D1", "entity_1_idx": [[128, 137]], "entity_1_idx_in_text_with_entity_marker": [132, 141], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk4", "entity_2_idx": [[138, 142]], "entity_2_idx_in_text_with_entity_marker": [151, 155], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p40", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, [E1]cyclin D1[/E1]-Cdk4, and [E2]cyclin D2[/E2]-Cdk4 complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclin D1", "entity_1_idx": [[128, 137]], "entity_1_idx_in_text_with_entity_marker": [132, 141], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin D2", "entity_2_idx": [[148, 157]], "entity_2_idx_in_text_with_entity_marker": [161, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p41", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, [E1]cyclin D1[/E1]-Cdk4, and cyclin D2-[E2]Cdk4[/E2] complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclin D1", "entity_1_idx": [[128, 137]], "entity_1_idx_in_text_with_entity_marker": [132, 141], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk4", "entity_2_idx": [[158, 162]], "entity_2_idx_in_text_with_entity_marker": [171, 175], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p42", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-[E1]Cdk4[/E1], and [E2]cyclin D2[/E2]-Cdk4 complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Cdk4", "entity_1_idx": [[138, 142]], "entity_1_idx_in_text_with_entity_marker": [142, 146], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin D2", "entity_2_idx": [[148, 157]], "entity_2_idx_in_text_with_entity_marker": [161, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p43", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-[E1]Cdk4[/E1], and cyclin D2-[E2]Cdk4[/E2] complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Cdk4", "entity_1_idx": [[138, 142]], "entity_1_idx_in_text_with_entity_marker": [142, 146], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk4", "entity_2_idx": [[158, 162]], "entity_2_idx_in_text_with_entity_marker": [171, 175], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1192_AIMed.d141.s1192.p44", "text": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes.", "text_with_entity_marker": "p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and [E1]cyclin D2[/E1]-[E2]Cdk4[/E2] complexes.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "cyclin D2", "entity_1_idx": [[148, 157]], "entity_1_idx_in_text_with_entity_marker": [152, 161], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk4", "entity_2_idx": [[158, 162]], "entity_2_idx_in_text_with_entity_marker": [171, 175], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d141.s1193_AIMed.d141.s1193.p0", "text": "Cotransfection experiments indicate that CIP1 and SV40 T antigen function in a mutually antagonistic manner to control cell cycle progression.", "text_with_entity_marker": "Cotransfection experiments indicate that [E1]CIP1[/E1] and [E2]SV40 T antigen[/E2] function in a mutually antagonistic manner to control cell cycle progression.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CIP1", "entity_1_idx": [[41, 45]], "entity_1_idx_in_text_with_entity_marker": [45, 49], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SV40 T antigen", "entity_2_idx": [[50, 64]], "entity_2_idx_in_text_with_entity_marker": [63, 77], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s334_AIMed.d39.s334.p0", "text": "Presenilin 1 suppresses the function of c-Jun homodimers via interaction with QM/Jif-1.", "text_with_entity_marker": "[E1]Presenilin 1[/E1] suppresses the function of [E2]c-Jun[/E2] homodimers via interaction with QM/Jif-1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Presenilin 1", "entity_1_idx": [[0, 12]], "entity_1_idx_in_text_with_entity_marker": [4, 16], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Jun", "entity_2_idx": [[40, 45]], "entity_2_idx_in_text_with_entity_marker": [53, 58], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s334_AIMed.d39.s334.p1", "text": "Presenilin 1 suppresses the function of c-Jun homodimers via interaction with QM/Jif-1.", "text_with_entity_marker": "[E1]Presenilin 1[/E1] suppresses the function of c-Jun homodimers via interaction with [E2]QM[/E2]/Jif-1.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Presenilin 1", "entity_1_idx": [[0, 12]], "entity_1_idx_in_text_with_entity_marker": [4, 16], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "QM", "entity_2_idx": [[78, 80]], "entity_2_idx_in_text_with_entity_marker": [91, 93], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s334_AIMed.d39.s334.p2", "text": "Presenilin 1 suppresses the function of c-Jun homodimers via interaction with QM/Jif-1.", "text_with_entity_marker": "[E1]Presenilin 1[/E1] suppresses the function of c-Jun homodimers via interaction with QM/[E2]Jif-1[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Presenilin 1", "entity_1_idx": [[0, 12]], "entity_1_idx_in_text_with_entity_marker": [4, 16], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jif-1", "entity_2_idx": [[81, 86]], "entity_2_idx_in_text_with_entity_marker": [94, 99], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s334_AIMed.d39.s334.p3", "text": "Presenilin 1 suppresses the function of c-Jun homodimers via interaction with QM/Jif-1.", "text_with_entity_marker": "Presenilin 1 suppresses the function of [E1]c-Jun[/E1] homodimers via interaction with [E2]QM[/E2]/Jif-1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Jun", "entity_1_idx": [[40, 45]], "entity_1_idx_in_text_with_entity_marker": [44, 49], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "QM", "entity_2_idx": [[78, 80]], "entity_2_idx_in_text_with_entity_marker": [91, 93], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s334_AIMed.d39.s334.p4", "text": "Presenilin 1 suppresses the function of c-Jun homodimers via interaction with QM/Jif-1.", "text_with_entity_marker": "Presenilin 1 suppresses the function of [E1]c-Jun[/E1] homodimers via interaction with QM/[E2]Jif-1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Jun", "entity_1_idx": [[40, 45]], "entity_1_idx_in_text_with_entity_marker": [44, 49], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jif-1", "entity_2_idx": [[81, 86]], "entity_2_idx_in_text_with_entity_marker": [94, 99], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s334_AIMed.d39.s334.p5", "text": "Presenilin 1 suppresses the function of c-Jun homodimers via interaction with QM/Jif-1.", "text_with_entity_marker": "Presenilin 1 suppresses the function of c-Jun homodimers via interaction with [E1]QM[/E1]/[E2]Jif-1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "QM", "entity_1_idx": [[78, 80]], "entity_1_idx_in_text_with_entity_marker": [82, 84], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jif-1", "entity_2_idx": [[81, 86]], "entity_2_idx_in_text_with_entity_marker": [94, 99], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s335_AIMed.d39.s335.p0", "text": "Presenilin 1 (PS1) is the causative gene for an autosomal dominant familial Alzheimer's disease (AD) mapped to chromosome 14.", "text_with_entity_marker": "[E1]Presenilin 1[/E1] ([E2]PS1[/E2]) is the causative gene for an autosomal dominant familial Alzheimer's disease (AD) mapped to chromosome 14.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Presenilin 1", "entity_1_idx": [[0, 12]], "entity_1_idx_in_text_with_entity_marker": [4, 16], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PS1", "entity_2_idx": [[14, 17]], "entity_2_idx_in_text_with_entity_marker": [27, 30], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s336_AIMed.d39.s336.p0", "text": "Here we show that QM/Jun-interacting factor (Jif)-1, a negative regulator of c-Jun, is a candidate to mediate the function of PS1 in the cell.", "text_with_entity_marker": "Here we show that [E1]QM[/E1]/[E2]Jun-interacting factor (Jif)-1[/E2], a negative regulator of c-Jun, is a candidate to mediate the function of PS1 in the cell.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "QM", "entity_1_idx": [[18, 20]], "entity_1_idx_in_text_with_entity_marker": [22, 24], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jun-interacting factor (Jif)-1", "entity_2_idx": [[21, 51]], "entity_2_idx_in_text_with_entity_marker": [34, 64], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s336_AIMed.d39.s336.p1", "text": "Here we show that QM/Jun-interacting factor (Jif)-1, a negative regulator of c-Jun, is a candidate to mediate the function of PS1 in the cell.", "text_with_entity_marker": "Here we show that [E1]QM[/E1]/Jun-interacting factor (Jif)-1, a negative regulator of [E2]c-Jun[/E2], is a candidate to mediate the function of PS1 in the cell.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "QM", "entity_1_idx": [[18, 20]], "entity_1_idx_in_text_with_entity_marker": [22, 24], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Jun", "entity_2_idx": [[77, 82]], "entity_2_idx_in_text_with_entity_marker": [90, 95], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s336_AIMed.d39.s336.p2", "text": "Here we show that QM/Jun-interacting factor (Jif)-1, a negative regulator of c-Jun, is a candidate to mediate the function of PS1 in the cell.", "text_with_entity_marker": "Here we show that [E1]QM[/E1]/Jun-interacting factor (Jif)-1, a negative regulator of c-Jun, is a candidate to mediate the function of [E2]PS1[/E2] in the cell.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "QM", "entity_1_idx": [[18, 20]], "entity_1_idx_in_text_with_entity_marker": [22, 24], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PS1", "entity_2_idx": [[126, 129]], "entity_2_idx_in_text_with_entity_marker": [139, 142], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s336_AIMed.d39.s336.p3", "text": "Here we show that QM/Jun-interacting factor (Jif)-1, a negative regulator of c-Jun, is a candidate to mediate the function of PS1 in the cell.", "text_with_entity_marker": "Here we show that QM/[E1]Jun-interacting factor (Jif)-1[/E1], a negative regulator of [E2]c-Jun[/E2], is a candidate to mediate the function of PS1 in the cell.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Jun-interacting factor (Jif)-1", "entity_1_idx": [[21, 51]], "entity_1_idx_in_text_with_entity_marker": [25, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Jun", "entity_2_idx": [[77, 82]], "entity_2_idx_in_text_with_entity_marker": [90, 95], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s336_AIMed.d39.s336.p4", "text": "Here we show that QM/Jun-interacting factor (Jif)-1, a negative regulator of c-Jun, is a candidate to mediate the function of PS1 in the cell.", "text_with_entity_marker": "Here we show that QM/[E1]Jun-interacting factor (Jif)-1[/E1], a negative regulator of c-Jun, is a candidate to mediate the function of [E2]PS1[/E2] in the cell.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Jun-interacting factor (Jif)-1", "entity_1_idx": [[21, 51]], "entity_1_idx_in_text_with_entity_marker": [25, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PS1", "entity_2_idx": [[126, 129]], "entity_2_idx_in_text_with_entity_marker": [139, 142], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s336_AIMed.d39.s336.p5", "text": "Here we show that QM/Jun-interacting factor (Jif)-1, a negative regulator of c-Jun, is a candidate to mediate the function of PS1 in the cell.", "text_with_entity_marker": "Here we show that QM/Jun-interacting factor (Jif)-1, a negative regulator of [E1]c-Jun[/E1], is a candidate to mediate the function of [E2]PS1[/E2] in the cell.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Jun", "entity_1_idx": [[77, 82]], "entity_1_idx_in_text_with_entity_marker": [81, 86], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PS1", "entity_2_idx": [[126, 129]], "entity_2_idx_in_text_with_entity_marker": [139, 142], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s337_AIMed.d39.s337.p0", "text": "We screened for proteins that bind to PS1 from a human embryonic brain cDNA library using the two-hybrid method and isolated one clone encoding the QM/Jif-1 gene.", "text_with_entity_marker": "We screened for proteins that bind to [E1]PS1[/E1] from a human embryonic brain cDNA library using the two-hybrid method and isolated one clone encoding the [E2]QM[/E2]/Jif-1 gene.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "PS1", "entity_1_idx": [[38, 41]], "entity_1_idx_in_text_with_entity_marker": [42, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "QM", "entity_2_idx": [[148, 150]], "entity_2_idx_in_text_with_entity_marker": [161, 163], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s337_AIMed.d39.s337.p1", "text": "We screened for proteins that bind to PS1 from a human embryonic brain cDNA library using the two-hybrid method and isolated one clone encoding the QM/Jif-1 gene.", "text_with_entity_marker": "We screened for proteins that bind to [E1]PS1[/E1] from a human embryonic brain cDNA library using the two-hybrid method and isolated one clone encoding the QM/[E2]Jif-1[/E2] gene.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "PS1", "entity_1_idx": [[38, 41]], "entity_1_idx_in_text_with_entity_marker": [42, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jif-1", "entity_2_idx": [[151, 156]], "entity_2_idx_in_text_with_entity_marker": [164, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s337_AIMed.d39.s337.p2", "text": "We screened for proteins that bind to PS1 from a human embryonic brain cDNA library using the two-hybrid method and isolated one clone encoding the QM/Jif-1 gene.", "text_with_entity_marker": "We screened for proteins that bind to PS1 from a human embryonic brain cDNA library using the two-hybrid method and isolated one clone encoding the [E1]QM[/E1]/[E2]Jif-1[/E2] gene.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "QM", "entity_1_idx": [[148, 150]], "entity_1_idx_in_text_with_entity_marker": [152, 154], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jif-1", "entity_2_idx": [[151, 156]], "entity_2_idx_in_text_with_entity_marker": [164, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s338_AIMed.d39.s338.p0", "text": "The binding of QM/Jif-1 to full-length PS1 was confirmed in vitro by pull-down assay, and in vivo by immunoprecipitation assays with human samples, including AD brains.", "text_with_entity_marker": "The binding of [E1]QM[/E1]/[E2]Jif-1[/E2] to full-length PS1 was confirmed in vitro by pull-down assay, and in vivo by immunoprecipitation assays with human samples, including AD brains.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "QM", "entity_1_idx": [[15, 17]], "entity_1_idx_in_text_with_entity_marker": [19, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jif-1", "entity_2_idx": [[18, 23]], "entity_2_idx_in_text_with_entity_marker": [31, 36], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s338_AIMed.d39.s338.p1", "text": "The binding of QM/Jif-1 to full-length PS1 was confirmed in vitro by pull-down assay, and in vivo by immunoprecipitation assays with human samples, including AD brains.", "text_with_entity_marker": "The binding of [E1]QM[/E1]/Jif-1 to full-length [E2]PS1[/E2] was confirmed in vitro by pull-down assay, and in vivo by immunoprecipitation assays with human samples, including AD brains.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "QM", "entity_1_idx": [[15, 17]], "entity_1_idx_in_text_with_entity_marker": [19, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PS1", "entity_2_idx": [[39, 42]], "entity_2_idx_in_text_with_entity_marker": [52, 55], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s338_AIMed.d39.s338.p2", "text": "The binding of QM/Jif-1 to full-length PS1 was confirmed in vitro by pull-down assay, and in vivo by immunoprecipitation assays with human samples, including AD brains.", "text_with_entity_marker": "The binding of QM/[E1]Jif-1[/E1] to full-length [E2]PS1[/E2] was confirmed in vitro by pull-down assay, and in vivo by immunoprecipitation assays with human samples, including AD brains.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Jif-1", "entity_1_idx": [[18, 23]], "entity_1_idx_in_text_with_entity_marker": [22, 27], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PS1", "entity_2_idx": [[39, 42]], "entity_2_idx_in_text_with_entity_marker": [52, 55], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s339_AIMed.d39.s339.p0", "text": "Immunoelectronmicroscopic analysis showed that QM/Jif-1 and PS1 are colocalized at the endoplasmic reticulum, and the nuclear matrix in human brain neurons.", "text_with_entity_marker": "Immunoelectronmicroscopic analysis showed that [E1]QM[/E1]/[E2]Jif-1[/E2] and PS1 are colocalized at the endoplasmic reticulum, and the nuclear matrix in human brain neurons.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "QM", "entity_1_idx": [[47, 49]], "entity_1_idx_in_text_with_entity_marker": [51, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jif-1", "entity_2_idx": [[50, 55]], "entity_2_idx_in_text_with_entity_marker": [63, 68], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s339_AIMed.d39.s339.p1", "text": "Immunoelectronmicroscopic analysis showed that QM/Jif-1 and PS1 are colocalized at the endoplasmic reticulum, and the nuclear matrix in human brain neurons.", "text_with_entity_marker": "Immunoelectronmicroscopic analysis showed that [E1]QM[/E1]/Jif-1 and [E2]PS1[/E2] are colocalized at the endoplasmic reticulum, and the nuclear matrix in human brain neurons.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "QM", "entity_1_idx": [[47, 49]], "entity_1_idx_in_text_with_entity_marker": [51, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PS1", "entity_2_idx": [[60, 63]], "entity_2_idx_in_text_with_entity_marker": [73, 76], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s339_AIMed.d39.s339.p2", "text": "Immunoelectronmicroscopic analysis showed that QM/Jif-1 and PS1 are colocalized at the endoplasmic reticulum, and the nuclear matrix in human brain neurons.", "text_with_entity_marker": "Immunoelectronmicroscopic analysis showed that QM/[E1]Jif-1[/E1] and [E2]PS1[/E2] are colocalized at the endoplasmic reticulum, and the nuclear matrix in human brain neurons.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Jif-1", "entity_1_idx": [[50, 55]], "entity_1_idx_in_text_with_entity_marker": [54, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PS1", "entity_2_idx": [[60, 63]], "entity_2_idx_in_text_with_entity_marker": [73, 76], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s340_AIMed.d39.s340.p0", "text": "Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.", "text_with_entity_marker": "Chloramphenicol acetyltransferase assays in F9 cells showed that [E1]PS1[/E1] suppresses transactivation by [E2]c-Jun[/E2]/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PS1", "entity_1_idx": [[65, 68]], "entity_1_idx_in_text_with_entity_marker": [69, 72], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Jun", "entity_2_idx": [[99, 104]], "entity_2_idx_in_text_with_entity_marker": [112, 117], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s340_AIMed.d39.s340.p1", "text": "Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.", "text_with_entity_marker": "Chloramphenicol acetyltransferase assays in F9 cells showed that [E1]PS1[/E1] suppresses transactivation by c-Jun/[E2]c-Jun[/E2] but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PS1", "entity_1_idx": [[65, 68]], "entity_1_idx_in_text_with_entity_marker": [69, 72], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Jun", "entity_2_idx": [[105, 110]], "entity_2_idx_in_text_with_entity_marker": [118, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s340_AIMed.d39.s340.p2", "text": "Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.", "text_with_entity_marker": "Chloramphenicol acetyltransferase assays in F9 cells showed that [E1]PS1[/E1] suppresses transactivation by c-Jun/c-Jun but not by [E2]c-Jun[/E2]/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PS1", "entity_1_idx": [[65, 68]], "entity_1_idx_in_text_with_entity_marker": [69, 72], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Jun", "entity_2_idx": [[122, 127]], "entity_2_idx_in_text_with_entity_marker": [135, 140], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s340_AIMed.d39.s340.p3", "text": "Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.", "text_with_entity_marker": "Chloramphenicol acetyltransferase assays in F9 cells showed that [E1]PS1[/E1] suppresses transactivation by c-Jun/c-Jun but not by c-Jun/[E2]c-Fos[/E2] heterodimers, consistent with the reported function of QM/Jif-1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PS1", "entity_1_idx": [[65, 68]], "entity_1_idx_in_text_with_entity_marker": [69, 72], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Fos", "entity_2_idx": [[128, 133]], "entity_2_idx_in_text_with_entity_marker": [141, 146], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s340_AIMed.d39.s340.p4", "text": "Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.", "text_with_entity_marker": "Chloramphenicol acetyltransferase assays in F9 cells showed that [E1]PS1[/E1] suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of [E2]QM[/E2]/Jif-1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PS1", "entity_1_idx": [[65, 68]], "entity_1_idx_in_text_with_entity_marker": [69, 72], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "QM", "entity_2_idx": [[189, 191]], "entity_2_idx_in_text_with_entity_marker": [202, 204], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s340_AIMed.d39.s340.p5", "text": "Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.", "text_with_entity_marker": "Chloramphenicol acetyltransferase assays in F9 cells showed that [E1]PS1[/E1] suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/[E2]Jif-1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PS1", "entity_1_idx": [[65, 68]], "entity_1_idx_in_text_with_entity_marker": [69, 72], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jif-1", "entity_2_idx": [[192, 197]], "entity_2_idx_in_text_with_entity_marker": [205, 210], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s340_AIMed.d39.s340.p6", "text": "Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.", "text_with_entity_marker": "Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by [E1]c-Jun[/E1]/[E2]c-Jun[/E2] but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "c-Jun", "entity_1_idx": [[99, 104]], "entity_1_idx_in_text_with_entity_marker": [103, 108], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Jun", "entity_2_idx": [[105, 110]], "entity_2_idx_in_text_with_entity_marker": [118, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s340_AIMed.d39.s340.p7", "text": "Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.", "text_with_entity_marker": "Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by [E1]c-Jun[/E1]/c-Jun but not by [E2]c-Jun[/E2]/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Jun", "entity_1_idx": [[99, 104]], "entity_1_idx_in_text_with_entity_marker": [103, 108], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Jun", "entity_2_idx": [[122, 127]], "entity_2_idx_in_text_with_entity_marker": [135, 140], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s340_AIMed.d39.s340.p8", "text": "Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.", "text_with_entity_marker": "Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by [E1]c-Jun[/E1]/c-Jun but not by c-Jun/[E2]c-Fos[/E2] heterodimers, consistent with the reported function of QM/Jif-1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Jun", "entity_1_idx": [[99, 104]], "entity_1_idx_in_text_with_entity_marker": [103, 108], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Fos", "entity_2_idx": [[128, 133]], "entity_2_idx_in_text_with_entity_marker": [141, 146], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s340_AIMed.d39.s340.p9", "text": "Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.", "text_with_entity_marker": "Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by [E1]c-Jun[/E1]/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of [E2]QM[/E2]/Jif-1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Jun", "entity_1_idx": [[99, 104]], "entity_1_idx_in_text_with_entity_marker": [103, 108], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "QM", "entity_2_idx": [[189, 191]], "entity_2_idx_in_text_with_entity_marker": [202, 204], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s340_AIMed.d39.s340.p10", "text": "Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.", "text_with_entity_marker": "Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by [E1]c-Jun[/E1]/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/[E2]Jif-1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Jun", "entity_1_idx": [[99, 104]], "entity_1_idx_in_text_with_entity_marker": [103, 108], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jif-1", "entity_2_idx": [[192, 197]], "entity_2_idx_in_text_with_entity_marker": [205, 210], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s340_AIMed.d39.s340.p11", "text": "Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.", "text_with_entity_marker": "Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/[E1]c-Jun[/E1] but not by [E2]c-Jun[/E2]/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Jun", "entity_1_idx": [[105, 110]], "entity_1_idx_in_text_with_entity_marker": [109, 114], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Jun", "entity_2_idx": [[122, 127]], "entity_2_idx_in_text_with_entity_marker": [135, 140], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s340_AIMed.d39.s340.p12", "text": "Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.", "text_with_entity_marker": "Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/[E1]c-Jun[/E1] but not by c-Jun/[E2]c-Fos[/E2] heterodimers, consistent with the reported function of QM/Jif-1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Jun", "entity_1_idx": [[105, 110]], "entity_1_idx_in_text_with_entity_marker": [109, 114], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Fos", "entity_2_idx": [[128, 133]], "entity_2_idx_in_text_with_entity_marker": [141, 146], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s340_AIMed.d39.s340.p13", "text": "Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.", "text_with_entity_marker": "Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/[E1]c-Jun[/E1] but not by c-Jun/c-Fos heterodimers, consistent with the reported function of [E2]QM[/E2]/Jif-1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Jun", "entity_1_idx": [[105, 110]], "entity_1_idx_in_text_with_entity_marker": [109, 114], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "QM", "entity_2_idx": [[189, 191]], "entity_2_idx_in_text_with_entity_marker": [202, 204], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s340_AIMed.d39.s340.p14", "text": "Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.", "text_with_entity_marker": "Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/[E1]c-Jun[/E1] but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/[E2]Jif-1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Jun", "entity_1_idx": [[105, 110]], "entity_1_idx_in_text_with_entity_marker": [109, 114], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jif-1", "entity_2_idx": [[192, 197]], "entity_2_idx_in_text_with_entity_marker": [205, 210], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s340_AIMed.d39.s340.p15", "text": "Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.", "text_with_entity_marker": "Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by [E1]c-Jun[/E1]/[E2]c-Fos[/E2] heterodimers, consistent with the reported function of QM/Jif-1.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "c-Jun", "entity_1_idx": [[122, 127]], "entity_1_idx_in_text_with_entity_marker": [126, 131], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Fos", "entity_2_idx": [[128, 133]], "entity_2_idx_in_text_with_entity_marker": [141, 146], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s340_AIMed.d39.s340.p16", "text": "Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.", "text_with_entity_marker": "Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by [E1]c-Jun[/E1]/c-Fos heterodimers, consistent with the reported function of [E2]QM[/E2]/Jif-1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Jun", "entity_1_idx": [[122, 127]], "entity_1_idx_in_text_with_entity_marker": [126, 131], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "QM", "entity_2_idx": [[189, 191]], "entity_2_idx_in_text_with_entity_marker": [202, 204], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s340_AIMed.d39.s340.p17", "text": "Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.", "text_with_entity_marker": "Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by [E1]c-Jun[/E1]/c-Fos heterodimers, consistent with the reported function of QM/[E2]Jif-1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Jun", "entity_1_idx": [[122, 127]], "entity_1_idx_in_text_with_entity_marker": [126, 131], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jif-1", "entity_2_idx": [[192, 197]], "entity_2_idx_in_text_with_entity_marker": [205, 210], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s340_AIMed.d39.s340.p18", "text": "Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.", "text_with_entity_marker": "Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/[E1]c-Fos[/E1] heterodimers, consistent with the reported function of [E2]QM[/E2]/Jif-1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Fos", "entity_1_idx": [[128, 133]], "entity_1_idx_in_text_with_entity_marker": [132, 137], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "QM", "entity_2_idx": [[189, 191]], "entity_2_idx_in_text_with_entity_marker": [202, 204], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s340_AIMed.d39.s340.p19", "text": "Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.", "text_with_entity_marker": "Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/[E1]c-Fos[/E1] heterodimers, consistent with the reported function of QM/[E2]Jif-1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Fos", "entity_1_idx": [[128, 133]], "entity_1_idx_in_text_with_entity_marker": [132, 137], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jif-1", "entity_2_idx": [[192, 197]], "entity_2_idx_in_text_with_entity_marker": [205, 210], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s340_AIMed.d39.s340.p20", "text": "Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of QM/Jif-1.", "text_with_entity_marker": "Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c-Jun/c-Jun but not by c-Jun/c-Fos heterodimers, consistent with the reported function of [E1]QM[/E1]/[E2]Jif-1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "QM", "entity_1_idx": [[189, 191]], "entity_1_idx_in_text_with_entity_marker": [193, 195], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jif-1", "entity_2_idx": [[192, 197]], "entity_2_idx_in_text_with_entity_marker": [205, 210], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s341_AIMed.d39.s341.p0", "text": "By monitoring fluorescent recombinant protein and by gel mobility shift assays, PS1 was shown to accelerate the translocation of QM from the cytoplasm to the nucleus and to thereby suppress the binding of c-Jun homodimer to 12-O-tetradecanoylphorbol-13- acetate (TPA)-responsive element (TRE).", "text_with_entity_marker": "By monitoring fluorescent recombinant protein and by gel mobility shift assays, [E1]PS1[/E1] was shown to accelerate the translocation of [E2]QM[/E2] from the cytoplasm to the nucleus and to thereby suppress the binding of c-Jun homodimer to 12-O-tetradecanoylphorbol-13- acetate (TPA)-responsive element (TRE).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PS1", "entity_1_idx": [[80, 83]], "entity_1_idx_in_text_with_entity_marker": [84, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "QM", "entity_2_idx": [[129, 131]], "entity_2_idx_in_text_with_entity_marker": [142, 144], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s341_AIMed.d39.s341.p1", "text": "By monitoring fluorescent recombinant protein and by gel mobility shift assays, PS1 was shown to accelerate the translocation of QM from the cytoplasm to the nucleus and to thereby suppress the binding of c-Jun homodimer to 12-O-tetradecanoylphorbol-13- acetate (TPA)-responsive element (TRE).", "text_with_entity_marker": "By monitoring fluorescent recombinant protein and by gel mobility shift assays, [E1]PS1[/E1] was shown to accelerate the translocation of QM from the cytoplasm to the nucleus and to thereby suppress the binding of [E2]c-Jun[/E2] homodimer to 12-O-tetradecanoylphorbol-13- acetate (TPA)-responsive element (TRE).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PS1", "entity_1_idx": [[80, 83]], "entity_1_idx_in_text_with_entity_marker": [84, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Jun", "entity_2_idx": [[205, 210]], "entity_2_idx_in_text_with_entity_marker": [218, 223], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s341_AIMed.d39.s341.p2", "text": "By monitoring fluorescent recombinant protein and by gel mobility shift assays, PS1 was shown to accelerate the translocation of QM from the cytoplasm to the nucleus and to thereby suppress the binding of c-Jun homodimer to 12-O-tetradecanoylphorbol-13- acetate (TPA)-responsive element (TRE).", "text_with_entity_marker": "By monitoring fluorescent recombinant protein and by gel mobility shift assays, PS1 was shown to accelerate the translocation of [E1]QM[/E1] from the cytoplasm to the nucleus and to thereby suppress the binding of [E2]c-Jun[/E2] homodimer to 12-O-tetradecanoylphorbol-13- acetate (TPA)-responsive element (TRE).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "QM", "entity_1_idx": [[129, 131]], "entity_1_idx_in_text_with_entity_marker": [133, 135], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Jun", "entity_2_idx": [[205, 210]], "entity_2_idx_in_text_with_entity_marker": [218, 223], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s342_AIMed.d39.s342.p0", "text": "PS1 suppressed c-jun-associated apoptosis by retinoic acid in F9 embryonic carcinoma cells, whereas this suppression of apoptosis is attenuated by mutation in PS1.", "text_with_entity_marker": "[E1]PS1[/E1] suppressed [E2]c-jun[/E2]-associated apoptosis by retinoic acid in F9 embryonic carcinoma cells, whereas this suppression of apoptosis is attenuated by mutation in PS1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PS1", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-jun", "entity_2_idx": [[15, 20]], "entity_2_idx_in_text_with_entity_marker": [28, 33], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s342_AIMed.d39.s342.p1", "text": "PS1 suppressed c-jun-associated apoptosis by retinoic acid in F9 embryonic carcinoma cells, whereas this suppression of apoptosis is attenuated by mutation in PS1.", "text_with_entity_marker": "[E1]PS1[/E1] suppressed c-jun-associated apoptosis by retinoic acid in F9 embryonic carcinoma cells, whereas this suppression of apoptosis is attenuated by mutation in [E2]PS1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PS1", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PS1", "entity_2_idx": [[159, 162]], "entity_2_idx_in_text_with_entity_marker": [172, 175], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s342_AIMed.d39.s342.p2", "text": "PS1 suppressed c-jun-associated apoptosis by retinoic acid in F9 embryonic carcinoma cells, whereas this suppression of apoptosis is attenuated by mutation in PS1.", "text_with_entity_marker": "PS1 suppressed [E1]c-jun[/E1]-associated apoptosis by retinoic acid in F9 embryonic carcinoma cells, whereas this suppression of apoptosis is attenuated by mutation in [E2]PS1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-jun", "entity_1_idx": [[15, 20]], "entity_1_idx_in_text_with_entity_marker": [19, 24], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PS1", "entity_2_idx": [[159, 162]], "entity_2_idx_in_text_with_entity_marker": [172, 175], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s343_AIMed.d39.s343.p0", "text": "Collectively, the novel function of PS1 via QM/Jif-1 influences c-jun-mediated transcription and apoptosis.", "text_with_entity_marker": "Collectively, the novel function of [E1]PS1[/E1] via [E2]QM[/E2]/Jif-1 influences c-jun-mediated transcription and apoptosis.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PS1", "entity_1_idx": [[36, 39]], "entity_1_idx_in_text_with_entity_marker": [40, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "QM", "entity_2_idx": [[44, 46]], "entity_2_idx_in_text_with_entity_marker": [57, 59], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s343_AIMed.d39.s343.p1", "text": "Collectively, the novel function of PS1 via QM/Jif-1 influences c-jun-mediated transcription and apoptosis.", "text_with_entity_marker": "Collectively, the novel function of [E1]PS1[/E1] via QM/[E2]Jif-1[/E2] influences c-jun-mediated transcription and apoptosis.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PS1", "entity_1_idx": [[36, 39]], "entity_1_idx_in_text_with_entity_marker": [40, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jif-1", "entity_2_idx": [[47, 52]], "entity_2_idx_in_text_with_entity_marker": [60, 65], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s343_AIMed.d39.s343.p2", "text": "Collectively, the novel function of PS1 via QM/Jif-1 influences c-jun-mediated transcription and apoptosis.", "text_with_entity_marker": "Collectively, the novel function of [E1]PS1[/E1] via QM/Jif-1 influences [E2]c-jun[/E2]-mediated transcription and apoptosis.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PS1", "entity_1_idx": [[36, 39]], "entity_1_idx_in_text_with_entity_marker": [40, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-jun", "entity_2_idx": [[64, 69]], "entity_2_idx_in_text_with_entity_marker": [77, 82], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s343_AIMed.d39.s343.p3", "text": "Collectively, the novel function of PS1 via QM/Jif-1 influences c-jun-mediated transcription and apoptosis.", "text_with_entity_marker": "Collectively, the novel function of PS1 via [E1]QM[/E1]/[E2]Jif-1[/E2] influences c-jun-mediated transcription and apoptosis.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "QM", "entity_1_idx": [[44, 46]], "entity_1_idx_in_text_with_entity_marker": [48, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jif-1", "entity_2_idx": [[47, 52]], "entity_2_idx_in_text_with_entity_marker": [60, 65], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s343_AIMed.d39.s343.p4", "text": "Collectively, the novel function of PS1 via QM/Jif-1 influences c-jun-mediated transcription and apoptosis.", "text_with_entity_marker": "Collectively, the novel function of PS1 via [E1]QM[/E1]/Jif-1 influences [E2]c-jun[/E2]-mediated transcription and apoptosis.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "QM", "entity_1_idx": [[44, 46]], "entity_1_idx_in_text_with_entity_marker": [48, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-jun", "entity_2_idx": [[64, 69]], "entity_2_idx_in_text_with_entity_marker": [77, 82], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d39.s343_AIMed.d39.s343.p5", "text": "Collectively, the novel function of PS1 via QM/Jif-1 influences c-jun-mediated transcription and apoptosis.", "text_with_entity_marker": "Collectively, the novel function of PS1 via QM/[E1]Jif-1[/E1] influences [E2]c-jun[/E2]-mediated transcription and apoptosis.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Jif-1", "entity_1_idx": [[47, 52]], "entity_1_idx_in_text_with_entity_marker": [51, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-jun", "entity_2_idx": [[64, 69]], "entity_2_idx_in_text_with_entity_marker": [77, 82], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d171.s1441_AIMed.d171.s1441.p0", "text": "Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex.", "text_with_entity_marker": "Crystal structure of the [E1]p27Kip1[/E1] cyclin-dependent-kinase inhibitor bound to the [E2]cyclin A[/E2]-Cdk2 complex.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p27Kip1", "entity_1_idx": [[25, 32]], "entity_1_idx_in_text_with_entity_marker": [29, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin A", "entity_2_idx": [[80, 88]], "entity_2_idx_in_text_with_entity_marker": [93, 101], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d171.s1441_AIMed.d171.s1441.p1", "text": "Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex.", "text_with_entity_marker": "Crystal structure of the [E1]p27Kip1[/E1] cyclin-dependent-kinase inhibitor bound to the cyclin A-[E2]Cdk2[/E2] complex.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p27Kip1", "entity_1_idx": [[25, 32]], "entity_1_idx_in_text_with_entity_marker": [29, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk2", "entity_2_idx": [[89, 93]], "entity_2_idx_in_text_with_entity_marker": [102, 106], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d171.s1441_AIMed.d171.s1441.p2", "text": "Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex.", "text_with_entity_marker": "Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the [E1]cyclin A[/E1]-[E2]Cdk2[/E2] complex.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "cyclin A", "entity_1_idx": [[80, 88]], "entity_1_idx_in_text_with_entity_marker": [84, 92], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk2", "entity_2_idx": [[89, 93]], "entity_2_idx_in_text_with_entity_marker": [102, 106], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d171.s1442_AIMed.d171.s1442.p0", "text": "The crystal structure of the human p27Kip1 kinase inhibitory domain bound to the phosphorylated cyclin A-cyclin-dependent kinase 2 (Cdk2) complex has been determined at 2.3 angstrom.", "text_with_entity_marker": "The crystal structure of the human [E1]p27Kip1 kinase[/E1] inhibitory domain bound to the phosphorylated [E2]cyclin A[/E2]-cyclin-dependent kinase 2 (Cdk2) complex has been determined at 2.3 angstrom.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p27Kip1 kinase", "entity_1_idx": [[35, 49]], "entity_1_idx_in_text_with_entity_marker": [39, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin A", "entity_2_idx": [[96, 104]], "entity_2_idx_in_text_with_entity_marker": [109, 117], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d171.s1442_AIMed.d171.s1442.p1", "text": "The crystal structure of the human p27Kip1 kinase inhibitory domain bound to the phosphorylated cyclin A-cyclin-dependent kinase 2 (Cdk2) complex has been determined at 2.3 angstrom.", "text_with_entity_marker": "The crystal structure of the human [E1]p27Kip1 kinase[/E1] inhibitory domain bound to the phosphorylated cyclin A-[E2]cyclin-dependent kinase 2[/E2] (Cdk2) complex has been determined at 2.3 angstrom.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p27Kip1 kinase", "entity_1_idx": [[35, 49]], "entity_1_idx_in_text_with_entity_marker": [39, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin-dependent kinase 2", "entity_2_idx": [[105, 130]], "entity_2_idx_in_text_with_entity_marker": [118, 143], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d171.s1442_AIMed.d171.s1442.p2", "text": "The crystal structure of the human p27Kip1 kinase inhibitory domain bound to the phosphorylated cyclin A-cyclin-dependent kinase 2 (Cdk2) complex has been determined at 2.3 angstrom.", "text_with_entity_marker": "The crystal structure of the human [E1]p27Kip1 kinase[/E1] inhibitory domain bound to the phosphorylated cyclin A-cyclin-dependent kinase 2 ([E2]Cdk2[/E2]) complex has been determined at 2.3 angstrom.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p27Kip1 kinase", "entity_1_idx": [[35, 49]], "entity_1_idx_in_text_with_entity_marker": [39, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk2", "entity_2_idx": [[132, 136]], "entity_2_idx_in_text_with_entity_marker": [145, 149], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d171.s1442_AIMed.d171.s1442.p3", "text": "The crystal structure of the human p27Kip1 kinase inhibitory domain bound to the phosphorylated cyclin A-cyclin-dependent kinase 2 (Cdk2) complex has been determined at 2.3 angstrom.", "text_with_entity_marker": "The crystal structure of the human p27Kip1 kinase inhibitory domain bound to the phosphorylated [E1]cyclin A[/E1]-[E2]cyclin-dependent kinase 2[/E2] (Cdk2) complex has been determined at 2.3 angstrom.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclin A", "entity_1_idx": [[96, 104]], "entity_1_idx_in_text_with_entity_marker": [100, 108], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin-dependent kinase 2", "entity_2_idx": [[105, 130]], "entity_2_idx_in_text_with_entity_marker": [118, 143], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d171.s1442_AIMed.d171.s1442.p4", "text": "The crystal structure of the human p27Kip1 kinase inhibitory domain bound to the phosphorylated cyclin A-cyclin-dependent kinase 2 (Cdk2) complex has been determined at 2.3 angstrom.", "text_with_entity_marker": "The crystal structure of the human p27Kip1 kinase inhibitory domain bound to the phosphorylated [E1]cyclin A[/E1]-cyclin-dependent kinase 2 ([E2]Cdk2[/E2]) complex has been determined at 2.3 angstrom.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "cyclin A", "entity_1_idx": [[96, 104]], "entity_1_idx_in_text_with_entity_marker": [100, 108], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk2", "entity_2_idx": [[132, 136]], "entity_2_idx_in_text_with_entity_marker": [145, 149], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d171.s1442_AIMed.d171.s1442.p5", "text": "The crystal structure of the human p27Kip1 kinase inhibitory domain bound to the phosphorylated cyclin A-cyclin-dependent kinase 2 (Cdk2) complex has been determined at 2.3 angstrom.", "text_with_entity_marker": "The crystal structure of the human p27Kip1 kinase inhibitory domain bound to the phosphorylated cyclin A-[E1]cyclin-dependent kinase 2[/E1] ([E2]Cdk2[/E2]) complex has been determined at 2.3 angstrom.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclin-dependent kinase 2", "entity_1_idx": [[105, 130]], "entity_1_idx_in_text_with_entity_marker": [109, 134], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk2", "entity_2_idx": [[132, 136]], "entity_2_idx_in_text_with_entity_marker": [145, 149], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d171.s1443_AIMed.d171.s1443.p0", "text": "p27Kip1 binds the complex as an extended structure interacting with both cyclin A and Cdk2.", "text_with_entity_marker": "[E1]p27Kip1[/E1] binds the complex as an extended structure interacting with both [E2]cyclin A[/E2] and Cdk2.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p27Kip1", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin A", "entity_2_idx": [[73, 81]], "entity_2_idx_in_text_with_entity_marker": [86, 94], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d171.s1443_AIMed.d171.s1443.p1", "text": "p27Kip1 binds the complex as an extended structure interacting with both cyclin A and Cdk2.", "text_with_entity_marker": "[E1]p27Kip1[/E1] binds the complex as an extended structure interacting with both cyclin A and [E2]Cdk2[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p27Kip1", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk2", "entity_2_idx": [[86, 90]], "entity_2_idx_in_text_with_entity_marker": [99, 103], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d171.s1443_AIMed.d171.s1443.p2", "text": "p27Kip1 binds the complex as an extended structure interacting with both cyclin A and Cdk2.", "text_with_entity_marker": "p27Kip1 binds the complex as an extended structure interacting with both [E1]cyclin A[/E1] and [E2]Cdk2[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclin A", "entity_1_idx": [[73, 81]], "entity_1_idx_in_text_with_entity_marker": [77, 85], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk2", "entity_2_idx": [[86, 90]], "entity_2_idx_in_text_with_entity_marker": [99, 103], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d20.s168_AIMed.d20.s168.p0", "text": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "text_with_entity_marker": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules [E1]tumour necrosis factors (TNF) alpha[/E1] and beta, [E2]transforming growth factors (TGF) beta1[/E2] and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "tumour necrosis factors (TNF) alpha", "entity_1_idx": [[155, 190]], "entity_1_idx_in_text_with_entity_marker": [159, 194], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "transforming growth factors (TGF) beta1", "entity_2_idx": [[201, 240]], "entity_2_idx_in_text_with_entity_marker": [214, 253], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d20.s168_AIMed.d20.s168.p1", "text": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "text_with_entity_marker": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules [E1]tumour necrosis factors (TNF) alpha[/E1] and beta, transforming growth factors (TGF) beta1 and 2, [E2]interleukin (IL) 1[/E2] and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "tumour necrosis factors (TNF) alpha", "entity_1_idx": [[155, 190]], "entity_1_idx_in_text_with_entity_marker": [159, 194], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin (IL) 1", "entity_2_idx": [[248, 266]], "entity_2_idx_in_text_with_entity_marker": [261, 279], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d20.s168_AIMed.d20.s168.p2", "text": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "text_with_entity_marker": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules [E1]tumour necrosis factors (TNF) alpha[/E1] and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist ([E2]IL 1ra[/E2]), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "tumour necrosis factors (TNF) alpha", "entity_1_idx": [[155, 190]], "entity_1_idx_in_text_with_entity_marker": [159, 194], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL 1ra", "entity_2_idx": [[296, 302]], "entity_2_idx_in_text_with_entity_marker": [309, 315], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d20.s168_AIMed.d20.s168.p3", "text": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "text_with_entity_marker": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules [E1]tumour necrosis factors (TNF) alpha[/E1] and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), [E2]CD14[/E2] (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "tumour necrosis factors (TNF) alpha", "entity_1_idx": [[155, 190]], "entity_1_idx_in_text_with_entity_marker": [159, 194], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD14", "entity_2_idx": [[305, 309]], "entity_2_idx_in_text_with_entity_marker": [318, 322], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d20.s168_AIMed.d20.s168.p4", "text": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "text_with_entity_marker": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules [E1]tumour necrosis factors (TNF) alpha[/E1] and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and [E2]platelet endothelial cell adhesion molecule (PECAM) 1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "tumour necrosis factors (TNF) alpha", "entity_1_idx": [[155, 190]], "entity_1_idx_in_text_with_entity_marker": [159, 194], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "platelet endothelial cell adhesion molecule (PECAM) 1", "entity_2_idx": [[372, 425]], "entity_2_idx_in_text_with_entity_marker": [385, 438], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d20.s168_AIMed.d20.s168.p5", "text": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "text_with_entity_marker": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, [E1]transforming growth factors (TGF) beta1[/E1] and 2, [E2]interleukin (IL) 1[/E2] and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "transforming growth factors (TGF) beta1", "entity_1_idx": [[201, 240]], "entity_1_idx_in_text_with_entity_marker": [205, 244], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin (IL) 1", "entity_2_idx": [[248, 266]], "entity_2_idx_in_text_with_entity_marker": [261, 279], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d20.s168_AIMed.d20.s168.p6", "text": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "text_with_entity_marker": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, [E1]transforming growth factors (TGF) beta1[/E1] and 2, interleukin (IL) 1 and its receptor antagonist ([E2]IL 1ra[/E2]), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "transforming growth factors (TGF) beta1", "entity_1_idx": [[201, 240]], "entity_1_idx_in_text_with_entity_marker": [205, 244], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL 1ra", "entity_2_idx": [[296, 302]], "entity_2_idx_in_text_with_entity_marker": [309, 315], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d20.s168_AIMed.d20.s168.p7", "text": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "text_with_entity_marker": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, [E1]transforming growth factors (TGF) beta1[/E1] and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), [E2]CD14[/E2] (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "transforming growth factors (TGF) beta1", "entity_1_idx": [[201, 240]], "entity_1_idx_in_text_with_entity_marker": [205, 244], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD14", "entity_2_idx": [[305, 309]], "entity_2_idx_in_text_with_entity_marker": [318, 322], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d20.s168_AIMed.d20.s168.p8", "text": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "text_with_entity_marker": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, [E1]transforming growth factors (TGF) beta1[/E1] and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and [E2]platelet endothelial cell adhesion molecule (PECAM) 1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "transforming growth factors (TGF) beta1", "entity_1_idx": [[201, 240]], "entity_1_idx_in_text_with_entity_marker": [205, 244], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "platelet endothelial cell adhesion molecule (PECAM) 1", "entity_2_idx": [[372, 425]], "entity_2_idx_in_text_with_entity_marker": [385, 438], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d20.s168_AIMed.d20.s168.p9", "text": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "text_with_entity_marker": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, [E1]interleukin (IL) 1[/E1] and its receptor antagonist ([E2]IL 1ra[/E2]), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin (IL) 1", "entity_1_idx": [[248, 266]], "entity_1_idx_in_text_with_entity_marker": [252, 270], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL 1ra", "entity_2_idx": [[296, 302]], "entity_2_idx_in_text_with_entity_marker": [309, 315], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d20.s168_AIMed.d20.s168.p10", "text": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "text_with_entity_marker": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, [E1]interleukin (IL) 1[/E1] and its receptor antagonist (IL 1ra), [E2]CD14[/E2] (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin (IL) 1", "entity_1_idx": [[248, 266]], "entity_1_idx_in_text_with_entity_marker": [252, 270], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD14", "entity_2_idx": [[305, 309]], "entity_2_idx_in_text_with_entity_marker": [318, 322], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d20.s168_AIMed.d20.s168.p11", "text": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "text_with_entity_marker": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, [E1]interleukin (IL) 1[/E1] and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and [E2]platelet endothelial cell adhesion molecule (PECAM) 1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin (IL) 1", "entity_1_idx": [[248, 266]], "entity_1_idx_in_text_with_entity_marker": [252, 270], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "platelet endothelial cell adhesion molecule (PECAM) 1", "entity_2_idx": [[372, 425]], "entity_2_idx_in_text_with_entity_marker": [385, 438], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d20.s168_AIMed.d20.s168.p12", "text": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "text_with_entity_marker": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist ([E1]IL 1ra[/E1]), [E2]CD14[/E2] (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL 1ra", "entity_1_idx": [[296, 302]], "entity_1_idx_in_text_with_entity_marker": [300, 306], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD14", "entity_2_idx": [[305, 309]], "entity_2_idx_in_text_with_entity_marker": [318, 322], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d20.s168_AIMed.d20.s168.p13", "text": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "text_with_entity_marker": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist ([E1]IL 1ra[/E1]), CD14 (the receptor for lipopolysaccharide), P and E selectins, and [E2]platelet endothelial cell adhesion molecule (PECAM) 1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL 1ra", "entity_1_idx": [[296, 302]], "entity_1_idx_in_text_with_entity_marker": [300, 306], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "platelet endothelial cell adhesion molecule (PECAM) 1", "entity_2_idx": [[372, 425]], "entity_2_idx_in_text_with_entity_marker": [385, 438], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d20.s168_AIMed.d20.s168.p14", "text": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "text_with_entity_marker": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), [E1]CD14[/E1] (the receptor for lipopolysaccharide), P and E selectins, and [E2]platelet endothelial cell adhesion molecule (PECAM) 1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD14", "entity_1_idx": [[305, 309]], "entity_1_idx_in_text_with_entity_marker": [309, 313], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "platelet endothelial cell adhesion molecule (PECAM) 1", "entity_2_idx": [[372, 425]], "entity_2_idx_in_text_with_entity_marker": [385, 438], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d83.s704_AIMed.d83.s704.p0", "text": "By rational mutagenesis, receptor-specific functional analysis, and visualization of complex formation in solution, we identified individual amino acid side chains involved specifically in the interaction of ciliary neurotrophic factor (CNTF) with CNTFR alpha and not with the beta-components, gp130 and LIFR.", "text_with_entity_marker": "By rational mutagenesis, receptor-specific functional analysis, and visualization of complex formation in solution, we identified individual amino acid side chains involved specifically in the interaction of [E1]ciliary neurotrophic factor[/E1] ([E2]CNTF[/E2]) with CNTFR alpha and not with the beta-components, gp130 and LIFR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ciliary neurotrophic factor", "entity_1_idx": [[208, 235]], "entity_1_idx_in_text_with_entity_marker": [212, 239], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CNTF", "entity_2_idx": [[237, 241]], "entity_2_idx_in_text_with_entity_marker": [250, 254], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d83.s704_AIMed.d83.s704.p1", "text": "By rational mutagenesis, receptor-specific functional analysis, and visualization of complex formation in solution, we identified individual amino acid side chains involved specifically in the interaction of ciliary neurotrophic factor (CNTF) with CNTFR alpha and not with the beta-components, gp130 and LIFR.", "text_with_entity_marker": "By rational mutagenesis, receptor-specific functional analysis, and visualization of complex formation in solution, we identified individual amino acid side chains involved specifically in the interaction of [E1]ciliary neurotrophic factor[/E1] (CNTF) with [E2]CNTFR alpha[/E2] and not with the beta-components, gp130 and LIFR.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "ciliary neurotrophic factor", "entity_1_idx": [[208, 235]], "entity_1_idx_in_text_with_entity_marker": [212, 239], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CNTFR alpha", "entity_2_idx": [[248, 259]], "entity_2_idx_in_text_with_entity_marker": [261, 272], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d83.s704_AIMed.d83.s704.p2", "text": "By rational mutagenesis, receptor-specific functional analysis, and visualization of complex formation in solution, we identified individual amino acid side chains involved specifically in the interaction of ciliary neurotrophic factor (CNTF) with CNTFR alpha and not with the beta-components, gp130 and LIFR.", "text_with_entity_marker": "By rational mutagenesis, receptor-specific functional analysis, and visualization of complex formation in solution, we identified individual amino acid side chains involved specifically in the interaction of [E1]ciliary neurotrophic factor[/E1] (CNTF) with CNTFR alpha and not with the beta-components, [E2]gp130[/E2] and LIFR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ciliary neurotrophic factor", "entity_1_idx": [[208, 235]], "entity_1_idx_in_text_with_entity_marker": [212, 239], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[294, 299]], "entity_2_idx_in_text_with_entity_marker": [307, 312], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d83.s704_AIMed.d83.s704.p3", "text": "By rational mutagenesis, receptor-specific functional analysis, and visualization of complex formation in solution, we identified individual amino acid side chains involved specifically in the interaction of ciliary neurotrophic factor (CNTF) with CNTFR alpha and not with the beta-components, gp130 and LIFR.", "text_with_entity_marker": "By rational mutagenesis, receptor-specific functional analysis, and visualization of complex formation in solution, we identified individual amino acid side chains involved specifically in the interaction of [E1]ciliary neurotrophic factor[/E1] (CNTF) with CNTFR alpha and not with the beta-components, gp130 and [E2]LIFR[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ciliary neurotrophic factor", "entity_1_idx": [[208, 235]], "entity_1_idx_in_text_with_entity_marker": [212, 239], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LIFR", "entity_2_idx": [[304, 308]], "entity_2_idx_in_text_with_entity_marker": [317, 321], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d83.s704_AIMed.d83.s704.p4", "text": "By rational mutagenesis, receptor-specific functional analysis, and visualization of complex formation in solution, we identified individual amino acid side chains involved specifically in the interaction of ciliary neurotrophic factor (CNTF) with CNTFR alpha and not with the beta-components, gp130 and LIFR.", "text_with_entity_marker": "By rational mutagenesis, receptor-specific functional analysis, and visualization of complex formation in solution, we identified individual amino acid side chains involved specifically in the interaction of ciliary neurotrophic factor ([E1]CNTF[/E1]) with [E2]CNTFR alpha[/E2] and not with the beta-components, gp130 and LIFR.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CNTF", "entity_1_idx": [[237, 241]], "entity_1_idx_in_text_with_entity_marker": [241, 245], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CNTFR alpha", "entity_2_idx": [[248, 259]], "entity_2_idx_in_text_with_entity_marker": [261, 272], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d83.s704_AIMed.d83.s704.p5", "text": "By rational mutagenesis, receptor-specific functional analysis, and visualization of complex formation in solution, we identified individual amino acid side chains involved specifically in the interaction of ciliary neurotrophic factor (CNTF) with CNTFR alpha and not with the beta-components, gp130 and LIFR.", "text_with_entity_marker": "By rational mutagenesis, receptor-specific functional analysis, and visualization of complex formation in solution, we identified individual amino acid side chains involved specifically in the interaction of ciliary neurotrophic factor ([E1]CNTF[/E1]) with CNTFR alpha and not with the beta-components, [E2]gp130[/E2] and LIFR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CNTF", "entity_1_idx": [[237, 241]], "entity_1_idx_in_text_with_entity_marker": [241, 245], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[294, 299]], "entity_2_idx_in_text_with_entity_marker": [307, 312], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d83.s704_AIMed.d83.s704.p6", "text": "By rational mutagenesis, receptor-specific functional analysis, and visualization of complex formation in solution, we identified individual amino acid side chains involved specifically in the interaction of ciliary neurotrophic factor (CNTF) with CNTFR alpha and not with the beta-components, gp130 and LIFR.", "text_with_entity_marker": "By rational mutagenesis, receptor-specific functional analysis, and visualization of complex formation in solution, we identified individual amino acid side chains involved specifically in the interaction of ciliary neurotrophic factor ([E1]CNTF[/E1]) with CNTFR alpha and not with the beta-components, gp130 and [E2]LIFR[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CNTF", "entity_1_idx": [[237, 241]], "entity_1_idx_in_text_with_entity_marker": [241, 245], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LIFR", "entity_2_idx": [[304, 308]], "entity_2_idx_in_text_with_entity_marker": [317, 321], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d83.s704_AIMed.d83.s704.p7", "text": "By rational mutagenesis, receptor-specific functional analysis, and visualization of complex formation in solution, we identified individual amino acid side chains involved specifically in the interaction of ciliary neurotrophic factor (CNTF) with CNTFR alpha and not with the beta-components, gp130 and LIFR.", "text_with_entity_marker": "By rational mutagenesis, receptor-specific functional analysis, and visualization of complex formation in solution, we identified individual amino acid side chains involved specifically in the interaction of ciliary neurotrophic factor (CNTF) with [E1]CNTFR alpha[/E1] and not with the beta-components, [E2]gp130[/E2] and LIFR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CNTFR alpha", "entity_1_idx": [[248, 259]], "entity_1_idx_in_text_with_entity_marker": [252, 263], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[294, 299]], "entity_2_idx_in_text_with_entity_marker": [307, 312], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d83.s704_AIMed.d83.s704.p8", "text": "By rational mutagenesis, receptor-specific functional analysis, and visualization of complex formation in solution, we identified individual amino acid side chains involved specifically in the interaction of ciliary neurotrophic factor (CNTF) with CNTFR alpha and not with the beta-components, gp130 and LIFR.", "text_with_entity_marker": "By rational mutagenesis, receptor-specific functional analysis, and visualization of complex formation in solution, we identified individual amino acid side chains involved specifically in the interaction of ciliary neurotrophic factor (CNTF) with [E1]CNTFR alpha[/E1] and not with the beta-components, gp130 and [E2]LIFR[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CNTFR alpha", "entity_1_idx": [[248, 259]], "entity_1_idx_in_text_with_entity_marker": [252, 263], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LIFR", "entity_2_idx": [[304, 308]], "entity_2_idx_in_text_with_entity_marker": [317, 321], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d83.s704_AIMed.d83.s704.p9", "text": "By rational mutagenesis, receptor-specific functional analysis, and visualization of complex formation in solution, we identified individual amino acid side chains involved specifically in the interaction of ciliary neurotrophic factor (CNTF) with CNTFR alpha and not with the beta-components, gp130 and LIFR.", "text_with_entity_marker": "By rational mutagenesis, receptor-specific functional analysis, and visualization of complex formation in solution, we identified individual amino acid side chains involved specifically in the interaction of ciliary neurotrophic factor (CNTF) with CNTFR alpha and not with the beta-components, [E1]gp130[/E1] and [E2]LIFR[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gp130", "entity_1_idx": [[294, 299]], "entity_1_idx_in_text_with_entity_marker": [298, 303], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LIFR", "entity_2_idx": [[304, 308]], "entity_2_idx_in_text_with_entity_marker": [317, 321], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d83.s707_AIMed.d83.s707.p0", "text": "Superposition of the CNTF and growth hormone structures showed that the location of these epitopes on CNTF is analogous to the location of the first and second receptor epitopes on the surface of growth hormone.", "text_with_entity_marker": "Superposition of the [E1]CNTF[/E1] and growth hormone structures showed that the location of these epitopes on [E2]CNTF[/E2] is analogous to the location of the first and second receptor epitopes on the surface of growth hormone.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CNTF", "entity_1_idx": [[21, 25]], "entity_1_idx_in_text_with_entity_marker": [25, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CNTF", "entity_2_idx": [[102, 106]], "entity_2_idx_in_text_with_entity_marker": [115, 119], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d140.s1180_AIMed.d140.s1180.p0", "text": "Cdi1, a human G1 and S phase protein phosphatase that associates with Cdk2.", "text_with_entity_marker": "[E1]Cdi1[/E1], a human G1 and S phase protein phosphatase that associates with [E2]Cdk2[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Cdi1", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk2", "entity_2_idx": [[70, 74]], "entity_2_idx_in_text_with_entity_marker": [83, 87], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d140.s1181_AIMed.d140.s1181.p0", "text": "We used the interaction trap, a yeast genetic selection for interacting proteins, to isolate human cyclin-dependent kinase interactor 1 (Cdi1).", "text_with_entity_marker": "We used the interaction trap, a yeast genetic selection for interacting proteins, to isolate human [E1]cyclin-dependent kinase interactor 1[/E1] ([E2]Cdi1[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclin-dependent kinase interactor 1", "entity_1_idx": [[99, 135]], "entity_1_idx_in_text_with_entity_marker": [103, 139], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdi1", "entity_2_idx": [[137, 141]], "entity_2_idx_in_text_with_entity_marker": [150, 154], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d140.s1182_AIMed.d140.s1182.p0", "text": "In yeast, Cdi1 interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and Cdk3, but not with Cdk4.", "text_with_entity_marker": "In yeast, [E1]Cdi1[/E1] interacts with cyclin-dependent kinases, including human [E2]Cdc2[/E2], Cdk2, and Cdk3, but not with Cdk4.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Cdi1", "entity_1_idx": [[10, 14]], "entity_1_idx_in_text_with_entity_marker": [14, 18], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdc2", "entity_2_idx": [[72, 76]], "entity_2_idx_in_text_with_entity_marker": [85, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d140.s1182_AIMed.d140.s1182.p1", "text": "In yeast, Cdi1 interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and Cdk3, but not with Cdk4.", "text_with_entity_marker": "In yeast, [E1]Cdi1[/E1] interacts with cyclin-dependent kinases, including human Cdc2, [E2]Cdk2[/E2], and Cdk3, but not with Cdk4.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Cdi1", "entity_1_idx": [[10, 14]], "entity_1_idx_in_text_with_entity_marker": [14, 18], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk2", "entity_2_idx": [[78, 82]], "entity_2_idx_in_text_with_entity_marker": [91, 95], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d140.s1182_AIMed.d140.s1182.p2", "text": "In yeast, Cdi1 interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and Cdk3, but not with Cdk4.", "text_with_entity_marker": "In yeast, [E1]Cdi1[/E1] interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and [E2]Cdk3[/E2], but not with Cdk4.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Cdi1", "entity_1_idx": [[10, 14]], "entity_1_idx_in_text_with_entity_marker": [14, 18], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk3", "entity_2_idx": [[88, 92]], "entity_2_idx_in_text_with_entity_marker": [101, 105], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d140.s1182_AIMed.d140.s1182.p3", "text": "In yeast, Cdi1 interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and Cdk3, but not with Cdk4.", "text_with_entity_marker": "In yeast, [E1]Cdi1[/E1] interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and Cdk3, but not with [E2]Cdk4[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Cdi1", "entity_1_idx": [[10, 14]], "entity_1_idx_in_text_with_entity_marker": [14, 18], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk4", "entity_2_idx": [[107, 111]], "entity_2_idx_in_text_with_entity_marker": [120, 124], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d140.s1182_AIMed.d140.s1182.p4", "text": "In yeast, Cdi1 interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and Cdk3, but not with Cdk4.", "text_with_entity_marker": "In yeast, Cdi1 interacts with cyclin-dependent kinases, including human [E1]Cdc2[/E1], [E2]Cdk2[/E2], and Cdk3, but not with Cdk4.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Cdc2", "entity_1_idx": [[72, 76]], "entity_1_idx_in_text_with_entity_marker": [76, 80], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk2", "entity_2_idx": [[78, 82]], "entity_2_idx_in_text_with_entity_marker": [91, 95], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d140.s1182_AIMed.d140.s1182.p5", "text": "In yeast, Cdi1 interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and Cdk3, but not with Cdk4.", "text_with_entity_marker": "In yeast, Cdi1 interacts with cyclin-dependent kinases, including human [E1]Cdc2[/E1], Cdk2, and [E2]Cdk3[/E2], but not with Cdk4.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Cdc2", "entity_1_idx": [[72, 76]], "entity_1_idx_in_text_with_entity_marker": [76, 80], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk3", "entity_2_idx": [[88, 92]], "entity_2_idx_in_text_with_entity_marker": [101, 105], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d140.s1182_AIMed.d140.s1182.p6", "text": "In yeast, Cdi1 interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and Cdk3, but not with Cdk4.", "text_with_entity_marker": "In yeast, Cdi1 interacts with cyclin-dependent kinases, including human [E1]Cdc2[/E1], Cdk2, and Cdk3, but not with [E2]Cdk4[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Cdc2", "entity_1_idx": [[72, 76]], "entity_1_idx_in_text_with_entity_marker": [76, 80], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk4", "entity_2_idx": [[107, 111]], "entity_2_idx_in_text_with_entity_marker": [120, 124], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d140.s1182_AIMed.d140.s1182.p7", "text": "In yeast, Cdi1 interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and Cdk3, but not with Cdk4.", "text_with_entity_marker": "In yeast, Cdi1 interacts with cyclin-dependent kinases, including human Cdc2, [E1]Cdk2[/E1], and [E2]Cdk3[/E2], but not with Cdk4.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Cdk2", "entity_1_idx": [[78, 82]], "entity_1_idx_in_text_with_entity_marker": [82, 86], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk3", "entity_2_idx": [[88, 92]], "entity_2_idx_in_text_with_entity_marker": [101, 105], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d140.s1182_AIMed.d140.s1182.p8", "text": "In yeast, Cdi1 interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and Cdk3, but not with Cdk4.", "text_with_entity_marker": "In yeast, Cdi1 interacts with cyclin-dependent kinases, including human Cdc2, [E1]Cdk2[/E1], and Cdk3, but not with [E2]Cdk4[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Cdk2", "entity_1_idx": [[78, 82]], "entity_1_idx_in_text_with_entity_marker": [82, 86], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk4", "entity_2_idx": [[107, 111]], "entity_2_idx_in_text_with_entity_marker": [120, 124], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d140.s1182_AIMed.d140.s1182.p9", "text": "In yeast, Cdi1 interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and Cdk3, but not with Cdk4.", "text_with_entity_marker": "In yeast, Cdi1 interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and [E1]Cdk3[/E1], but not with [E2]Cdk4[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Cdk3", "entity_1_idx": [[88, 92]], "entity_1_idx_in_text_with_entity_marker": [92, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk4", "entity_2_idx": [[107, 111]], "entity_2_idx_in_text_with_entity_marker": [120, 124], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d140.s1183_AIMed.d140.s1183.p0", "text": "In HeLa cells, Cdi1 is expressed at the G1 to S transition, and the protein forms stable complexes with Cdk2.", "text_with_entity_marker": "In HeLa cells, [E1]Cdi1[/E1] is expressed at the G1 to S transition, and the protein forms stable complexes with [E2]Cdk2[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Cdi1", "entity_1_idx": [[15, 19]], "entity_1_idx_in_text_with_entity_marker": [19, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk2", "entity_2_idx": [[104, 108]], "entity_2_idx_in_text_with_entity_marker": [117, 121], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d140.s1186_AIMed.d140.s1186.p0", "text": "Overexpression of wild-type Cdi1 delays progression through the cell cycle in yeast and HeLa cells; delay is dependent on Cdi1 phosphatase activity.", "text_with_entity_marker": "Overexpression of wild-type [E1]Cdi1[/E1] delays progression through the cell cycle in yeast and HeLa cells; delay is dependent on [E2]Cdi1[/E2] phosphatase activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Cdi1", "entity_1_idx": [[28, 32]], "entity_1_idx_in_text_with_entity_marker": [32, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdi1", "entity_2_idx": [[122, 126]], "entity_2_idx_in_text_with_entity_marker": [135, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d221.s1921_AIMed.d221.s1921.p0", "text": "A region of the beta subunit of the interferon alpha receptor different from box 1 interacts with Jak1 and is sufficient to activate the Jak-Stat pathway and induce an antiviral state.", "text_with_entity_marker": "A region of the beta subunit of the [E1-E2]interferon alpha[/E1] receptor[/E2] different from box 1 interacts with Jak1 and is sufficient to activate the Jak-Stat pathway and induce an antiviral state.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interferon alpha", "entity_1_idx": [[36, 52]], "entity_1_idx_in_text_with_entity_marker": [43, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interferon alpha[/E1] receptor", "entity_2_idx": [[36, 61]], "entity_2_idx_in_text_with_entity_marker": [43, 73], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d221.s1921_AIMed.d221.s1921.p1", "text": "A region of the beta subunit of the interferon alpha receptor different from box 1 interacts with Jak1 and is sufficient to activate the Jak-Stat pathway and induce an antiviral state.", "text_with_entity_marker": "A region of the beta subunit of the [E1]interferon alpha[/E1] receptor different from box 1 interacts with [E2]Jak1[/E2] and is sufficient to activate the Jak-Stat pathway and induce an antiviral state.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interferon alpha", "entity_1_idx": [[36, 52]], "entity_1_idx_in_text_with_entity_marker": [40, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jak1", "entity_2_idx": [[98, 102]], "entity_2_idx_in_text_with_entity_marker": [111, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d221.s1921_AIMed.d221.s1921.p2", "text": "A region of the beta subunit of the interferon alpha receptor different from box 1 interacts with Jak1 and is sufficient to activate the Jak-Stat pathway and induce an antiviral state.", "text_with_entity_marker": "A region of the beta subunit of the [E1]interferon alpha[/E1] receptor different from box 1 interacts with Jak1 and is sufficient to activate the [E2]Jak[/E2]-Stat pathway and induce an antiviral state.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interferon alpha", "entity_1_idx": [[36, 52]], "entity_1_idx_in_text_with_entity_marker": [40, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jak", "entity_2_idx": [[137, 140]], "entity_2_idx_in_text_with_entity_marker": [150, 153], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d221.s1921_AIMed.d221.s1921.p3", "text": "A region of the beta subunit of the interferon alpha receptor different from box 1 interacts with Jak1 and is sufficient to activate the Jak-Stat pathway and induce an antiviral state.", "text_with_entity_marker": "A region of the beta subunit of the [E1]interferon alpha receptor[/E1] different from box 1 interacts with [E2]Jak1[/E2] and is sufficient to activate the Jak-Stat pathway and induce an antiviral state.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "interferon alpha receptor", "entity_1_idx": [[36, 61]], "entity_1_idx_in_text_with_entity_marker": [40, 65], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jak1", "entity_2_idx": [[98, 102]], "entity_2_idx_in_text_with_entity_marker": [111, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d221.s1921_AIMed.d221.s1921.p4", "text": "A region of the beta subunit of the interferon alpha receptor different from box 1 interacts with Jak1 and is sufficient to activate the Jak-Stat pathway and induce an antiviral state.", "text_with_entity_marker": "A region of the beta subunit of the [E1]interferon alpha receptor[/E1] different from box 1 interacts with Jak1 and is sufficient to activate the [E2]Jak[/E2]-Stat pathway and induce an antiviral state.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interferon alpha receptor", "entity_1_idx": [[36, 61]], "entity_1_idx_in_text_with_entity_marker": [40, 65], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jak", "entity_2_idx": [[137, 140]], "entity_2_idx_in_text_with_entity_marker": [150, 153], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d221.s1921_AIMed.d221.s1921.p5", "text": "A region of the beta subunit of the interferon alpha receptor different from box 1 interacts with Jak1 and is sufficient to activate the Jak-Stat pathway and induce an antiviral state.", "text_with_entity_marker": "A region of the beta subunit of the interferon alpha receptor different from box 1 interacts with [E1]Jak1[/E1] and is sufficient to activate the [E2]Jak[/E2]-Stat pathway and induce an antiviral state.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Jak1", "entity_1_idx": [[98, 102]], "entity_1_idx_in_text_with_entity_marker": [102, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jak", "entity_2_idx": [[137, 140]], "entity_2_idx_in_text_with_entity_marker": [150, 153], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d221.s1922_AIMed.d221.s1922.p0", "text": "Coexpression of the alpha and betaL subunits of the human interferon alpha (IFNalpha) receptor is required for the induction of an antiviral state by human IFNalpha.", "text_with_entity_marker": "Coexpression of the alpha and betaL subunits of the human [E1]interferon alpha[/E1] ([E2]IFNalpha[/E2]) receptor is required for the induction of an antiviral state by human IFNalpha.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interferon alpha", "entity_1_idx": [[58, 74]], "entity_1_idx_in_text_with_entity_marker": [62, 78], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFNalpha", "entity_2_idx": [[76, 84]], "entity_2_idx_in_text_with_entity_marker": [89, 97], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d221.s1922_AIMed.d221.s1922.p1", "text": "Coexpression of the alpha and betaL subunits of the human interferon alpha (IFNalpha) receptor is required for the induction of an antiviral state by human IFNalpha.", "text_with_entity_marker": "Coexpression of the alpha and betaL subunits of the human [E1-E2]interferon alpha[/E1] (IFNalpha) receptor[/E2] is required for the induction of an antiviral state by human IFNalpha.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interferon alpha", "entity_1_idx": [[58, 74]], "entity_1_idx_in_text_with_entity_marker": [65, 81], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interferon alpha[/E1] (IFNalpha) receptor", "entity_2_idx": [[58, 94]], "entity_2_idx_in_text_with_entity_marker": [65, 106], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d221.s1922_AIMed.d221.s1922.p2", "text": "Coexpression of the alpha and betaL subunits of the human interferon alpha (IFNalpha) receptor is required for the induction of an antiviral state by human IFNalpha.", "text_with_entity_marker": "Coexpression of the alpha and betaL subunits of the human [E1]interferon alpha[/E1] (IFNalpha) receptor is required for the induction of an antiviral state by human [E2]IFNalpha[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interferon alpha", "entity_1_idx": [[58, 74]], "entity_1_idx_in_text_with_entity_marker": [62, 78], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFNalpha", "entity_2_idx": [[156, 164]], "entity_2_idx_in_text_with_entity_marker": [169, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d221.s1922_AIMed.d221.s1922.p3", "text": "Coexpression of the alpha and betaL subunits of the human interferon alpha (IFNalpha) receptor is required for the induction of an antiviral state by human IFNalpha.", "text_with_entity_marker": "Coexpression of the alpha and betaL subunits of the human [E1]interferon alpha (IFNalpha) receptor[/E1][E2]IFNalpha[/E2]) receptor is required for the induction of an antiviral state by human IFNalpha.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interferon alpha (IFNalpha) receptor", "entity_1_idx": [[58, 94]], "entity_1_idx_in_text_with_entity_marker": [62, 98], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFNalpha", "entity_2_idx": [[76, 84]], "entity_2_idx_in_text_with_entity_marker": [107, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d221.s1922_AIMed.d221.s1922.p4", "text": "Coexpression of the alpha and betaL subunits of the human interferon alpha (IFNalpha) receptor is required for the induction of an antiviral state by human IFNalpha.", "text_with_entity_marker": "Coexpression of the alpha and betaL subunits of the human interferon alpha ([E1]IFNalpha[/E1]) receptor is required for the induction of an antiviral state by human [E2]IFNalpha[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFNalpha", "entity_1_idx": [[76, 84]], "entity_1_idx_in_text_with_entity_marker": [80, 88], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFNalpha", "entity_2_idx": [[156, 164]], "entity_2_idx_in_text_with_entity_marker": [169, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d221.s1922_AIMed.d221.s1922.p5", "text": "Coexpression of the alpha and betaL subunits of the human interferon alpha (IFNalpha) receptor is required for the induction of an antiviral state by human IFNalpha.", "text_with_entity_marker": "Coexpression of the alpha and betaL subunits of the human [E1]interferon alpha (IFNalpha) receptor[/E1] is required for the induction of an antiviral state by human [E2]IFNalpha[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interferon alpha (IFNalpha) receptor", "entity_1_idx": [[58, 94]], "entity_1_idx_in_text_with_entity_marker": [62, 98], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFNalpha", "entity_2_idx": [[156, 164]], "entity_2_idx_in_text_with_entity_marker": [169, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d221.s1924_AIMed.d221.s1924.p0", "text": "Our results demonstrated that the first 82 amino acids (AAs) (AAs 265-346) of the cytoplasmic domain of the betaL chain are sufficient to activate the Jak-Stat pathway and trigger an antiviral state after IFNalpha2 binding to the receptor.", "text_with_entity_marker": "Our results demonstrated that the first 82 amino acids (AAs) (AAs 265-346) of the cytoplasmic domain of the betaL chain are sufficient to activate the [E1]Jak[/E1]-Stat pathway and trigger an antiviral state after [E2]IFNalpha2[/E2] binding to the receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Jak", "entity_1_idx": [[151, 154]], "entity_1_idx_in_text_with_entity_marker": [155, 158], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFNalpha2", "entity_2_idx": [[205, 214]], "entity_2_idx_in_text_with_entity_marker": [218, 227], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d221.s1925_AIMed.d221.s1925.p0", "text": "This region of the betaL chain, required for Jak1 binding and activation, contains the Box 1 motif that is important for the interaction of some cytokine receptors with Jak kinases.", "text_with_entity_marker": "This region of the betaL chain, required for [E1]Jak1[/E1] binding and activation, contains the Box 1 motif that is important for the interaction of some cytokine receptors with [E2]Jak[/E2] kinases.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Jak1", "entity_1_idx": [[45, 49]], "entity_1_idx_in_text_with_entity_marker": [49, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jak", "entity_2_idx": [[169, 172]], "entity_2_idx_in_text_with_entity_marker": [182, 185], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d19.s162_AIMed.d19.s162.p0", "text": "Several genes are involved in this process, and two have been the focus of recent interest: the natural resistance-associated protein (NRAMP1) gene and the genes coding for the vitamin D receptor.", "text_with_entity_marker": "Several genes are involved in this process, and two have been the focus of recent interest: the [E1]natural resistance-associated protein[/E1] ([E2]NRAMP1[/E2]) gene and the genes coding for the vitamin D receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "natural resistance-associated protein", "entity_1_idx": [[96, 133]], "entity_1_idx_in_text_with_entity_marker": [100, 137], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NRAMP1", "entity_2_idx": [[135, 141]], "entity_2_idx_in_text_with_entity_marker": [148, 154], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d19.s162_AIMed.d19.s162.p1", "text": "Several genes are involved in this process, and two have been the focus of recent interest: the natural resistance-associated protein (NRAMP1) gene and the genes coding for the vitamin D receptor.", "text_with_entity_marker": "Several genes are involved in this process, and two have been the focus of recent interest: the [E1]natural resistance-associated protein[/E1] (NRAMP1) gene and the genes coding for the [E2]vitamin D receptor[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "natural resistance-associated protein", "entity_1_idx": [[96, 133]], "entity_1_idx_in_text_with_entity_marker": [100, 137], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "vitamin D receptor", "entity_2_idx": [[177, 195]], "entity_2_idx_in_text_with_entity_marker": [190, 208], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d19.s162_AIMed.d19.s162.p2", "text": "Several genes are involved in this process, and two have been the focus of recent interest: the natural resistance-associated protein (NRAMP1) gene and the genes coding for the vitamin D receptor.", "text_with_entity_marker": "Several genes are involved in this process, and two have been the focus of recent interest: the natural resistance-associated protein ([E1]NRAMP1[/E1]) gene and the genes coding for the [E2]vitamin D receptor[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NRAMP1", "entity_1_idx": [[135, 141]], "entity_1_idx_in_text_with_entity_marker": [139, 145], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "vitamin D receptor", "entity_2_idx": [[177, 195]], "entity_2_idx_in_text_with_entity_marker": [190, 208], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d135.s1147_AIMed.d135.s1147.p0", "text": "Tumor necrosis factor (TNF) and lymphotoxin-alpha (LT-alpha) are members of a family of secreted and cell surface cytokines that participate in the regulation of immune and inflammatory responses.", "text_with_entity_marker": "Tumor necrosis factor (TNF) and [E1]lymphotoxin-alpha[/E1] ([E2]LT-alpha[/E2]) are members of a family of secreted and cell surface cytokines that participate in the regulation of immune and inflammatory responses.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "lymphotoxin-alpha", "entity_1_idx": [[32, 49]], "entity_1_idx_in_text_with_entity_marker": [36, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LT-alpha", "entity_2_idx": [[51, 59]], "entity_2_idx_in_text_with_entity_marker": [64, 72], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d135.s1148_AIMed.d135.s1148.p0", "text": "The cell surface form of LT-alpha is assembled during biosynthesis as a heteromeric complex with lymphotoxin-beta (LT-beta), a type II transmembrane protein that is another member of the TNF ligand family.", "text_with_entity_marker": "The cell surface form of [E1]LT-alpha[/E1] is assembled during biosynthesis as a heteromeric complex with [E2]lymphotoxin-beta[/E2] (LT-beta), a type II transmembrane protein that is another member of the TNF ligand family.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "LT-alpha", "entity_1_idx": [[25, 33]], "entity_1_idx_in_text_with_entity_marker": [29, 37], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "lymphotoxin-beta", "entity_2_idx": [[97, 113]], "entity_2_idx_in_text_with_entity_marker": [110, 126], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d135.s1148_AIMed.d135.s1148.p1", "text": "The cell surface form of LT-alpha is assembled during biosynthesis as a heteromeric complex with lymphotoxin-beta (LT-beta), a type II transmembrane protein that is another member of the TNF ligand family.", "text_with_entity_marker": "The cell surface form of [E1]LT-alpha[/E1] is assembled during biosynthesis as a heteromeric complex with lymphotoxin-beta ([E2]LT-beta[/E2]), a type II transmembrane protein that is another member of the TNF ligand family.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "LT-alpha", "entity_1_idx": [[25, 33]], "entity_1_idx_in_text_with_entity_marker": [29, 37], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LT-beta", "entity_2_idx": [[115, 122]], "entity_2_idx_in_text_with_entity_marker": [128, 135], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d135.s1148_AIMed.d135.s1148.p2", "text": "The cell surface form of LT-alpha is assembled during biosynthesis as a heteromeric complex with lymphotoxin-beta (LT-beta), a type II transmembrane protein that is another member of the TNF ligand family.", "text_with_entity_marker": "The cell surface form of LT-alpha is assembled during biosynthesis as a heteromeric complex with [E1]lymphotoxin-beta[/E1] ([E2]LT-beta[/E2]), a type II transmembrane protein that is another member of the TNF ligand family.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "lymphotoxin-beta", "entity_1_idx": [[97, 113]], "entity_1_idx_in_text_with_entity_marker": [101, 117], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LT-beta", "entity_2_idx": [[115, 122]], "entity_2_idx_in_text_with_entity_marker": [128, 135], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d135.s1149_AIMed.d135.s1149.p0", "text": "Secreted LT-alpha is a homotrimer that binds to distinct TNF receptors of 60 and 80 kilodaltons; however, these receptors do not recognize the major cell surface LT-alpha-LT-beta complex.", "text_with_entity_marker": "Secreted [E1]LT-alpha[/E1] is a homotrimer that binds to distinct TNF receptors of 60 and 80 kilodaltons; however, these receptors do not recognize the major cell surface [E2]LT-alpha[/E2]-LT-beta complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LT-alpha", "entity_1_idx": [[9, 17]], "entity_1_idx_in_text_with_entity_marker": [13, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LT-alpha", "entity_2_idx": [[162, 170]], "entity_2_idx_in_text_with_entity_marker": [175, 183], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d135.s1149_AIMed.d135.s1149.p1", "text": "Secreted LT-alpha is a homotrimer that binds to distinct TNF receptors of 60 and 80 kilodaltons; however, these receptors do not recognize the major cell surface LT-alpha-LT-beta complex.", "text_with_entity_marker": "Secreted [E1]LT-alpha[/E1] is a homotrimer that binds to distinct TNF receptors of 60 and 80 kilodaltons; however, these receptors do not recognize the major cell surface LT-alpha-[E2]LT-beta[/E2] complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LT-alpha", "entity_1_idx": [[9, 17]], "entity_1_idx_in_text_with_entity_marker": [13, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LT-beta", "entity_2_idx": [[171, 178]], "entity_2_idx_in_text_with_entity_marker": [184, 191], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d135.s1149_AIMed.d135.s1149.p2", "text": "Secreted LT-alpha is a homotrimer that binds to distinct TNF receptors of 60 and 80 kilodaltons; however, these receptors do not recognize the major cell surface LT-alpha-LT-beta complex.", "text_with_entity_marker": "Secreted LT-alpha is a homotrimer that binds to distinct TNF receptors of 60 and 80 kilodaltons; however, these receptors do not recognize the major cell surface [E1]LT-alpha[/E1]-[E2]LT-beta[/E2] complex.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "LT-alpha", "entity_1_idx": [[162, 170]], "entity_1_idx_in_text_with_entity_marker": [166, 174], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LT-beta", "entity_2_idx": [[171, 178]], "entity_2_idx_in_text_with_entity_marker": [184, 191], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d135.s1150_AIMed.d135.s1150.p0", "text": "A receptor specific for human LT-beta was identified, which suggests that cell surface LT may have functions that are distinct from those of secreted LT-alpha.", "text_with_entity_marker": "A receptor specific for human [E1]LT-beta[/E1] was identified, which suggests that cell surface LT may have functions that are distinct from those of secreted [E2]LT-alpha[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LT-beta", "entity_1_idx": [[30, 37]], "entity_1_idx_in_text_with_entity_marker": [34, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LT-alpha", "entity_2_idx": [[150, 158]], "entity_2_idx_in_text_with_entity_marker": [163, 171], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d43.s375_AIMed.d43.s375.p0", "text": "Although the individual amino acids in TrkA involved in binding to nerve growth factor (NGF) and those in TrkC involved in binding to neurotrophin-3 have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.", "text_with_entity_marker": "Although the individual amino acids in [E1]TrkA[/E1] involved in binding to [E2]nerve growth factor[/E2] (NGF) and those in TrkC involved in binding to neurotrophin-3 have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TrkA", "entity_1_idx": [[39, 43]], "entity_1_idx_in_text_with_entity_marker": [43, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "nerve growth factor", "entity_2_idx": [[67, 86]], "entity_2_idx_in_text_with_entity_marker": [80, 99], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d43.s375_AIMed.d43.s375.p1", "text": "Although the individual amino acids in TrkA involved in binding to nerve growth factor (NGF) and those in TrkC involved in binding to neurotrophin-3 have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.", "text_with_entity_marker": "Although the individual amino acids in [E1]TrkA[/E1] involved in binding to nerve growth factor ([E2]NGF[/E2]) and those in TrkC involved in binding to neurotrophin-3 have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TrkA", "entity_1_idx": [[39, 43]], "entity_1_idx_in_text_with_entity_marker": [43, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NGF", "entity_2_idx": [[88, 91]], "entity_2_idx_in_text_with_entity_marker": [101, 104], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d43.s375_AIMed.d43.s375.p2", "text": "Although the individual amino acids in TrkA involved in binding to nerve growth factor (NGF) and those in TrkC involved in binding to neurotrophin-3 have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.", "text_with_entity_marker": "Although the individual amino acids in [E1]TrkA[/E1] involved in binding to nerve growth factor (NGF) and those in [E2]TrkC[/E2] involved in binding to neurotrophin-3 have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TrkA", "entity_1_idx": [[39, 43]], "entity_1_idx_in_text_with_entity_marker": [43, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TrkC", "entity_2_idx": [[106, 110]], "entity_2_idx_in_text_with_entity_marker": [119, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d43.s375_AIMed.d43.s375.p3", "text": "Although the individual amino acids in TrkA involved in binding to nerve growth factor (NGF) and those in TrkC involved in binding to neurotrophin-3 have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.", "text_with_entity_marker": "Although the individual amino acids in [E1]TrkA[/E1] involved in binding to nerve growth factor (NGF) and those in TrkC involved in binding to [E2]neurotrophin-3[/E2] have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TrkA", "entity_1_idx": [[39, 43]], "entity_1_idx_in_text_with_entity_marker": [43, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "neurotrophin-3", "entity_2_idx": [[134, 148]], "entity_2_idx_in_text_with_entity_marker": [147, 161], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d43.s375_AIMed.d43.s375.p4", "text": "Although the individual amino acids in TrkA involved in binding to nerve growth factor (NGF) and those in TrkC involved in binding to neurotrophin-3 have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.", "text_with_entity_marker": "Although the individual amino acids in TrkA involved in binding to [E1]nerve growth factor[/E1] ([E2]NGF[/E2]) and those in TrkC involved in binding to neurotrophin-3 have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "nerve growth factor", "entity_1_idx": [[67, 86]], "entity_1_idx_in_text_with_entity_marker": [71, 90], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NGF", "entity_2_idx": [[88, 91]], "entity_2_idx_in_text_with_entity_marker": [101, 104], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d43.s375_AIMed.d43.s375.p5", "text": "Although the individual amino acids in TrkA involved in binding to nerve growth factor (NGF) and those in TrkC involved in binding to neurotrophin-3 have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.", "text_with_entity_marker": "Although the individual amino acids in TrkA involved in binding to [E1]nerve growth factor[/E1] (NGF) and those in [E2]TrkC[/E2] involved in binding to neurotrophin-3 have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "nerve growth factor", "entity_1_idx": [[67, 86]], "entity_1_idx_in_text_with_entity_marker": [71, 90], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TrkC", "entity_2_idx": [[106, 110]], "entity_2_idx_in_text_with_entity_marker": [119, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d43.s375_AIMed.d43.s375.p6", "text": "Although the individual amino acids in TrkA involved in binding to nerve growth factor (NGF) and those in TrkC involved in binding to neurotrophin-3 have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.", "text_with_entity_marker": "Although the individual amino acids in TrkA involved in binding to [E1]nerve growth factor[/E1] (NGF) and those in TrkC involved in binding to [E2]neurotrophin-3[/E2] have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "nerve growth factor", "entity_1_idx": [[67, 86]], "entity_1_idx_in_text_with_entity_marker": [71, 90], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "neurotrophin-3", "entity_2_idx": [[134, 148]], "entity_2_idx_in_text_with_entity_marker": [147, 161], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d43.s375_AIMed.d43.s375.p7", "text": "Although the individual amino acids in TrkA involved in binding to nerve growth factor (NGF) and those in TrkC involved in binding to neurotrophin-3 have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.", "text_with_entity_marker": "Although the individual amino acids in TrkA involved in binding to nerve growth factor ([E1]NGF[/E1]) and those in [E2]TrkC[/E2] involved in binding to neurotrophin-3 have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NGF", "entity_1_idx": [[88, 91]], "entity_1_idx_in_text_with_entity_marker": [92, 95], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TrkC", "entity_2_idx": [[106, 110]], "entity_2_idx_in_text_with_entity_marker": [119, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d43.s375_AIMed.d43.s375.p8", "text": "Although the individual amino acids in TrkA involved in binding to nerve growth factor (NGF) and those in TrkC involved in binding to neurotrophin-3 have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.", "text_with_entity_marker": "Although the individual amino acids in TrkA involved in binding to nerve growth factor ([E1]NGF[/E1]) and those in TrkC involved in binding to [E2]neurotrophin-3[/E2] have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NGF", "entity_1_idx": [[88, 91]], "entity_1_idx_in_text_with_entity_marker": [92, 95], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "neurotrophin-3", "entity_2_idx": [[134, 148]], "entity_2_idx_in_text_with_entity_marker": [147, 161], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d43.s375_AIMed.d43.s375.p9", "text": "Although the individual amino acids in TrkA involved in binding to nerve growth factor (NGF) and those in TrkC involved in binding to neurotrophin-3 have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.", "text_with_entity_marker": "Although the individual amino acids in TrkA involved in binding to nerve growth factor (NGF) and those in [E1]TrkC[/E1] involved in binding to [E2]neurotrophin-3[/E2] have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TrkC", "entity_1_idx": [[106, 110]], "entity_1_idx_in_text_with_entity_marker": [110, 114], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "neurotrophin-3", "entity_2_idx": [[134, 148]], "entity_2_idx_in_text_with_entity_marker": [147, 161], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d43.s376_AIMed.d43.s376.p0", "text": "In this study, a minimum set of residues in the human TrkC second immunoglobulin-like domain, which does not bind nerve growth factor (NGF), were substituted with those from human TrkA.", "text_with_entity_marker": "In this study, a minimum set of residues in the human [E1]TrkC[/E1] second immunoglobulin-like domain, which does not bind [E2]nerve growth factor[/E2] (NGF), were substituted with those from human TrkA.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TrkC", "entity_1_idx": [[54, 58]], "entity_1_idx_in_text_with_entity_marker": [58, 62], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "nerve growth factor", "entity_2_idx": [[114, 133]], "entity_2_idx_in_text_with_entity_marker": [127, 146], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d43.s376_AIMed.d43.s376.p1", "text": "In this study, a minimum set of residues in the human TrkC second immunoglobulin-like domain, which does not bind nerve growth factor (NGF), were substituted with those from human TrkA.", "text_with_entity_marker": "In this study, a minimum set of residues in the human [E1]TrkC[/E1] second immunoglobulin-like domain, which does not bind nerve growth factor ([E2]NGF[/E2]), were substituted with those from human TrkA.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TrkC", "entity_1_idx": [[54, 58]], "entity_1_idx_in_text_with_entity_marker": [58, 62], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NGF", "entity_2_idx": [[135, 138]], "entity_2_idx_in_text_with_entity_marker": [148, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d43.s376_AIMed.d43.s376.p2", "text": "In this study, a minimum set of residues in the human TrkC second immunoglobulin-like domain, which does not bind nerve growth factor (NGF), were substituted with those from human TrkA.", "text_with_entity_marker": "In this study, a minimum set of residues in the human [E1]TrkC[/E1] second immunoglobulin-like domain, which does not bind nerve growth factor (NGF), were substituted with those from human [E2]TrkA[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TrkC", "entity_1_idx": [[54, 58]], "entity_1_idx_in_text_with_entity_marker": [58, 62], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TrkA", "entity_2_idx": [[180, 184]], "entity_2_idx_in_text_with_entity_marker": [193, 197], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d43.s376_AIMed.d43.s376.p3", "text": "In this study, a minimum set of residues in the human TrkC second immunoglobulin-like domain, which does not bind nerve growth factor (NGF), were substituted with those from human TrkA.", "text_with_entity_marker": "In this study, a minimum set of residues in the human TrkC second immunoglobulin-like domain, which does not bind [E1]nerve growth factor[/E1] ([E2]NGF[/E2]), were substituted with those from human TrkA.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "nerve growth factor", "entity_1_idx": [[114, 133]], "entity_1_idx_in_text_with_entity_marker": [118, 137], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NGF", "entity_2_idx": [[135, 138]], "entity_2_idx_in_text_with_entity_marker": [148, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d43.s376_AIMed.d43.s376.p4", "text": "In this study, a minimum set of residues in the human TrkC second immunoglobulin-like domain, which does not bind nerve growth factor (NGF), were substituted with those from human TrkA.", "text_with_entity_marker": "In this study, a minimum set of residues in the human TrkC second immunoglobulin-like domain, which does not bind [E1]nerve growth factor[/E1] (NGF), were substituted with those from human [E2]TrkA[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "nerve growth factor", "entity_1_idx": [[114, 133]], "entity_1_idx_in_text_with_entity_marker": [118, 137], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TrkA", "entity_2_idx": [[180, 184]], "entity_2_idx_in_text_with_entity_marker": [193, 197], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d43.s376_AIMed.d43.s376.p5", "text": "In this study, a minimum set of residues in the human TrkC second immunoglobulin-like domain, which does not bind nerve growth factor (NGF), were substituted with those from human TrkA.", "text_with_entity_marker": "In this study, a minimum set of residues in the human TrkC second immunoglobulin-like domain, which does not bind nerve growth factor ([E1]NGF[/E1]), were substituted with those from human [E2]TrkA[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NGF", "entity_1_idx": [[135, 138]], "entity_1_idx_in_text_with_entity_marker": [139, 142], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TrkA", "entity_2_idx": [[180, 184]], "entity_2_idx_in_text_with_entity_marker": [193, 197], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d43.s377_AIMed.d43.s377.p0", "text": "The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained neurotrophin-3 binding equivalent to TrkC, and also bound brain-derived neurotrophin, although with lower affinity compared with TrkB.", "text_with_entity_marker": "The resulting Trk variant recruited binding of [E1]NGF[/E1] equivalent to [E2]TrkA[/E2], maintained neurotrophin-3 binding equivalent to TrkC, and also bound brain-derived neurotrophin, although with lower affinity compared with TrkB.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "NGF", "entity_1_idx": [[47, 50]], "entity_1_idx_in_text_with_entity_marker": [51, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TrkA", "entity_2_idx": [[65, 69]], "entity_2_idx_in_text_with_entity_marker": [78, 82], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d43.s377_AIMed.d43.s377.p1", "text": "The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained neurotrophin-3 binding equivalent to TrkC, and also bound brain-derived neurotrophin, although with lower affinity compared with TrkB.", "text_with_entity_marker": "The resulting Trk variant recruited binding of [E1]NGF[/E1] equivalent to TrkA, maintained [E2]neurotrophin-3[/E2] binding equivalent to TrkC, and also bound brain-derived neurotrophin, although with lower affinity compared with TrkB.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NGF", "entity_1_idx": [[47, 50]], "entity_1_idx_in_text_with_entity_marker": [51, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "neurotrophin-3", "entity_2_idx": [[82, 96]], "entity_2_idx_in_text_with_entity_marker": [95, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d43.s377_AIMed.d43.s377.p2", "text": "The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained neurotrophin-3 binding equivalent to TrkC, and also bound brain-derived neurotrophin, although with lower affinity compared with TrkB.", "text_with_entity_marker": "The resulting Trk variant recruited binding of [E1]NGF[/E1] equivalent to TrkA, maintained neurotrophin-3 binding equivalent to [E2]TrkC[/E2], and also bound brain-derived neurotrophin, although with lower affinity compared with TrkB.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NGF", "entity_1_idx": [[47, 50]], "entity_1_idx_in_text_with_entity_marker": [51, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TrkC", "entity_2_idx": [[119, 123]], "entity_2_idx_in_text_with_entity_marker": [132, 136], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d43.s377_AIMed.d43.s377.p3", "text": "The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained neurotrophin-3 binding equivalent to TrkC, and also bound brain-derived neurotrophin, although with lower affinity compared with TrkB.", "text_with_entity_marker": "The resulting Trk variant recruited binding of [E1]NGF[/E1] equivalent to TrkA, maintained neurotrophin-3 binding equivalent to TrkC, and also bound [E2]brain-derived neurotrophin[/E2], although with lower affinity compared with TrkB.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NGF", "entity_1_idx": [[47, 50]], "entity_1_idx_in_text_with_entity_marker": [51, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "brain-derived neurotrophin", "entity_2_idx": [[140, 166]], "entity_2_idx_in_text_with_entity_marker": [153, 179], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d43.s377_AIMed.d43.s377.p4", "text": "The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained neurotrophin-3 binding equivalent to TrkC, and also bound brain-derived neurotrophin, although with lower affinity compared with TrkB.", "text_with_entity_marker": "The resulting Trk variant recruited binding of [E1]NGF[/E1] equivalent to TrkA, maintained neurotrophin-3 binding equivalent to TrkC, and also bound brain-derived neurotrophin, although with lower affinity compared with [E2]TrkB[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NGF", "entity_1_idx": [[47, 50]], "entity_1_idx_in_text_with_entity_marker": [51, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TrkB", "entity_2_idx": [[211, 215]], "entity_2_idx_in_text_with_entity_marker": [224, 228], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d43.s377_AIMed.d43.s377.p5", "text": "The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained neurotrophin-3 binding equivalent to TrkC, and also bound brain-derived neurotrophin, although with lower affinity compared with TrkB.", "text_with_entity_marker": "The resulting Trk variant recruited binding of NGF equivalent to [E1]TrkA[/E1], maintained [E2]neurotrophin-3[/E2] binding equivalent to TrkC, and also bound brain-derived neurotrophin, although with lower affinity compared with TrkB.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TrkA", "entity_1_idx": [[65, 69]], "entity_1_idx_in_text_with_entity_marker": [69, 73], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "neurotrophin-3", "entity_2_idx": [[82, 96]], "entity_2_idx_in_text_with_entity_marker": [95, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d43.s377_AIMed.d43.s377.p6", "text": "The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained neurotrophin-3 binding equivalent to TrkC, and also bound brain-derived neurotrophin, although with lower affinity compared with TrkB.", "text_with_entity_marker": "The resulting Trk variant recruited binding of NGF equivalent to [E1]TrkA[/E1], maintained neurotrophin-3 binding equivalent to [E2]TrkC[/E2], and also bound brain-derived neurotrophin, although with lower affinity compared with TrkB.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TrkA", "entity_1_idx": [[65, 69]], "entity_1_idx_in_text_with_entity_marker": [69, 73], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TrkC", "entity_2_idx": [[119, 123]], "entity_2_idx_in_text_with_entity_marker": [132, 136], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d43.s377_AIMed.d43.s377.p7", "text": "The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained neurotrophin-3 binding equivalent to TrkC, and also bound brain-derived neurotrophin, although with lower affinity compared with TrkB.", "text_with_entity_marker": "The resulting Trk variant recruited binding of NGF equivalent to [E1]TrkA[/E1], maintained neurotrophin-3 binding equivalent to TrkC, and also bound [E2]brain-derived neurotrophin[/E2], although with lower affinity compared with TrkB.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TrkA", "entity_1_idx": [[65, 69]], "entity_1_idx_in_text_with_entity_marker": [69, 73], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "brain-derived neurotrophin", "entity_2_idx": [[140, 166]], "entity_2_idx_in_text_with_entity_marker": [153, 179], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d43.s377_AIMed.d43.s377.p8", "text": "The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained neurotrophin-3 binding equivalent to TrkC, and also bound brain-derived neurotrophin, although with lower affinity compared with TrkB.", "text_with_entity_marker": "The resulting Trk variant recruited binding of NGF equivalent to [E1]TrkA[/E1], maintained neurotrophin-3 binding equivalent to TrkC, and also bound brain-derived neurotrophin, although with lower affinity compared with [E2]TrkB[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TrkA", "entity_1_idx": [[65, 69]], "entity_1_idx_in_text_with_entity_marker": [69, 73], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TrkB", "entity_2_idx": [[211, 215]], "entity_2_idx_in_text_with_entity_marker": [224, 228], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d43.s377_AIMed.d43.s377.p9", "text": "The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained neurotrophin-3 binding equivalent to TrkC, and also bound brain-derived neurotrophin, although with lower affinity compared with TrkB.", "text_with_entity_marker": "The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained [E1]neurotrophin-3[/E1] binding equivalent to [E2]TrkC[/E2], and also bound brain-derived neurotrophin, although with lower affinity compared with TrkB.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "neurotrophin-3", "entity_1_idx": [[82, 96]], "entity_1_idx_in_text_with_entity_marker": [86, 100], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TrkC", "entity_2_idx": [[119, 123]], "entity_2_idx_in_text_with_entity_marker": [132, 136], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d43.s377_AIMed.d43.s377.p10", "text": "The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained neurotrophin-3 binding equivalent to TrkC, and also bound brain-derived neurotrophin, although with lower affinity compared with TrkB.", "text_with_entity_marker": "The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained [E1]neurotrophin-3[/E1] binding equivalent to TrkC, and also bound [E2]brain-derived neurotrophin[/E2], although with lower affinity compared with TrkB.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "neurotrophin-3", "entity_1_idx": [[82, 96]], "entity_1_idx_in_text_with_entity_marker": [86, 100], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "brain-derived neurotrophin", "entity_2_idx": [[140, 166]], "entity_2_idx_in_text_with_entity_marker": [153, 179], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d43.s377_AIMed.d43.s377.p11", "text": "The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained neurotrophin-3 binding equivalent to TrkC, and also bound brain-derived neurotrophin, although with lower affinity compared with TrkB.", "text_with_entity_marker": "The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained [E1]neurotrophin-3[/E1] binding equivalent to TrkC, and also bound brain-derived neurotrophin, although with lower affinity compared with [E2]TrkB[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "neurotrophin-3", "entity_1_idx": [[82, 96]], "entity_1_idx_in_text_with_entity_marker": [86, 100], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TrkB", "entity_2_idx": [[211, 215]], "entity_2_idx_in_text_with_entity_marker": [224, 228], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d43.s377_AIMed.d43.s377.p12", "text": "The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained neurotrophin-3 binding equivalent to TrkC, and also bound brain-derived neurotrophin, although with lower affinity compared with TrkB.", "text_with_entity_marker": "The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained neurotrophin-3 binding equivalent to [E1]TrkC[/E1], and also bound [E2]brain-derived neurotrophin[/E2], although with lower affinity compared with TrkB.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TrkC", "entity_1_idx": [[119, 123]], "entity_1_idx_in_text_with_entity_marker": [123, 127], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "brain-derived neurotrophin", "entity_2_idx": [[140, 166]], "entity_2_idx_in_text_with_entity_marker": [153, 179], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d43.s377_AIMed.d43.s377.p13", "text": "The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained neurotrophin-3 binding equivalent to TrkC, and also bound brain-derived neurotrophin, although with lower affinity compared with TrkB.", "text_with_entity_marker": "The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained neurotrophin-3 binding equivalent to [E1]TrkC[/E1], and also bound brain-derived neurotrophin, although with lower affinity compared with [E2]TrkB[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TrkC", "entity_1_idx": [[119, 123]], "entity_1_idx_in_text_with_entity_marker": [123, 127], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TrkB", "entity_2_idx": [[211, 215]], "entity_2_idx_in_text_with_entity_marker": [224, 228], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d43.s377_AIMed.d43.s377.p14", "text": "The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained neurotrophin-3 binding equivalent to TrkC, and also bound brain-derived neurotrophin, although with lower affinity compared with TrkB.", "text_with_entity_marker": "The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained neurotrophin-3 binding equivalent to TrkC, and also bound [E1]brain-derived neurotrophin[/E1], although with lower affinity compared with [E2]TrkB[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "brain-derived neurotrophin", "entity_1_idx": [[140, 166]], "entity_1_idx_in_text_with_entity_marker": [144, 170], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TrkB", "entity_2_idx": [[211, 215]], "entity_2_idx_in_text_with_entity_marker": [224, 228], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d54.s473_AIMed.d54.s473.p0", "text": "Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor.", "text_with_entity_marker": "[E1]Platelet-derived growth factor C[/E1] ([E2]PDGF-C[/E2]), a novel growth factor that binds to PDGF alpha and beta receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Platelet-derived growth factor C", "entity_1_idx": [[0, 32]], "entity_1_idx_in_text_with_entity_marker": [4, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PDGF-C", "entity_2_idx": [[34, 40]], "entity_2_idx_in_text_with_entity_marker": [47, 53], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d54.s473_AIMed.d54.s473.p1", "text": "Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor.", "text_with_entity_marker": "[E1]Platelet-derived growth factor C[/E1] (PDGF-C), a novel growth factor that binds to [E2]PDGF alpha[/E2] and beta receptor.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Platelet-derived growth factor C", "entity_1_idx": [[0, 32]], "entity_1_idx_in_text_with_entity_marker": [4, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PDGF alpha", "entity_2_idx": [[79, 89]], "entity_2_idx_in_text_with_entity_marker": [92, 102], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d54.s473_AIMed.d54.s473.p2", "text": "Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor.", "text_with_entity_marker": "Platelet-derived growth factor C ([E1]PDGF-C[/E1]), a novel growth factor that binds to [E2]PDGF alpha[/E2] and beta receptor.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "PDGF-C", "entity_1_idx": [[34, 40]], "entity_1_idx_in_text_with_entity_marker": [38, 44], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PDGF alpha", "entity_2_idx": [[79, 89]], "entity_2_idx_in_text_with_entity_marker": [92, 102], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d54.s475_AIMed.d54.s475.p0", "text": "PDGF-C is a multidomain protein with the N-terminal region homologous to the extracellular CUB domain of neuropilin-1, and the C-terminal region consists of a growth factor domain (GFD) with homology to vascular endothelial growth factor (25%) and PDGF A-chain (23%).", "text_with_entity_marker": "[E1]PDGF-C[/E1] is a multidomain protein with the N-terminal region homologous to the extracellular CUB domain of [E2]neuropilin-1[/E2], and the C-terminal region consists of a growth factor domain (GFD) with homology to vascular endothelial growth factor (25%) and PDGF A-chain (23%).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PDGF-C", "entity_1_idx": [[0, 6]], "entity_1_idx_in_text_with_entity_marker": [4, 10], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "neuropilin-1", "entity_2_idx": [[105, 117]], "entity_2_idx_in_text_with_entity_marker": [118, 130], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d54.s475_AIMed.d54.s475.p1", "text": "PDGF-C is a multidomain protein with the N-terminal region homologous to the extracellular CUB domain of neuropilin-1, and the C-terminal region consists of a growth factor domain (GFD) with homology to vascular endothelial growth factor (25%) and PDGF A-chain (23%).", "text_with_entity_marker": "[E1]PDGF-C[/E1] is a multidomain protein with the N-terminal region homologous to the extracellular CUB domain of neuropilin-1, and the C-terminal region consists of a growth factor domain (GFD) with homology to vascular [E2]endothelial growth factor[/E2] (25%) and PDGF A-chain (23%).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PDGF-C", "entity_1_idx": [[0, 6]], "entity_1_idx_in_text_with_entity_marker": [4, 10], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "endothelial growth factor", "entity_2_idx": [[212, 237]], "entity_2_idx_in_text_with_entity_marker": [225, 250], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d54.s475_AIMed.d54.s475.p2", "text": "PDGF-C is a multidomain protein with the N-terminal region homologous to the extracellular CUB domain of neuropilin-1, and the C-terminal region consists of a growth factor domain (GFD) with homology to vascular endothelial growth factor (25%) and PDGF A-chain (23%).", "text_with_entity_marker": "[E1]PDGF-C[/E1] is a multidomain protein with the N-terminal region homologous to the extracellular CUB domain of neuropilin-1, and the C-terminal region consists of a growth factor domain (GFD) with homology to vascular endothelial growth factor (25%) and [E2]PDGF A[/E2]-chain (23%).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PDGF-C", "entity_1_idx": [[0, 6]], "entity_1_idx_in_text_with_entity_marker": [4, 10], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PDGF A", "entity_2_idx": [[248, 254]], "entity_2_idx_in_text_with_entity_marker": [261, 267], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d54.s475_AIMed.d54.s475.p3", "text": "PDGF-C is a multidomain protein with the N-terminal region homologous to the extracellular CUB domain of neuropilin-1, and the C-terminal region consists of a growth factor domain (GFD) with homology to vascular endothelial growth factor (25%) and PDGF A-chain (23%).", "text_with_entity_marker": "PDGF-C is a multidomain protein with the N-terminal region homologous to the extracellular CUB domain of [E1]neuropilin-1[/E1], and the C-terminal region consists of a growth factor domain (GFD) with homology to vascular [E2]endothelial growth factor[/E2] (25%) and PDGF A-chain (23%).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "neuropilin-1", "entity_1_idx": [[105, 117]], "entity_1_idx_in_text_with_entity_marker": [109, 121], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "endothelial growth factor", "entity_2_idx": [[212, 237]], "entity_2_idx_in_text_with_entity_marker": [225, 250], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d54.s475_AIMed.d54.s475.p4", "text": "PDGF-C is a multidomain protein with the N-terminal region homologous to the extracellular CUB domain of neuropilin-1, and the C-terminal region consists of a growth factor domain (GFD) with homology to vascular endothelial growth factor (25%) and PDGF A-chain (23%).", "text_with_entity_marker": "PDGF-C is a multidomain protein with the N-terminal region homologous to the extracellular CUB domain of [E1]neuropilin-1[/E1], and the C-terminal region consists of a growth factor domain (GFD) with homology to vascular endothelial growth factor (25%) and [E2]PDGF A[/E2]-chain (23%).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "neuropilin-1", "entity_1_idx": [[105, 117]], "entity_1_idx_in_text_with_entity_marker": [109, 121], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PDGF A", "entity_2_idx": [[248, 254]], "entity_2_idx_in_text_with_entity_marker": [261, 267], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d54.s475_AIMed.d54.s475.p5", "text": "PDGF-C is a multidomain protein with the N-terminal region homologous to the extracellular CUB domain of neuropilin-1, and the C-terminal region consists of a growth factor domain (GFD) with homology to vascular endothelial growth factor (25%) and PDGF A-chain (23%).", "text_with_entity_marker": "PDGF-C is a multidomain protein with the N-terminal region homologous to the extracellular CUB domain of neuropilin-1, and the C-terminal region consists of a growth factor domain (GFD) with homology to vascular [E1]endothelial growth factor[/E1] (25%) and [E2]PDGF A[/E2]-chain (23%).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "endothelial growth factor", "entity_1_idx": [[212, 237]], "entity_1_idx_in_text_with_entity_marker": [216, 241], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PDGF A", "entity_2_idx": [[248, 254]], "entity_2_idx_in_text_with_entity_marker": [261, 267], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d54.s477_AIMed.d54.s477.p0", "text": "Competition binding and immunoprecipitation studies on cells bearing both PDGF alpha and beta receptors reveal a high affinity binding of recombinant GFD (PDGF-CC) to PDGF receptor-alpha homodimers and PDGF receptor-alpha/beta heterodimers.", "text_with_entity_marker": "Competition binding and immunoprecipitation studies on cells bearing both [E1]PDGF alpha[/E1] and beta receptors reveal a high affinity binding of recombinant GFD ([E2]PDGF-CC[/E2]) to PDGF receptor-alpha homodimers and PDGF receptor-alpha/beta heterodimers.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PDGF alpha", "entity_1_idx": [[74, 84]], "entity_1_idx_in_text_with_entity_marker": [78, 88], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PDGF-CC", "entity_2_idx": [[155, 162]], "entity_2_idx_in_text_with_entity_marker": [168, 175], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d54.s477_AIMed.d54.s477.p1", "text": "Competition binding and immunoprecipitation studies on cells bearing both PDGF alpha and beta receptors reveal a high affinity binding of recombinant GFD (PDGF-CC) to PDGF receptor-alpha homodimers and PDGF receptor-alpha/beta heterodimers.", "text_with_entity_marker": "Competition binding and immunoprecipitation studies on cells bearing both [E1]PDGF alpha[/E1] and beta receptors reveal a high affinity binding of recombinant GFD (PDGF-CC) to [E2]PDGF receptor-alpha[/E2] homodimers and PDGF receptor-alpha/beta heterodimers.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PDGF alpha", "entity_1_idx": [[74, 84]], "entity_1_idx_in_text_with_entity_marker": [78, 88], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PDGF receptor-alpha", "entity_2_idx": [[167, 186]], "entity_2_idx_in_text_with_entity_marker": [180, 199], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d54.s477_AIMed.d54.s477.p2", "text": "Competition binding and immunoprecipitation studies on cells bearing both PDGF alpha and beta receptors reveal a high affinity binding of recombinant GFD (PDGF-CC) to PDGF receptor-alpha homodimers and PDGF receptor-alpha/beta heterodimers.", "text_with_entity_marker": "Competition binding and immunoprecipitation studies on cells bearing both [E1]PDGF alpha[/E1] and beta receptors reveal a high affinity binding of recombinant GFD (PDGF-CC) to PDGF receptor-alpha homodimers and [E2]PDGF receptor-alpha[/E2]/beta heterodimers.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PDGF alpha", "entity_1_idx": [[74, 84]], "entity_1_idx_in_text_with_entity_marker": [78, 88], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PDGF receptor-alpha", "entity_2_idx": [[202, 221]], "entity_2_idx_in_text_with_entity_marker": [215, 234], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d54.s477_AIMed.d54.s477.p3", "text": "Competition binding and immunoprecipitation studies on cells bearing both PDGF alpha and beta receptors reveal a high affinity binding of recombinant GFD (PDGF-CC) to PDGF receptor-alpha homodimers and PDGF receptor-alpha/beta heterodimers.", "text_with_entity_marker": "Competition binding and immunoprecipitation studies on cells bearing both PDGF alpha and beta receptors reveal a high affinity binding of recombinant GFD ([E1]PDGF-CC[/E1]) to [E2]PDGF receptor-alpha[/E2] homodimers and PDGF receptor-alpha/beta heterodimers.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "PDGF-CC", "entity_1_idx": [[155, 162]], "entity_1_idx_in_text_with_entity_marker": [159, 166], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PDGF receptor-alpha", "entity_2_idx": [[167, 186]], "entity_2_idx_in_text_with_entity_marker": [180, 199], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d54.s477_AIMed.d54.s477.p4", "text": "Competition binding and immunoprecipitation studies on cells bearing both PDGF alpha and beta receptors reveal a high affinity binding of recombinant GFD (PDGF-CC) to PDGF receptor-alpha homodimers and PDGF receptor-alpha/beta heterodimers.", "text_with_entity_marker": "Competition binding and immunoprecipitation studies on cells bearing both PDGF alpha and beta receptors reveal a high affinity binding of recombinant GFD ([E1]PDGF-CC[/E1]) to PDGF receptor-alpha homodimers and [E2]PDGF receptor-alpha[/E2]/beta heterodimers.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "PDGF-CC", "entity_1_idx": [[155, 162]], "entity_1_idx_in_text_with_entity_marker": [159, 166], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PDGF receptor-alpha", "entity_2_idx": [[202, 221]], "entity_2_idx_in_text_with_entity_marker": [215, 234], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d54.s477_AIMed.d54.s477.p5", "text": "Competition binding and immunoprecipitation studies on cells bearing both PDGF alpha and beta receptors reveal a high affinity binding of recombinant GFD (PDGF-CC) to PDGF receptor-alpha homodimers and PDGF receptor-alpha/beta heterodimers.", "text_with_entity_marker": "Competition binding and immunoprecipitation studies on cells bearing both PDGF alpha and beta receptors reveal a high affinity binding of recombinant GFD (PDGF-CC) to [E1]PDGF receptor-alpha[/E1] homodimers and [E2]PDGF receptor-alpha[/E2]/beta heterodimers.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PDGF receptor-alpha", "entity_1_idx": [[167, 186]], "entity_1_idx_in_text_with_entity_marker": [171, 190], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PDGF receptor-alpha", "entity_2_idx": [[202, 221]], "entity_2_idx_in_text_with_entity_marker": [215, 234], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d54.s478_AIMed.d54.s478.p0", "text": "PDGF-CC exhibits greater mitogenic potency than PDGF-AA and comparable or greater mitogenic activity than PDGF-AB and PDGF-BB on several mesenchymal cell types.", "text_with_entity_marker": "[E1]PDGF-CC[/E1] exhibits greater mitogenic potency than [E2]PDGF-AA[/E2] and comparable or greater mitogenic activity than PDGF-AB and PDGF-BB on several mesenchymal cell types.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PDGF-CC", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PDGF-AA", "entity_2_idx": [[48, 55]], "entity_2_idx_in_text_with_entity_marker": [61, 68], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d54.s478_AIMed.d54.s478.p1", "text": "PDGF-CC exhibits greater mitogenic potency than PDGF-AA and comparable or greater mitogenic activity than PDGF-AB and PDGF-BB on several mesenchymal cell types.", "text_with_entity_marker": "[E1]PDGF-CC[/E1] exhibits greater mitogenic potency than PDGF-AA and comparable or greater mitogenic activity than [E2]PDGF-AB[/E2] and PDGF-BB on several mesenchymal cell types.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PDGF-CC", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PDGF-AB", "entity_2_idx": [[106, 113]], "entity_2_idx_in_text_with_entity_marker": [119, 126], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d54.s478_AIMed.d54.s478.p2", "text": "PDGF-CC exhibits greater mitogenic potency than PDGF-AA and comparable or greater mitogenic activity than PDGF-AB and PDGF-BB on several mesenchymal cell types.", "text_with_entity_marker": "[E1]PDGF-CC[/E1] exhibits greater mitogenic potency than PDGF-AA and comparable or greater mitogenic activity than PDGF-AB and [E2]PDGF-BB[/E2] on several mesenchymal cell types.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PDGF-CC", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PDGF-BB", "entity_2_idx": [[118, 125]], "entity_2_idx_in_text_with_entity_marker": [131, 138], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d54.s478_AIMed.d54.s478.p3", "text": "PDGF-CC exhibits greater mitogenic potency than PDGF-AA and comparable or greater mitogenic activity than PDGF-AB and PDGF-BB on several mesenchymal cell types.", "text_with_entity_marker": "PDGF-CC exhibits greater mitogenic potency than [E1]PDGF-AA[/E1] and comparable or greater mitogenic activity than [E2]PDGF-AB[/E2] and PDGF-BB on several mesenchymal cell types.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PDGF-AA", "entity_1_idx": [[48, 55]], "entity_1_idx_in_text_with_entity_marker": [52, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PDGF-AB", "entity_2_idx": [[106, 113]], "entity_2_idx_in_text_with_entity_marker": [119, 126], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d54.s478_AIMed.d54.s478.p4", "text": "PDGF-CC exhibits greater mitogenic potency than PDGF-AA and comparable or greater mitogenic activity than PDGF-AB and PDGF-BB on several mesenchymal cell types.", "text_with_entity_marker": "PDGF-CC exhibits greater mitogenic potency than [E1]PDGF-AA[/E1] and comparable or greater mitogenic activity than PDGF-AB and [E2]PDGF-BB[/E2] on several mesenchymal cell types.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PDGF-AA", "entity_1_idx": [[48, 55]], "entity_1_idx_in_text_with_entity_marker": [52, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PDGF-BB", "entity_2_idx": [[118, 125]], "entity_2_idx_in_text_with_entity_marker": [131, 138], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d54.s478_AIMed.d54.s478.p5", "text": "PDGF-CC exhibits greater mitogenic potency than PDGF-AA and comparable or greater mitogenic activity than PDGF-AB and PDGF-BB on several mesenchymal cell types.", "text_with_entity_marker": "PDGF-CC exhibits greater mitogenic potency than PDGF-AA and comparable or greater mitogenic activity than [E1]PDGF-AB[/E1] and [E2]PDGF-BB[/E2] on several mesenchymal cell types.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PDGF-AB", "entity_1_idx": [[106, 113]], "entity_1_idx_in_text_with_entity_marker": [110, 117], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PDGF-BB", "entity_2_idx": [[118, 125]], "entity_2_idx_in_text_with_entity_marker": [131, 138], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d54.s479_AIMed.d54.s479.p0", "text": "Analysis of PDGF-CC in vivo in a diabetic mouse model of delayed wound healing showed that PDGF-CC significantly enhanced repair of a full-thickness skin excision.", "text_with_entity_marker": "Analysis of [E1]PDGF-CC[/E1] in vivo in a diabetic mouse model of delayed wound healing showed that [E2]PDGF-CC[/E2] significantly enhanced repair of a full-thickness skin excision.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PDGF-CC", "entity_1_idx": [[12, 19]], "entity_1_idx_in_text_with_entity_marker": [16, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PDGF-CC", "entity_2_idx": [[91, 98]], "entity_2_idx_in_text_with_entity_marker": [104, 111], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d54.s480_AIMed.d54.s480.p0", "text": "Together, these studies describe a third member of the PDGF family (PDGF-C) as a potent mitogen for cells of mesenchymal origin in in vitro and in vivo systems with a binding pattern similar to PDGF-AB.", "text_with_entity_marker": "Together, these studies describe a third member of the PDGF family ([E1]PDGF-C[/E1]) as a potent mitogen for cells of mesenchymal origin in in vitro and in vivo systems with a binding pattern similar to [E2]PDGF-AB[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PDGF-C", "entity_1_idx": [[68, 74]], "entity_1_idx_in_text_with_entity_marker": [72, 78], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PDGF-AB", "entity_2_idx": [[194, 201]], "entity_2_idx_in_text_with_entity_marker": [207, 214], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d172.s1446_AIMed.d172.s1446.p0", "text": "Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4.", "text_with_entity_marker": "[E1-E2]Vascular endothelial growth factor[/E1]-related protein[/E2]: a ligand and specific activator of the tyrosine kinase receptor Flt4.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Vascular endothelial growth factor", "entity_1_idx": [[0, 34]], "entity_1_idx_in_text_with_entity_marker": [7, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Vascular endothelial growth factor[/E1]-related protein", "entity_2_idx": [[0, 50]], "entity_2_idx_in_text_with_entity_marker": [7, 62], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d172.s1446_AIMed.d172.s1446.p1", "text": "Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4.", "text_with_entity_marker": "[E1]Vascular endothelial growth factor[/E1]-related protein: a ligand and specific activator of the tyrosine kinase receptor [E2]Flt4[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Vascular endothelial growth factor", "entity_1_idx": [[0, 34]], "entity_1_idx_in_text_with_entity_marker": [4, 38], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Flt4", "entity_2_idx": [[116, 120]], "entity_2_idx_in_text_with_entity_marker": [129, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d172.s1446_AIMed.d172.s1446.p2", "text": "Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4.", "text_with_entity_marker": "[E1]Vascular endothelial growth factor-related protein[/E1]: a ligand and specific activator of the tyrosine kinase receptor [E2]Flt4[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Vascular endothelial growth factor-related protein", "entity_1_idx": [[0, 50]], "entity_1_idx_in_text_with_entity_marker": [4, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Flt4", "entity_2_idx": [[116, 120]], "entity_2_idx_in_text_with_entity_marker": [129, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d172.s1447_AIMed.d172.s1447.p0", "text": "The tyrosine kinases Flt4, Flt1, and Flk1 (or KDR) constitute a family of endothelial cell-specific receptors with seven immunoglobulin-like domains and a split kinase domain.", "text_with_entity_marker": "The tyrosine kinases [E1]Flt4[/E1], [E2]Flt1[/E2], and Flk1 (or KDR) constitute a family of endothelial cell-specific receptors with seven immunoglobulin-like domains and a split kinase domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Flt4", "entity_1_idx": [[21, 25]], "entity_1_idx_in_text_with_entity_marker": [25, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Flt1", "entity_2_idx": [[27, 31]], "entity_2_idx_in_text_with_entity_marker": [40, 44], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d172.s1447_AIMed.d172.s1447.p1", "text": "The tyrosine kinases Flt4, Flt1, and Flk1 (or KDR) constitute a family of endothelial cell-specific receptors with seven immunoglobulin-like domains and a split kinase domain.", "text_with_entity_marker": "The tyrosine kinases [E1]Flt4[/E1], Flt1, and [E2]Flk1[/E2] (or KDR) constitute a family of endothelial cell-specific receptors with seven immunoglobulin-like domains and a split kinase domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Flt4", "entity_1_idx": [[21, 25]], "entity_1_idx_in_text_with_entity_marker": [25, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Flk1", "entity_2_idx": [[37, 41]], "entity_2_idx_in_text_with_entity_marker": [50, 54], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d172.s1447_AIMed.d172.s1447.p2", "text": "The tyrosine kinases Flt4, Flt1, and Flk1 (or KDR) constitute a family of endothelial cell-specific receptors with seven immunoglobulin-like domains and a split kinase domain.", "text_with_entity_marker": "The tyrosine kinases [E1]Flt4[/E1], Flt1, and Flk1 (or [E2]KDR[/E2]) constitute a family of endothelial cell-specific receptors with seven immunoglobulin-like domains and a split kinase domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Flt4", "entity_1_idx": [[21, 25]], "entity_1_idx_in_text_with_entity_marker": [25, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KDR", "entity_2_idx": [[46, 49]], "entity_2_idx_in_text_with_entity_marker": [59, 62], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d172.s1447_AIMed.d172.s1447.p3", "text": "The tyrosine kinases Flt4, Flt1, and Flk1 (or KDR) constitute a family of endothelial cell-specific receptors with seven immunoglobulin-like domains and a split kinase domain.", "text_with_entity_marker": "The tyrosine kinases Flt4, [E1]Flt1[/E1], and [E2]Flk1[/E2] (or KDR) constitute a family of endothelial cell-specific receptors with seven immunoglobulin-like domains and a split kinase domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Flt1", "entity_1_idx": [[27, 31]], "entity_1_idx_in_text_with_entity_marker": [31, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Flk1", "entity_2_idx": [[37, 41]], "entity_2_idx_in_text_with_entity_marker": [50, 54], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d172.s1447_AIMed.d172.s1447.p4", "text": "The tyrosine kinases Flt4, Flt1, and Flk1 (or KDR) constitute a family of endothelial cell-specific receptors with seven immunoglobulin-like domains and a split kinase domain.", "text_with_entity_marker": "The tyrosine kinases Flt4, [E1]Flt1[/E1], and Flk1 (or [E2]KDR[/E2]) constitute a family of endothelial cell-specific receptors with seven immunoglobulin-like domains and a split kinase domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Flt1", "entity_1_idx": [[27, 31]], "entity_1_idx_in_text_with_entity_marker": [31, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KDR", "entity_2_idx": [[46, 49]], "entity_2_idx_in_text_with_entity_marker": [59, 62], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d172.s1447_AIMed.d172.s1447.p5", "text": "The tyrosine kinases Flt4, Flt1, and Flk1 (or KDR) constitute a family of endothelial cell-specific receptors with seven immunoglobulin-like domains and a split kinase domain.", "text_with_entity_marker": "The tyrosine kinases Flt4, Flt1, and [E1]Flk1[/E1] (or [E2]KDR[/E2]) constitute a family of endothelial cell-specific receptors with seven immunoglobulin-like domains and a split kinase domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Flk1", "entity_1_idx": [[37, 41]], "entity_1_idx_in_text_with_entity_marker": [41, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KDR", "entity_2_idx": [[46, 49]], "entity_2_idx_in_text_with_entity_marker": [59, 62], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d172.s1448_AIMed.d172.s1448.p0", "text": "Flt1 and Flk1 have been shown to play key roles in vascular development; these two receptors bind and are activated by vascular endothelial growth factor (VEGF).", "text_with_entity_marker": "[E1]Flt1[/E1] and [E2]Flk1[/E2] have been shown to play key roles in vascular development; these two receptors bind and are activated by vascular endothelial growth factor (VEGF).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Flt1", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Flk1", "entity_2_idx": [[9, 13]], "entity_2_idx_in_text_with_entity_marker": [22, 26], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d172.s1448_AIMed.d172.s1448.p1", "text": "Flt1 and Flk1 have been shown to play key roles in vascular development; these two receptors bind and are activated by vascular endothelial growth factor (VEGF).", "text_with_entity_marker": "[E1]Flt1[/E1] and Flk1 have been shown to play key roles in vascular development; these two receptors bind and are activated by [E2]vascular endothelial growth factor[/E2] (VEGF).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Flt1", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "vascular endothelial growth factor", "entity_2_idx": [[119, 153]], "entity_2_idx_in_text_with_entity_marker": [132, 166], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d172.s1448_AIMed.d172.s1448.p2", "text": "Flt1 and Flk1 have been shown to play key roles in vascular development; these two receptors bind and are activated by vascular endothelial growth factor (VEGF).", "text_with_entity_marker": "[E1]Flt1[/E1] and Flk1 have been shown to play key roles in vascular development; these two receptors bind and are activated by vascular endothelial growth factor ([E2]VEGF[/E2]).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Flt1", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "VEGF", "entity_2_idx": [[155, 159]], "entity_2_idx_in_text_with_entity_marker": [168, 172], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d172.s1448_AIMed.d172.s1448.p3", "text": "Flt1 and Flk1 have been shown to play key roles in vascular development; these two receptors bind and are activated by vascular endothelial growth factor (VEGF).", "text_with_entity_marker": "Flt1 and [E1]Flk1[/E1] have been shown to play key roles in vascular development; these two receptors bind and are activated by [E2]vascular endothelial growth factor[/E2] (VEGF).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Flk1", "entity_1_idx": [[9, 13]], "entity_1_idx_in_text_with_entity_marker": [13, 17], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "vascular endothelial growth factor", "entity_2_idx": [[119, 153]], "entity_2_idx_in_text_with_entity_marker": [132, 166], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d172.s1448_AIMed.d172.s1448.p4", "text": "Flt1 and Flk1 have been shown to play key roles in vascular development; these two receptors bind and are activated by vascular endothelial growth factor (VEGF).", "text_with_entity_marker": "Flt1 and [E1]Flk1[/E1] have been shown to play key roles in vascular development; these two receptors bind and are activated by vascular endothelial growth factor ([E2]VEGF[/E2]).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Flk1", "entity_1_idx": [[9, 13]], "entity_1_idx_in_text_with_entity_marker": [13, 17], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "VEGF", "entity_2_idx": [[155, 159]], "entity_2_idx_in_text_with_entity_marker": [168, 172], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d172.s1448_AIMed.d172.s1448.p5", "text": "Flt1 and Flk1 have been shown to play key roles in vascular development; these two receptors bind and are activated by vascular endothelial growth factor (VEGF).", "text_with_entity_marker": "Flt1 and Flk1 have been shown to play key roles in vascular development; these two receptors bind and are activated by [E1]vascular endothelial growth factor[/E1] ([E2]VEGF[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "vascular endothelial growth factor", "entity_1_idx": [[119, 153]], "entity_1_idx_in_text_with_entity_marker": [123, 157], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "VEGF", "entity_2_idx": [[155, 159]], "entity_2_idx_in_text_with_entity_marker": [168, 172], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d172.s1451_AIMed.d172.s1451.p0", "text": "This protein, designated VEGF-related protein (VRP), specifically binds to the extracellular domain of Flt4, stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.", "text_with_entity_marker": "This protein, designated [E1-E2]VEGF[/E1]-related protein[/E2] (VRP), specifically binds to the extracellular domain of Flt4, stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "VEGF", "entity_1_idx": [[25, 29]], "entity_1_idx_in_text_with_entity_marker": [32, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "VEGF[/E1]-related protein", "entity_2_idx": [[25, 45]], "entity_2_idx_in_text_with_entity_marker": [32, 57], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d172.s1451_AIMed.d172.s1451.p1", "text": "This protein, designated VEGF-related protein (VRP), specifically binds to the extracellular domain of Flt4, stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.", "text_with_entity_marker": "This protein, designated [E1]VEGF[/E1]-related protein ([E2]VRP[/E2]), specifically binds to the extracellular domain of Flt4, stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "VEGF", "entity_1_idx": [[25, 29]], "entity_1_idx_in_text_with_entity_marker": [29, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "VRP", "entity_2_idx": [[47, 50]], "entity_2_idx_in_text_with_entity_marker": [60, 63], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d172.s1451_AIMed.d172.s1451.p2", "text": "This protein, designated VEGF-related protein (VRP), specifically binds to the extracellular domain of Flt4, stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.", "text_with_entity_marker": "This protein, designated [E1]VEGF[/E1]-related protein (VRP), specifically binds to the extracellular domain of [E2]Flt4[/E2], stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "VEGF", "entity_1_idx": [[25, 29]], "entity_1_idx_in_text_with_entity_marker": [29, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Flt4", "entity_2_idx": [[103, 107]], "entity_2_idx_in_text_with_entity_marker": [116, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d172.s1451_AIMed.d172.s1451.p3", "text": "This protein, designated VEGF-related protein (VRP), specifically binds to the extracellular domain of Flt4, stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.", "text_with_entity_marker": "This protein, designated [E1]VEGF[/E1]-related protein (VRP), specifically binds to the extracellular domain of Flt4, stimulates the tyrosine phosphorylation of [E2]Flt4[/E2] expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "VEGF", "entity_1_idx": [[25, 29]], "entity_1_idx_in_text_with_entity_marker": [29, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Flt4", "entity_2_idx": [[152, 156]], "entity_2_idx_in_text_with_entity_marker": [165, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d172.s1451_AIMed.d172.s1451.p4", "text": "This protein, designated VEGF-related protein (VRP), specifically binds to the extracellular domain of Flt4, stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.", "text_with_entity_marker": "This protein, designated [E1]VEGF-related protein[/E1] ([E2]VRP[/E2]), specifically binds to the extracellular domain of Flt4, stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "VEGF-related protein", "entity_1_idx": [[25, 45]], "entity_1_idx_in_text_with_entity_marker": [29, 49], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "VRP", "entity_2_idx": [[47, 50]], "entity_2_idx_in_text_with_entity_marker": [60, 63], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d172.s1451_AIMed.d172.s1451.p5", "text": "This protein, designated VEGF-related protein (VRP), specifically binds to the extracellular domain of Flt4, stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.", "text_with_entity_marker": "This protein, designated [E1]VEGF-related protein[/E1] (VRP), specifically binds to the extracellular domain of [E2]Flt4[/E2], stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "VEGF-related protein", "entity_1_idx": [[25, 45]], "entity_1_idx_in_text_with_entity_marker": [29, 49], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Flt4", "entity_2_idx": [[103, 107]], "entity_2_idx_in_text_with_entity_marker": [116, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d172.s1451_AIMed.d172.s1451.p6", "text": "This protein, designated VEGF-related protein (VRP), specifically binds to the extracellular domain of Flt4, stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.", "text_with_entity_marker": "This protein, designated [E1]VEGF-related protein[/E1] (VRP), specifically binds to the extracellular domain of Flt4, stimulates the tyrosine phosphorylation of [E2]Flt4[/E2] expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "VEGF-related protein", "entity_1_idx": [[25, 45]], "entity_1_idx_in_text_with_entity_marker": [29, 49], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Flt4", "entity_2_idx": [[152, 156]], "entity_2_idx_in_text_with_entity_marker": [165, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d172.s1451_AIMed.d172.s1451.p7", "text": "This protein, designated VEGF-related protein (VRP), specifically binds to the extracellular domain of Flt4, stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.", "text_with_entity_marker": "This protein, designated VEGF-related protein ([E1]VRP[/E1]), specifically binds to the extracellular domain of [E2]Flt4[/E2], stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "VRP", "entity_1_idx": [[47, 50]], "entity_1_idx_in_text_with_entity_marker": [51, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Flt4", "entity_2_idx": [[103, 107]], "entity_2_idx_in_text_with_entity_marker": [116, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d172.s1451_AIMed.d172.s1451.p8", "text": "This protein, designated VEGF-related protein (VRP), specifically binds to the extracellular domain of Flt4, stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.", "text_with_entity_marker": "This protein, designated VEGF-related protein ([E1]VRP[/E1]), specifically binds to the extracellular domain of Flt4, stimulates the tyrosine phosphorylation of [E2]Flt4[/E2] expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "VRP", "entity_1_idx": [[47, 50]], "entity_1_idx_in_text_with_entity_marker": [51, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Flt4", "entity_2_idx": [[152, 156]], "entity_2_idx_in_text_with_entity_marker": [165, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d172.s1451_AIMed.d172.s1451.p9", "text": "This protein, designated VEGF-related protein (VRP), specifically binds to the extracellular domain of Flt4, stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.", "text_with_entity_marker": "This protein, designated VEGF-related protein (VRP), specifically binds to the extracellular domain of [E1]Flt4[/E1], stimulates the tyrosine phosphorylation of [E2]Flt4[/E2] expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Flt4", "entity_1_idx": [[103, 107]], "entity_1_idx_in_text_with_entity_marker": [107, 111], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Flt4", "entity_2_idx": [[152, 156]], "entity_2_idx_in_text_with_entity_marker": [165, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d172.s1452_AIMed.d172.s1452.p0", "text": "VRP fails to bind appreciably to the extracellular domain of Flt1 or Flk1.", "text_with_entity_marker": "[E1]VRP[/E1] fails to bind appreciably to the extracellular domain of [E2]Flt1[/E2] or Flk1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "VRP", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Flt1", "entity_2_idx": [[61, 65]], "entity_2_idx_in_text_with_entity_marker": [74, 78], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d172.s1452_AIMed.d172.s1452.p1", "text": "VRP fails to bind appreciably to the extracellular domain of Flt1 or Flk1.", "text_with_entity_marker": "[E1]VRP[/E1] fails to bind appreciably to the extracellular domain of Flt1 or [E2]Flk1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "VRP", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Flk1", "entity_2_idx": [[69, 73]], "entity_2_idx_in_text_with_entity_marker": [82, 86], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d172.s1452_AIMed.d172.s1452.p2", "text": "VRP fails to bind appreciably to the extracellular domain of Flt1 or Flk1.", "text_with_entity_marker": "VRP fails to bind appreciably to the extracellular domain of [E1]Flt1[/E1] or [E2]Flk1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Flt1", "entity_1_idx": [[61, 65]], "entity_1_idx_in_text_with_entity_marker": [65, 69], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Flk1", "entity_2_idx": [[69, 73]], "entity_2_idx_in_text_with_entity_marker": [82, 86], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d164.s1378_AIMed.d164.s1378.p0", "text": "The splicing factor U2AF (U2 snRNP auxiliary factor) is a heterodimer with subunits of 65 and 35 kD (U2AF65 and U2AF35).", "text_with_entity_marker": "The splicing factor U2AF (U2 snRNP auxiliary factor) is a heterodimer with subunits of 65 and 35 kD ([E1]U2AF65[/E1] and [E2]U2AF35[/E2]).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "U2AF65", "entity_1_idx": [[101, 107]], "entity_1_idx_in_text_with_entity_marker": [105, 111], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "U2AF35", "entity_2_idx": [[112, 118]], "entity_2_idx_in_text_with_entity_marker": [125, 131], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d164.s1379_AIMed.d164.s1379.p0", "text": "U2AF65 binds specifically to 3' splice sites, but previous studies failed to demonstrate a function for U2AF35.", "text_with_entity_marker": "[E1]U2AF65[/E1] binds specifically to 3' splice sites, but previous studies failed to demonstrate a function for [E2]U2AF35[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "U2AF65", "entity_1_idx": [[0, 6]], "entity_1_idx_in_text_with_entity_marker": [4, 10], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "U2AF35", "entity_2_idx": [[104, 110]], "entity_2_idx_in_text_with_entity_marker": [117, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d164.s1381_AIMed.d164.s1381.p0", "text": "Nuclear extracts deficient in U2AF35 were inactive; however, both constitutive and enhancer-dependent splicing could be restored by the addition of purified recombinant U2AF35.", "text_with_entity_marker": "Nuclear extracts deficient in [E1]U2AF35[/E1] were inactive; however, both constitutive and enhancer-dependent splicing could be restored by the addition of purified recombinant [E2]U2AF35[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "U2AF35", "entity_1_idx": [[30, 36]], "entity_1_idx_in_text_with_entity_marker": [34, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "U2AF35", "entity_2_idx": [[169, 175]], "entity_2_idx_in_text_with_entity_marker": [182, 188], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d164.s1382_AIMed.d164.s1382.p0", "text": "In vitro protein-RNA interaction studies with pre-mRNAs containing either a constitutive or regulated splicing enhancer revealed that U2AF35 directly mediates interactions between U2AF65 and proteins bound to the enhancers.", "text_with_entity_marker": "In vitro protein-RNA interaction studies with pre-mRNAs containing either a constitutive or regulated splicing enhancer revealed that [E1]U2AF35[/E1] directly mediates interactions between [E2]U2AF65[/E2] and proteins bound to the enhancers.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "U2AF35", "entity_1_idx": [[134, 140]], "entity_1_idx_in_text_with_entity_marker": [138, 144], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "U2AF65", "entity_2_idx": [[180, 186]], "entity_2_idx_in_text_with_entity_marker": [193, 199], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d164.s1383_AIMed.d164.s1383.p0", "text": "Thus, U2AF35 functions as a bridge between U2AF65 and the enhancer complex to recruit U2AF65 to the adjacent intron.", "text_with_entity_marker": "Thus, [E1]U2AF35[/E1] functions as a bridge between [E2]U2AF65[/E2] and the enhancer complex to recruit U2AF65 to the adjacent intron.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "U2AF35", "entity_1_idx": [[6, 12]], "entity_1_idx_in_text_with_entity_marker": [10, 16], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "U2AF65", "entity_2_idx": [[43, 49]], "entity_2_idx_in_text_with_entity_marker": [56, 62], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d164.s1383_AIMed.d164.s1383.p1", "text": "Thus, U2AF35 functions as a bridge between U2AF65 and the enhancer complex to recruit U2AF65 to the adjacent intron.", "text_with_entity_marker": "Thus, [E1]U2AF35[/E1] functions as a bridge between U2AF65 and the enhancer complex to recruit [E2]U2AF65[/E2] to the adjacent intron.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "U2AF35", "entity_1_idx": [[6, 12]], "entity_1_idx_in_text_with_entity_marker": [10, 16], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "U2AF65", "entity_2_idx": [[86, 92]], "entity_2_idx_in_text_with_entity_marker": [99, 105], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d164.s1383_AIMed.d164.s1383.p2", "text": "Thus, U2AF35 functions as a bridge between U2AF65 and the enhancer complex to recruit U2AF65 to the adjacent intron.", "text_with_entity_marker": "Thus, U2AF35 functions as a bridge between [E1]U2AF65[/E1] and the enhancer complex to recruit [E2]U2AF65[/E2] to the adjacent intron.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "U2AF65", "entity_1_idx": [[43, 49]], "entity_1_idx_in_text_with_entity_marker": [47, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "U2AF65", "entity_2_idx": [[86, 92]], "entity_2_idx_in_text_with_entity_marker": [99, 105], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d29.s243_AIMed.d29.s243.p0", "text": "We have probed an epitope sequence (His18-Pro19-Lys20-Phe21) in interleukin-8 (IL-8) by site-directed mutagenesis.", "text_with_entity_marker": "We have probed an epitope sequence (His18-Pro19-Lys20-Phe21) in [E1]interleukin-8[/E1] ([E2]IL-8[/E2]) by site-directed mutagenesis.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin-8", "entity_1_idx": [[64, 77]], "entity_1_idx_in_text_with_entity_marker": [68, 81], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-8", "entity_2_idx": [[79, 83]], "entity_2_idx_in_text_with_entity_marker": [92, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d29.s244_AIMed.d29.s244.p0", "text": "This work shows that single and double Ala substitutions of His18 and Phe21 in IL-8 reduced up to 77-fold the binding affinity to IL-8 receptor subtypes A (CXCR1) and B (CXCR2) and to the Duffy antigen.", "text_with_entity_marker": "This work shows that single and double Ala substitutions of His18 and Phe21 in [E1]IL-8[/E1] reduced up to 77-fold the binding affinity to [E2]IL-8[/E2] receptor subtypes A (CXCR1) and B (CXCR2) and to the Duffy antigen.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-8", "entity_1_idx": [[79, 83]], "entity_1_idx_in_text_with_entity_marker": [83, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-8", "entity_2_idx": [[130, 134]], "entity_2_idx_in_text_with_entity_marker": [143, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d29.s244_AIMed.d29.s244.p1", "text": "This work shows that single and double Ala substitutions of His18 and Phe21 in IL-8 reduced up to 77-fold the binding affinity to IL-8 receptor subtypes A (CXCR1) and B (CXCR2) and to the Duffy antigen.", "text_with_entity_marker": "This work shows that single and double Ala substitutions of His18 and Phe21 in [E1]IL-8[/E1] reduced up to 77-fold the binding affinity to [E2]IL-8 receptor subtypes A[/E2] (CXCR1) and B (CXCR2) and to the Duffy antigen.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-8", "entity_1_idx": [[79, 83]], "entity_1_idx_in_text_with_entity_marker": [83, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-8 receptor subtypes A", "entity_2_idx": [[130, 154]], "entity_2_idx_in_text_with_entity_marker": [143, 167], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d29.s244_AIMed.d29.s244.p2", "text": "This work shows that single and double Ala substitutions of His18 and Phe21 in IL-8 reduced up to 77-fold the binding affinity to IL-8 receptor subtypes A (CXCR1) and B (CXCR2) and to the Duffy antigen.", "text_with_entity_marker": "This work shows that single and double Ala substitutions of His18 and Phe21 in [E1]IL-8[/E1] reduced up to 77-fold the binding affinity to IL-8 receptor subtypes A ([E2]CXCR1[/E2]) and B (CXCR2) and to the Duffy antigen.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-8", "entity_1_idx": [[79, 83]], "entity_1_idx_in_text_with_entity_marker": [83, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CXCR1", "entity_2_idx": [[156, 161]], "entity_2_idx_in_text_with_entity_marker": [169, 174], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d29.s244_AIMed.d29.s244.p3", "text": "This work shows that single and double Ala substitutions of His18 and Phe21 in IL-8 reduced up to 77-fold the binding affinity to IL-8 receptor subtypes A (CXCR1) and B (CXCR2) and to the Duffy antigen.", "text_with_entity_marker": "This work shows that single and double Ala substitutions of His18 and Phe21 in [E1]IL-8[/E1] reduced up to 77-fold the binding affinity to IL-8 receptor subtypes A (CXCR1) and B ([E2]CXCR2[/E2]) and to the Duffy antigen.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-8", "entity_1_idx": [[79, 83]], "entity_1_idx_in_text_with_entity_marker": [83, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CXCR2", "entity_2_idx": [[170, 175]], "entity_2_idx_in_text_with_entity_marker": [183, 188], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d29.s244_AIMed.d29.s244.p4", "text": "This work shows that single and double Ala substitutions of His18 and Phe21 in IL-8 reduced up to 77-fold the binding affinity to IL-8 receptor subtypes A (CXCR1) and B (CXCR2) and to the Duffy antigen.", "text_with_entity_marker": "This work shows that single and double Ala substitutions of His18 and Phe21 in [E1]IL-8[/E1] reduced up to 77-fold the binding affinity to IL-8 receptor subtypes A (CXCR1) and B (CXCR2) and to the [E2]Duffy antigen[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-8", "entity_1_idx": [[79, 83]], "entity_1_idx_in_text_with_entity_marker": [83, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Duffy antigen", "entity_2_idx": [[188, 201]], "entity_2_idx_in_text_with_entity_marker": [201, 214], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d29.s244_AIMed.d29.s244.p5", "text": "This work shows that single and double Ala substitutions of His18 and Phe21 in IL-8 reduced up to 77-fold the binding affinity to IL-8 receptor subtypes A (CXCR1) and B (CXCR2) and to the Duffy antigen.", "text_with_entity_marker": "This work shows that single and double Ala substitutions of His18 and Phe21 in IL-8 reduced up to 77-fold the binding affinity to [E1-E2]IL-8[/E1] receptor subtypes A[/E2] (CXCR1) and B (CXCR2) and to the Duffy antigen.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-8", "entity_1_idx": [[130, 134]], "entity_1_idx_in_text_with_entity_marker": [137, 141], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-8[/E1] receptor subtypes A", "entity_2_idx": [[130, 154]], "entity_2_idx_in_text_with_entity_marker": [137, 166], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d29.s244_AIMed.d29.s244.p6", "text": "This work shows that single and double Ala substitutions of His18 and Phe21 in IL-8 reduced up to 77-fold the binding affinity to IL-8 receptor subtypes A (CXCR1) and B (CXCR2) and to the Duffy antigen.", "text_with_entity_marker": "This work shows that single and double Ala substitutions of His18 and Phe21 in IL-8 reduced up to 77-fold the binding affinity to [E1]IL-8[/E1] receptor subtypes A ([E2]CXCR1[/E2]) and B (CXCR2) and to the Duffy antigen.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-8", "entity_1_idx": [[130, 134]], "entity_1_idx_in_text_with_entity_marker": [134, 138], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CXCR1", "entity_2_idx": [[156, 161]], "entity_2_idx_in_text_with_entity_marker": [169, 174], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d29.s244_AIMed.d29.s244.p7", "text": "This work shows that single and double Ala substitutions of His18 and Phe21 in IL-8 reduced up to 77-fold the binding affinity to IL-8 receptor subtypes A (CXCR1) and B (CXCR2) and to the Duffy antigen.", "text_with_entity_marker": "This work shows that single and double Ala substitutions of His18 and Phe21 in IL-8 reduced up to 77-fold the binding affinity to [E1]IL-8[/E1] receptor subtypes A (CXCR1) and B ([E2]CXCR2[/E2]) and to the Duffy antigen.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-8", "entity_1_idx": [[130, 134]], "entity_1_idx_in_text_with_entity_marker": [134, 138], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CXCR2", "entity_2_idx": [[170, 175]], "entity_2_idx_in_text_with_entity_marker": [183, 188], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d29.s244_AIMed.d29.s244.p8", "text": "This work shows that single and double Ala substitutions of His18 and Phe21 in IL-8 reduced up to 77-fold the binding affinity to IL-8 receptor subtypes A (CXCR1) and B (CXCR2) and to the Duffy antigen.", "text_with_entity_marker": "This work shows that single and double Ala substitutions of His18 and Phe21 in IL-8 reduced up to 77-fold the binding affinity to [E1]IL-8[/E1] receptor subtypes A (CXCR1) and B (CXCR2) and to the [E2]Duffy antigen[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-8", "entity_1_idx": [[130, 134]], "entity_1_idx_in_text_with_entity_marker": [134, 138], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Duffy antigen", "entity_2_idx": [[188, 201]], "entity_2_idx_in_text_with_entity_marker": [201, 214], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d29.s244_AIMed.d29.s244.p9", "text": "This work shows that single and double Ala substitutions of His18 and Phe21 in IL-8 reduced up to 77-fold the binding affinity to IL-8 receptor subtypes A (CXCR1) and B (CXCR2) and to the Duffy antigen.", "text_with_entity_marker": "This work shows that single and double Ala substitutions of His18 and Phe21 in IL-8 reduced up to 77-fold the binding affinity to [E1]IL-8 receptor subtypes A[/E1] ([E2]CXCR1[/E2]) and B (CXCR2) and to the Duffy antigen.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-8 receptor subtypes A", "entity_1_idx": [[130, 154]], "entity_1_idx_in_text_with_entity_marker": [134, 158], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CXCR1", "entity_2_idx": [[156, 161]], "entity_2_idx_in_text_with_entity_marker": [169, 174], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d29.s244_AIMed.d29.s244.p10", "text": "This work shows that single and double Ala substitutions of His18 and Phe21 in IL-8 reduced up to 77-fold the binding affinity to IL-8 receptor subtypes A (CXCR1) and B (CXCR2) and to the Duffy antigen.", "text_with_entity_marker": "This work shows that single and double Ala substitutions of His18 and Phe21 in IL-8 reduced up to 77-fold the binding affinity to [E1]IL-8 receptor subtypes A[/E1] (CXCR1) and B ([E2]CXCR2[/E2]) and to the Duffy antigen.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-8 receptor subtypes A", "entity_1_idx": [[130, 154]], "entity_1_idx_in_text_with_entity_marker": [134, 158], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CXCR2", "entity_2_idx": [[170, 175]], "entity_2_idx_in_text_with_entity_marker": [183, 188], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d29.s244_AIMed.d29.s244.p11", "text": "This work shows that single and double Ala substitutions of His18 and Phe21 in IL-8 reduced up to 77-fold the binding affinity to IL-8 receptor subtypes A (CXCR1) and B (CXCR2) and to the Duffy antigen.", "text_with_entity_marker": "This work shows that single and double Ala substitutions of His18 and Phe21 in IL-8 reduced up to 77-fold the binding affinity to [E1]IL-8 receptor subtypes A[/E1] (CXCR1) and B (CXCR2) and to the [E2]Duffy antigen[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-8 receptor subtypes A", "entity_1_idx": [[130, 154]], "entity_1_idx_in_text_with_entity_marker": [134, 158], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Duffy antigen", "entity_2_idx": [[188, 201]], "entity_2_idx_in_text_with_entity_marker": [201, 214], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d29.s244_AIMed.d29.s244.p12", "text": "This work shows that single and double Ala substitutions of His18 and Phe21 in IL-8 reduced up to 77-fold the binding affinity to IL-8 receptor subtypes A (CXCR1) and B (CXCR2) and to the Duffy antigen.", "text_with_entity_marker": "This work shows that single and double Ala substitutions of His18 and Phe21 in IL-8 reduced up to 77-fold the binding affinity to IL-8 receptor subtypes A ([E1]CXCR1[/E1]) and B ([E2]CXCR2[/E2]) and to the Duffy antigen.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CXCR1", "entity_1_idx": [[156, 161]], "entity_1_idx_in_text_with_entity_marker": [160, 165], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CXCR2", "entity_2_idx": [[170, 175]], "entity_2_idx_in_text_with_entity_marker": [183, 188], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d29.s244_AIMed.d29.s244.p13", "text": "This work shows that single and double Ala substitutions of His18 and Phe21 in IL-8 reduced up to 77-fold the binding affinity to IL-8 receptor subtypes A (CXCR1) and B (CXCR2) and to the Duffy antigen.", "text_with_entity_marker": "This work shows that single and double Ala substitutions of His18 and Phe21 in IL-8 reduced up to 77-fold the binding affinity to IL-8 receptor subtypes A ([E1]CXCR1[/E1]) and B (CXCR2) and to the [E2]Duffy antigen[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CXCR1", "entity_1_idx": [[156, 161]], "entity_1_idx_in_text_with_entity_marker": [160, 165], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Duffy antigen", "entity_2_idx": [[188, 201]], "entity_2_idx_in_text_with_entity_marker": [201, 214], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d29.s244_AIMed.d29.s244.p14", "text": "This work shows that single and double Ala substitutions of His18 and Phe21 in IL-8 reduced up to 77-fold the binding affinity to IL-8 receptor subtypes A (CXCR1) and B (CXCR2) and to the Duffy antigen.", "text_with_entity_marker": "This work shows that single and double Ala substitutions of His18 and Phe21 in IL-8 reduced up to 77-fold the binding affinity to IL-8 receptor subtypes A (CXCR1) and B ([E1]CXCR2[/E1]) and to the [E2]Duffy antigen[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CXCR2", "entity_1_idx": [[170, 175]], "entity_1_idx_in_text_with_entity_marker": [174, 179], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Duffy antigen", "entity_2_idx": [[188, 201]], "entity_2_idx_in_text_with_entity_marker": [201, 214], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d29.s245_AIMed.d29.s245.p0", "text": "These Ala mutants triggered neutrophil degranulation and induced calcium responses mediated by CXCR1 and CXCR2.", "text_with_entity_marker": "These Ala mutants triggered neutrophil degranulation and induced calcium responses mediated by [E1]CXCR1[/E1] and [E2]CXCR2[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CXCR1", "entity_1_idx": [[95, 100]], "entity_1_idx_in_text_with_entity_marker": [99, 104], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CXCR2", "entity_2_idx": [[105, 110]], "entity_2_idx_in_text_with_entity_marker": [118, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d29.s246_AIMed.d29.s246.p0", "text": "Single Asp or Ser substitutions, H18D, F21D, F21S, and double substitutions, H18A/F21D, H18A/F21S, and H18D/F21D, reduced up to 431-fold the binding affinity to CXCR1, CXCR2, and the Duffy antigen.", "text_with_entity_marker": "Single Asp or Ser substitutions, H18D, F21D, F21S, and double substitutions, H18A/F21D, H18A/F21S, and H18D/F21D, reduced up to 431-fold the binding affinity to [E1]CXCR1[/E1], [E2]CXCR2[/E2], and the Duffy antigen.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CXCR1", "entity_1_idx": [[161, 166]], "entity_1_idx_in_text_with_entity_marker": [165, 170], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CXCR2", "entity_2_idx": [[168, 173]], "entity_2_idx_in_text_with_entity_marker": [181, 186], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d29.s246_AIMed.d29.s246.p1", "text": "Single Asp or Ser substitutions, H18D, F21D, F21S, and double substitutions, H18A/F21D, H18A/F21S, and H18D/F21D, reduced up to 431-fold the binding affinity to CXCR1, CXCR2, and the Duffy antigen.", "text_with_entity_marker": "Single Asp or Ser substitutions, H18D, F21D, F21S, and double substitutions, H18A/F21D, H18A/F21S, and H18D/F21D, reduced up to 431-fold the binding affinity to [E1]CXCR1[/E1], CXCR2, and the [E2]Duffy antigen[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CXCR1", "entity_1_idx": [[161, 166]], "entity_1_idx_in_text_with_entity_marker": [165, 170], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Duffy antigen", "entity_2_idx": [[183, 196]], "entity_2_idx_in_text_with_entity_marker": [196, 209], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d29.s246_AIMed.d29.s246.p2", "text": "Single Asp or Ser substitutions, H18D, F21D, F21S, and double substitutions, H18A/F21D, H18A/F21S, and H18D/F21D, reduced up to 431-fold the binding affinity to CXCR1, CXCR2, and the Duffy antigen.", "text_with_entity_marker": "Single Asp or Ser substitutions, H18D, F21D, F21S, and double substitutions, H18A/F21D, H18A/F21S, and H18D/F21D, reduced up to 431-fold the binding affinity to CXCR1, [E1]CXCR2[/E1], and the [E2]Duffy antigen[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CXCR2", "entity_1_idx": [[168, 173]], "entity_1_idx_in_text_with_entity_marker": [172, 177], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Duffy antigen", "entity_2_idx": [[183, 196]], "entity_2_idx_in_text_with_entity_marker": [196, 209], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d29.s249_AIMed.d29.s249.p0", "text": "This study demonstrates that IL-8 recognizes and activates CXCR1, CXCR2, and the Duffy antigen by distinct mechanisms.", "text_with_entity_marker": "This study demonstrates that [E1]IL-8[/E1] recognizes and activates [E2]CXCR1[/E2], CXCR2, and the Duffy antigen by distinct mechanisms.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-8", "entity_1_idx": [[29, 33]], "entity_1_idx_in_text_with_entity_marker": [33, 37], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CXCR1", "entity_2_idx": [[59, 64]], "entity_2_idx_in_text_with_entity_marker": [72, 77], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d29.s249_AIMed.d29.s249.p1", "text": "This study demonstrates that IL-8 recognizes and activates CXCR1, CXCR2, and the Duffy antigen by distinct mechanisms.", "text_with_entity_marker": "This study demonstrates that [E1]IL-8[/E1] recognizes and activates CXCR1, [E2]CXCR2[/E2], and the Duffy antigen by distinct mechanisms.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-8", "entity_1_idx": [[29, 33]], "entity_1_idx_in_text_with_entity_marker": [33, 37], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CXCR2", "entity_2_idx": [[66, 71]], "entity_2_idx_in_text_with_entity_marker": [79, 84], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d29.s249_AIMed.d29.s249.p2", "text": "This study demonstrates that IL-8 recognizes and activates CXCR1, CXCR2, and the Duffy antigen by distinct mechanisms.", "text_with_entity_marker": "This study demonstrates that [E1]IL-8[/E1] recognizes and activates CXCR1, CXCR2, and the [E2]Duffy antigen[/E2] by distinct mechanisms.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-8", "entity_1_idx": [[29, 33]], "entity_1_idx_in_text_with_entity_marker": [33, 37], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Duffy antigen", "entity_2_idx": [[81, 94]], "entity_2_idx_in_text_with_entity_marker": [94, 107], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d29.s249_AIMed.d29.s249.p3", "text": "This study demonstrates that IL-8 recognizes and activates CXCR1, CXCR2, and the Duffy antigen by distinct mechanisms.", "text_with_entity_marker": "This study demonstrates that IL-8 recognizes and activates [E1]CXCR1[/E1], [E2]CXCR2[/E2], and the Duffy antigen by distinct mechanisms.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CXCR1", "entity_1_idx": [[59, 64]], "entity_1_idx_in_text_with_entity_marker": [63, 68], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CXCR2", "entity_2_idx": [[66, 71]], "entity_2_idx_in_text_with_entity_marker": [79, 84], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d29.s249_AIMed.d29.s249.p4", "text": "This study demonstrates that IL-8 recognizes and activates CXCR1, CXCR2, and the Duffy antigen by distinct mechanisms.", "text_with_entity_marker": "This study demonstrates that IL-8 recognizes and activates [E1]CXCR1[/E1], CXCR2, and the [E2]Duffy antigen[/E2] by distinct mechanisms.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CXCR1", "entity_1_idx": [[59, 64]], "entity_1_idx_in_text_with_entity_marker": [63, 68], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Duffy antigen", "entity_2_idx": [[81, 94]], "entity_2_idx_in_text_with_entity_marker": [94, 107], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d29.s249_AIMed.d29.s249.p5", "text": "This study demonstrates that IL-8 recognizes and activates CXCR1, CXCR2, and the Duffy antigen by distinct mechanisms.", "text_with_entity_marker": "This study demonstrates that IL-8 recognizes and activates CXCR1, [E1]CXCR2[/E1], and the [E2]Duffy antigen[/E2] by distinct mechanisms.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CXCR2", "entity_1_idx": [[66, 71]], "entity_1_idx_in_text_with_entity_marker": [70, 75], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Duffy antigen", "entity_2_idx": [[81, 94]], "entity_2_idx_in_text_with_entity_marker": [94, 107], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
